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ABSTRACT 
Neuroinflammation has emerged as a pathological component of 
neurodegenerative disease onset and progression, including Parkinson’s disease. Given 
the current absence of disease-modifying therapies for this progressive disorder, 
approaches have now begun to explore the inflammatory burden that detrimental host 
factors place on the brain and how they can drive disease development. Our lab has 
identified the novel expression of the double-stranded RNA-dependent protein kinase 
(PKR) within the rodent brain following i) metabolic inflammation (diet-induced 
obesity), ii) viral infection (non-neurotropic influenza), and iii) bacterial sepsis 
(lipopolysaccharide). PKR stereotypically functions as an antiviral kinase, but has been 
implicated as a signal transduction element in response to a number of cell stresses. This 
biological target has been proposed to be upstream of inflammatory signaling cascades 
that contribute to, and aggravate, Parkinsonian pathology. By studying CNS PKR 
expression in three host conditions known to perturb CNS homeostasis through pro-
inflammatory insult of the brain, our lab has characterized the cellular and molecular 
level expression of PKR in animal models and attempted to determine this signal’s 
possible role in Parkinson’s disease pathogenesis. Our results suggest that PKR serves as 
a cell stress signal that may precede neurodegeneration and functions to promote 
apoptosis and inflammation. Studying PKR’s expression across a broad variety of host 
states may lead to the development of meaningful anti-inflammatory therapeutics that 
may be used against Parkinson’s disease and related conditions. 
 
1 
CHAPTER 1.    GENERAL INTRODUCTION  
 
Organization of the Dissertation 
This dissertation is a collection of manuscripts that are in preparation for peer-
reviewed publication. This dissertation is comprised of five chapters: a general introduction 
and literature review, three original research papers, and a final discussion that summarizes, 
synthesizes, and integrates this work as a whole. An acknowledgements section follows. 
References for each original chapter can be found at the end of their respective chapter. The 
references for the literature review and final discussion are found at the end of this 
dissertation. Figures for each chapter will be found at the end of that respective chapter and 
the numbering for figures will be specific to each respective chapter.  
The Introduction to the Dissertation introduces the emergence of neuroinflammation 
in neurodegenerative disease and its potential to shape the future therapeutic landscape 
within neurology. An in-depth review of this information can be found in the literature 
review within chapter 1. This includes information on i) Parkinson’s disease, covering the 
clinical presentation down to the cellular deficits of pathophysiology, ii) peripheral 
inflammation and its infiltration of the central nervous system, followed by iii) the role of 
chronic inflammation in host factor detriments, and finally iv) how PKR may serve as a 
novel neuroinflammatory mechanism. Chapters 2, 3, and 4 discuss PKR’s role in 
neuroinflammation by investigating its resulting expression from LPS challenge, influenza 
infection, and diet-induced obesity, respectively. Additionally, PKR’s relevancy to 
neurodegeneration in these studies is assessed by studying whether these host conditions can 
predispose animals to greater Parkinsonian toxicity. Attention is brought to the downstream 
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cell signaling events that may govern a PKR-mediated stress response to neuroinflammatory 
insult. The original experimental data and results of these studies was collected by the author 
of this dissertation during the course of his doctoral work as a graduate student in the 
Interdepartmental Neuroscience Graduate Program, working in the Department of 
Kinesiology, under the supervision of his major professor Marian L. Kohut. 
Introduction to the Dissertation 
The pathological development of neurodegenerative diseases had long been thought 
to occur in conjunction with the clinical manifestation of symptoms. That is, symptoms 
would not arise in a patient unless there was a primary pathology acting on the brain and 
promoting dysfunction. However, dogma surrounding how these diseases develop and 
progress in the brain has steadily transformed to accept the notion that neurodegenerative 
diseases progressively occur decades prior to the onset symptoms. This has prompted 
research efforts to identify processes that occur early in the brain, which may lead to the 
development of diagnostics and therapeutic interventions that can modify the course of 
neurodegeneration, and not just treat symptoms.  
As a relatively “young” field of research, neuroimmunology has impressively 
demonstrated how peripheral inflammation can promote dysfunction of the central nervous 
system (CNS) (Dantzer & Kelley, 1989, 2007). Early studies using potent immune stimuli to 
interrogate cross-talk between the peripheral and central immune systems showed that 
inflammation is a disease process that can promote neuronal dysfunction through the 
enhanced expression of pro-inflammatory cytokines and that these inflammatory signals are 
capable of disrupting behavioral and cognitive function (Capuron, Ravaud, & Dantzer, 2000; 
Cremona, Goujon, Kelley, Dantzer, & Parnet, 1998; Dantzer, 2001b; Konsman, Parnet, & 
Dantzer, 2002). As it became dubbed, neuroinflammation has emerged as a cellular process 
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that can not only drive the development of neurodegeneration in the brain, but dictate disease 
severity. Clinically in PD, this disease state progression is often best observed by examining 
non-motor symptoms (Chaudhuri & Schapira, 2009; Poewe et al., 2017), which are an under-
appreciated component of this neurodegenerative disease. 
As for what states produce neuroinflammation, a broad range of host conditions can 
produce inflammatory events that become broadcast to the CNS and disrupt homeostasis 
through the aberrant activation of microglia, the brain’s resident inflammatory effector cell. 
These cells are largely implicated as the primary effectors that promote and sustain 
neuroinflammation, and have emerged as therapeutic candidates in PD (Amor, Puentes, 
Baker, & van der Valk, 2010; Q. Wang, Liu, & Zhou, 2015). The challenge with this area of 
research is identifying neuroinflammatory events that reliably indicate CNS dysfunction and 
that are not dependent to a specific inflammatory context. 
This work attempts to address these current gaps by studying a proposed stress signal 
in the brain, which is activated by a broad collection of both chronic and acute inflammatory 
insults, and determine its relevancy to Parkinson’s disease development. Overall, this 
research i) identifies a conserved neuroinflammatory-related event following various immune 
challenges, ii) highlights the importance of modifiable lifestyle factors and the necessity to 
maintain wellness through personal and preventative health measures, and iii) adds to the 
rapidly-growing body of literature implicating the immune system as an essential regulator of 
disease state susceptibility.  
Literature Review 
The Burden of Neurodegenerative Disease 
Given their substantial burden on human health and disease, neurodegenerative 
diseases (NDDs) have become vilified in recent years. Dogmatically considered age-
4 
dependent diseases, neurodegeneration is defined as the sporadic, progressive loss of neurons 
in the central nervous system (CNS) that leads to a subsequent loss of host function. 
Although the temporal and regional kinetics of their pathological hallmarks vary between 
individual diseases, neurodegeneration encompasses a spectrum of similar cellular and 
molecular dysfunction. These conserved, spectral hallmarks grossly consist of proteinopathy 
deposition that progressively causes neuronal cell death and is responsible for the clinically 
observable behavioral deficits associated with a given NDD (Amor et al., 2014; Erkkinen, 
Kim, & Geschwind, 2018; Perry, 2004; Walsh & Selkoe, 2016).   
While the study of an individual NDD presents its own unique subset of challenges, 
multiple diseases are considered neurodegenerative, suggesting that therapeutic gains of one 
disease advance the therapeutic gain of another disease (Erkkinen et al., 2018). The most 
prevalent neurodegenerative disease in the U.S., Alzheimer’s disease (AD), currently affects 
5.4 million adults (AA, 2016), with approximately 1 million Americans having Parkinson’s 
disease (PD) (PDF, 2017), fewer than 20,000 living with Amyotrophic lateral sclerosis 
(ALS) (May Clinic, 2018), and approximately 200,000 living with multiple sclerosis (MS) 
(Mayo Clinic, 2018). The clinical diagnosis, management, and treatment of any given NDD 
is further complicated by its umbrella of disease-specific subtypes.  For example, AD can 
present as either Mild Cognitive Impairment or Vascular Dementia, while PD may clinically 
present as either Lewy Body Dementia or Multiple Systems Atrophy (Jankovic, 2008). 
Furthermore, symptoms of these NDD subtypes commonly overlap with one another, such as 
memory loss. Considering that neither AD or PD have quantitative, physiological diagnostic  
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diagnoses are an unfortunate, yet realistic aspect in the clinical management of these 
disorders (Splete, 2006) 
The average age of diagnosis for AD and PD is approximately 60 years of age (Clark 
& Kodadek, 2016). By this point in time, the neurodegenerative cascades that pathologically 
define a NDD have been developing for years prior (Ascherio & Schwarzschild, 2016; 
Hirsch, Jette, Frolkis, Steeves, & Pringsheim, 2016). Observations such as these underscore 
the clinical need for reliable, physiological measures that are predictive of future NDD onset 
(i.e., biomarkers). However, the inherent nature of finding a biological target that can reliably 
predict a future disease state, at a time when no symptoms are present, is enormously 
difficult. Although individual NDDs vary by clinical symptoms and pathological signatures, 
there are shared features that underlie and connect these diseases along a spectrum. 
Identifying a biomarker for one NDD will insurmountably benefit that specific disease, but it 
will also provide insight on related spectral disease states. In other words, the therapeutic 
gains of one NDD disease, will likely produce gains in another. 
This dissertation will specifically focus on Parkinson’s disease (PD), but with an 
understanding that the challenges and limitations associated with this individual disease are 
similar when applied to related NDDs. We will begin by defining and reviewing what is 
currently known about PD, how the disease is pathologically believed to manifest within the 
brain, the cellular and molecular deficits associated with these changes, and what host 
conditions may serve as risk factors. From this, we will bring attention to the role of 
neuroinflammation as a cellular event that precedes bona fide neurodegeneration and discuss 
how various host states have the capacity to exacerbate these inflammatory changes. 
Following this will be a discussion on a novel CNS therapeutic target identified by our lab, 
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RNA-dependent protein kinase (PKR), the characterization of its CNS expression, and its 
validity as a potential PD biomarker. It is with great hope that this basic work can contribute 
to and help shape what we know about PD, thereby reducing its malicious burden on human 
health. 
Parkinson’s Disease: What We Do and Do Not Know 
PD is characterized by the progressive loss of dopaminergic neurons within the 
substantia nigra. The premature death of these cells leads to striatal dopamine deficiency, 
which subsequently results in loss of voluntary motor function.  This pathophysiology has 
dogmatically characterized PD as an age-dependent motor disorder for the past 200 years.  
However, the past 30 years have been illuminating for our basic understanding of how cell 
loss is accelerated in PD and the events that regulate these detriments.  To understand the 
challenges that face PD and what further knowledge is needed to reduce its burden on human 
health, we’ll take a top-down approach when discussing current knowledge.  Beginning with 
a description of PD’s clinical presentation, we’ll discuss current risk factors, and then 
transition into the pathogenesis of PD in the brain and how those events account for disease 
symptoms. 
Clinical presentation 
In the U.S., the annual incidence of PD is estimated at 60,000 adults, with a 
prevalence rate of 1,000,000 adults living with PD. Although estimates vary based on study 
design, this translates to 21 cases per 100,000 (Savica, Grossardt, Bower, Ahlskog, & Rocca, 
2013). Worldwide, prevalence rates of PD are estimated at 0.3% for the general population 
(Pringsheim, Jette, Frolkis, & Steeves, 2014), these rates exponentially increase with age.  
With the average age of diagnoses being 60 years old, it is not common for cases before 50 
years old. Incidence rates substantially increase from 60-90 years of age. (Twelves, Perkins, 
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& Counsell, 2003). The disease is twice as common among men, compared to women 
(Hirsch et al., 2016; Pringsheim et al., 2014). As for ethnical differences,  PD appears less 
common in African Americans and Asians within the U.S., but there are not any major 
differences among other groups (Van Den Eeden et al., 2003). 
Motor symptoms 
Although it is the 2nd most common neurodegenerative condition (Poewe et al., 
2017), PD is the single most common movement disorder, having more cases than 
amyotrophic lateral sclerosis, multiple sclerosis, and muscular dystrophy combined 
("Statistics on Parkinson's," 2017). As a movement disorder, PD is predominantly 
characterized by bradykinesia, with patients inevitably experiencing a reduction in the 
amplitude and frequency of movements.  This reduced range of motion coincides with 
muscle rigidity, postural instability, gait freezing, a resting tremor, and a reduced ability to 
initiate planned motor movement (Poewe et al., 2017). Clinically, a PD diagnosis diverges 
into two primary subtypes: a tremor-dominant form that affects relatively younger patients, 
and a postural imbalance and gait disorder (PIGD) form that affects older patients. This 
classification becomes meaningful for patient prognosis because the tremor-dominant is 
associated with a progressive decline of motor function, while PIGD has a much more rapid 
decay of motor function (Selikhova et al., 2009). 
Neurobiology of motor deficits 
What largely accounts for these classic signs and symptoms are dopaminergic deficits 
to the thalamic-cortico-basal ganglia circuits.  The basal ganglia are responsible for the 
control of goal-directed motor behavior.  When dopaminergic neurons in the substantia nigra 
die, there is a stochastic reduction in dopaminergic transmission to the striatum, located in 
the forebrain.  This loss of excitatory dopamine opposition results in a net inhibitory output 
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from the thalamus to the cortex, as a result of increased GABAergic output from basal 
ganglia neurons.  The resulting hyper-inhibition of thalamic-cortical projections produces the 
hallmark motor symptoms of PD (bradykinesia, rigidity, and/or tremor), and whose 
appearance marks the early, clinical stage of PD (Poewe et al., 2017). 
Non-motor symptoms 
When Dr. James Parkinson first described PD in 1817 as “shaking palsy” and his 
initial characterization of the condition has largely remained true for the past 200 years.  
However, what he initially left out from his clinical assessment was the appearance of non-
motor symptoms, claiming that PD occurs with, “…the senses and intellects being 
uninjured.” (Parkinson, 2002).  More recent developments in the past 20 years have 
expanded our clinical outlook of PD to include non-motor symptoms, which are observed to 
antedate motor symptoms and can carry predictive validity for determining at-risk patients 
(Chaudhuri & Schapira, 2009; Postuma & Berg, 2016).  In addition, the identification and 
management of these non-motor symptoms has a large potential to influence patient quality 
of life (Greenwell, Gray, van Wersch, van Schaik, & Walker, 2015).  Encouraging studies 
that examine non-motor symptoms in at-risk populations will be beneficial to research 
communities who seek to identify and characterize preclinical biomarkers, as the presentation 
of motor deficits is too late of an end point for effective clinical management (Postuma & 
Berg, 2016). 
The spectrum of non-motor PD features carries a high degree of heterogeneity.  These  
can include, but are not limited to: REM sleep-behavior disorder, psychosis, dementia, 
depression, autonomic dysfunction (orthostatic hypertension, swallowing impairments, 
urogenital dysfunction, and constipation), and reduced olfactory discrimination (Chaudhuri 
& Schapira, 2009).  As varied as they might be, one longitudinal study observed that non-
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motor features are highly prevalent among PD patients. Although 74% of the original 136 
participants died by the study endpoint, a 20-year study based in Sydney reported that 
dementia was present in 83% of its 20-year survivors, 48% experienced orthostatic 
hypertension, urinary incontinence in 71%, hallucinatory psychoses in 74%, and 48% 
experienced choking (M. A. Hely, Reid, Adena, Halliday, & Morris, 2008).  While the decay 
of motor symptoms appears to asymptote in a finite period of time, it’s the progression of 
non-motor symptoms that become responsible for and dominate patient disability over time 
(Mariese A Hely, Morris, Reid, & Trafficante, 2005).   
Although these symptoms are often under-recognized and under-reported, they 
highlight the evolution of our understanding of PD and underscore the importance of not 
dogmatically viewing PD as a pure motor disorder.  Additionally, as these features appear 
prior to movement deficits and persist through disease advancement, they indirectly implicate 
broader pathological features. Identifying and characterizing what these features may be 
presents an advantageous approach to the future PD outlook and management. 
Parkinsonian classification 
Major changes in PD outlook have occurred in the manner that we clinically 
characterize this disease. PD is not simply an over-arching, all-encompassing 
neurodegenerative condition, but is purely one clinical subset that occurs under an umbrella 
of Parkinsonian Syndrome. Approximately 10% of confirmed PD diagnoses are 
misdiagnosed as ‘Parkinsonism’, a collection of Parkinsonian syndromes. These individual 
syndromes can often be difficult to define because they closely mimic true PD, which is 
predominantly idiopathic in origin, making them difficult to initially diagnose ("Parkinson's 
Disease vs Parkinsonism," 2017).  
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While subtypes do exist, the most common PD syndromes are: multiple systems 
atrophy (MSA), supranuclear palsy (PSP), Lewy Body Dementia (LBD), and corticobasal 
degeneration (CBD). The defining diagnostic features of MSA are progressive and severe 
autonomic dysfunction, which occurs early and dominates the clinical presentation.  These 
symptoms involve a combination of urinary incontinence, constipation, orthostatic 
hypertension, and erectile dysfunction.  Patients with PSP present almost synonymously as 
PD patients, but are often clinically distinguished when they exhibit resistance to levodopa 
therapy.  The dominant PSP-subtype, referred to as Richardson syndrome, presents with a 
unique eye movement (a supranuclear vertical gaze palsy).  In addition to levodopa 
resistance, this feature distinguishes PSP from classic PD.  As for LBD, it often doesn’t 
present with a motor deficit, but is associated with progressive shifts in personality, 
decreased empathy towards others, and possibly visual psychosis.  LBD may precede PD, or 
occur subsequently.  CBD is one of the more challenging Parkinsonian syndromes to 
clinically diagnose, due to its extensively variable phenotype.  This condition can present as 
any other PD syndrome (D. R. Williams & Litvan, 2013).  Collectively, the variability in 
clinical presentation among Parkinsonian syndrome can produce error rates as high as 24%, 
even when diagnosed by movement disorder specialists (Hughes, Daniel, Kilford, & Lees, 
1992). 
This discussion is not to draw attention to the lapses in the clarity of diagnostic 
criteria for PD. Rather, it is to provide evidence that our outlook on what we thought PD was 
as a disease state has enormously expanded.  As a scientific community devoted to reducing 
the burden that PD places on human health, it is important to consider these changes and 
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apply our ever-expanding knowledge to these contexts. In doing so, we can successfully gain 
new insight that may shape the future diagnosis and treatment of PD. 
Current diagnostic criteria 
Current diagnostic criteria revolve around two primary clinical features in PD 
patients: the presence of bradykinesia and the addition of either muscle rigidity, or a resting 
tremor (Tolosa, Wenning, & Poewe, 2006).  With the average age of onset being near 60 
years of age, the average duration from diagnosis to time of death is 14 years.  With early 
onset PD occurring in the mid-40s, symptoms tend to progress much slower and the average 
time from diagnosis to death is 24 years (Selikhova et al., 2009).  Bradykinesia can often be 
patient-reported as “slowing down” and is clinically assessed through repetitive finger 
tapping, hand opening, and or foot/toe tapping.  Typically, these movements will diminish in 
amplitude and frequency within a 15 second.  Early in disease progression, rigidity may 
manifest as pain, but is characterized by increased resistance in movements.  Tremor is one 
of the stereotypical symptoms of PD.  It increases in patients maintaining a fixed posture and 
can become particularly apparent in tasks that require deliberate mental concentration (D. R. 
Williams & Litvan, 2013).  It is imperative to note that PD diagnosis is purely established 
from clinical observations and patient medical history; there are currently no 
physiological/biochemical assays, neuroimaging techniques, or genetic screening tests 
available.   
PD risk factors 
While genome-wide association studies (GWAS) studies have identified a number of 
polymorphisms that provide insight into the genetic basis of PD, these heritable, early-onset 
forms only comprise approximately 5-10% of cases (Poewe et al., 2017).  For these cases, 
certain inheritance patterns have emerged.  For example, point-mutations and duplications 
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that occur to the SNCA gene, an α-synuclein encoding gene, are associated with an 
autosomal dominant form of early PD (Soldner et al., 2016).  Other mutations associated 
with autosomal dominant PD include LRRK2, which are associated with autophagy and 
mitochondrial impairments (Bose & Beal, 2016).  Conversely, autosomal recessive forms are 
associated with mutations to the Park2 and Pink1 genes, which are associated with oxidative 
stress and have a role in mitophagy (Pickrell & Youle, 2015).  While the study of these 
mutations has produced disease state insight, genetic testing is not a routine clinical practice 
and it does not currently appear to have an impact on the clinical management of PD. 
Environmental and host risk factors are believed to have the greatest capacity to influence the 
risk of PD, although it is difficult to understand the causal impact that these individual risk 
factors may have on the overall course of PD progression. 
Environmental risk factors 
Although the environmental etiology of PD is richly multifactorial, it is important to 
identify and understand these individual factors to gain a global overview of its pathogenesis.  
Through this understanding, research communities may identify new cellular and molecular 
signatures that could be targeted for therapeutic intervention.  The environmental risk factors 
identified as having some of the largest contributions to PD pathogenesis are air pollution, 
history of respiratory infections, heavy metal exposure, and pesticide exposure. 
Although an arguably under-studied risk factor for NDD’s, air pollution represents a 
potent source of noxious environmental stimuli with an established capacity to perturb CNS 
tissue homeostasis (M. L. Block & Calderon-Garciduenas, 2009; Craig et al., 2008).  The 
composition of particulate matter and level of exposure varies widely, making it a challenge 
for epidemiologists to understand the causal interaction between air pollution and CNS 
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detriments.  However, a working definition of particulate matter is a mixture consisting of 
gases, organic compounds, and metals.  The two primary fractions of particulate matter 
implicated in CNS disease, PM2.5 and UFPM, are largely derived from metal processing 
facilities and mobile exhaust emissions, respectively (Craig et al., 2008). 
Another understudied environmental risk factor for PD are respiratory viral 
infections, which is a relationship that has been recognized since the 1970s (Moore, 1977).  
The causative pathogen implicated are influenza viruses.  Initial epidemiological evidence 
came from a high incidence of post-encephalitic Parkinson’s following the 1918 Spanish 
influenza pandemic (Kristensson, 2006) suggesting that peripheral immune challenges are 
capable of perturbing CNS homeostasis by producing aberrant, systemic inflammatory 
responses (J. A. Majde, 2010).  While there are neurotropic strains of influenza that can 
directly infect CNS tissue, namely H5N1 avian influenza ((H. Jang et al., 2009), seasonal 
influenza are largely believed to be incapable of direct CNS infection and the subsequent 
production of clinical neuropathology.  However, there have been reports of mouse-adapted 
human viruses (A/PR/8/34) that are capable of producing viral replication intermediates 
within the olfactory bulb of C57 mice (Jeannine A Majde et al., 2007).  While the reports on 
the neurotropism of seasonal influenza viruses have been limited, it is largely agreed that 
mild seasonal infections in a given host produce sickness behaviors that are the result of glial 
cell activation by peripheral cytokines (Dantzer & Kelley, 2007; Konsman et al., 2002; J. A. 
Majde, 2010).  The more these events occur over a lifetime, the higher the propensity for an 
overzealous immune response to produce CNS derangements.  
Both epidemiological and mechanistic evidence has implicated chronic heavy metal 
exposure (iron, manganese, and mercury) as an additional Parkinson’s risk factor.  While 
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metals have numerous homeostatic roles, its accumulation within the CNS promotes toxicity 
that breeds oxidative stress through mitochondrial dysfunction.  These events augment 
additional intracellular dysfunction such as, ER stress, autophagy dysfunction, mis-folding of 
proteins, and apoptosis (P. Chen, Miah, & Aschner, 2016; Wright & Baccarelli, 2007; J. 
Zhang et al., 2013).  Manganese primarily serves as a respiratory Parkinsonian toxicant from 
hazardous occupations, such as welding and mining (Kwakye, Paoliello, Mukhopadhyay, 
Bowman, & Aschner, 2015).  While manganese toxicity produces a variety of cellular 
derangements, its mechanism of action related to neuronal death has been linked to aberrant 
proteolytic cleavage of protein kinase C-δ, (Latchoumycandane et al., 2005), which has 
relevancy for NF-κB inflammatory signaling (Gordon et al., 2016). Environmentally-derived 
copper, cadmium, and lead are additional metals implicated in PD pathogenesis and all 
similarly exert toxicity through oxidative stress mechanisms that are capable of exacerbating 
α-synuclein pathologies (P. Chen et al., 2016). 
Host factor detriments 
It has become increasingly more recognized that lifestyle factors have a large 
potential to influence one’s probability of crossing the threshold towards a Parkinson’s 
disease state phenotype.  Understanding these various factors and their contribution to PD 
pathogenesis holds great promise for potential clinical interventions because these factors are 
largely modifiable.   
Age remains the single greatest risk factor for PD (Poewe et al., 2017; Wyss-Corey, 
2016).  While there is no process that can delay or halt the process of aging, we have seen 
impressive increases in human life expectancy over the past century (Dong, Milholland, & 
Vijg, 2016).  Although projections for whether lifespan will continue to increase are readily 
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contested (Brown, Albers, & Ritchie, 2017), a reasonable interpretation of this trend is that 
increased aging has and will continue to place a substantial burden on human health and 
disease.  As for PD, age is the single greatest risk factor and that risk substantially increases 
beginning around 60 years of age (Driver, Logroscino, Gaziano, & Kurth, 2009; Reeve, 
Simcox, & Turnbull, 2014).  
Obesity is a detrimental host condition linked with numerous chronic disease states 
and pathologically carries a slew of molecular and cellular dysfunction.  Epidemiological 
evidence of obesity as a risk factor for PD has been mixed based on existing studies.  There 
have been no significant relationships between Body Mass Index (BMI) as a measure of 
overall obesity, however, as a measure of central obesity greater waist circumference and 
waist-to-hip ratio were associated with greater risk in a population of non-smokers (H. Chen 
et al., 2004).  Others meta-analyses have observed similar trends where there has been no 
difference between BMI and PD risk among overweight and obese groups (J. Chen et al., 
2014).  However, Type 2 Diabetes (T2D) has a clear risk association with PD (Santiago & 
Potashkin, 2013).  Animal studies have provided robust evidence that obesity predisposes the 
brain to Parkinsonian insult and can result in a greater degree of dopaminergic degeneration 
(M. Bousquet et al., 2012; L. Wang et al., 2014).  The pathological basis for this relationship 
has largely been associated with chronic, peripheral inflammatory events which will be 
explored later in this review. 
Famed cases of Parkinsonism among professional athletes, such as Muhammed Ali, 
have highlighted the basic notion that head injury can potentiate a neurodegenerative 
cascade.  This relationship has largely been linked to chronic traumatic encephalopathy 
(CTE), a neurodegenerative tauopathy that results from repetitive, mild, sub-concussive head 
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trauma (Brody, Benetatos, Bennett, Klemenhagen, & Mac Donald, 2015; Gardner & Yaffe, 
2015).  While predominantly associated with Alzheimer’s neuropathology, tau pathology is 
integral to Parkinsonian pathogenesis and it is believed to have a synergistic effect on α-
synuclein aggregation and deposition (Clinton, Blurton-Jones, Myczek, Trojanowski, & 
LaFerla, 2010; Lei et al., 2010).  Although the mechanism of how tau may drive disease state 
development in PD is unclear, the neuroinflammatory response resulting from head trauma is 
clearly recognized (Ramlackhansingh et al., 2011).  These injuries have a potent capacity to 
injure neurons, disrupt blood-brain barrier integrity, and activate microglia that can persist 
for years after injury in humans (Gentleman et al., 2004).   
 While aging, diet, and injury have the capacity to potentiate neurodegenerative 
dysfunction, there is not direct causality between their occurrence and PD incidence.  
However, when these host factors are considered in combination, they have a more readily 
acknowledged ability to augment neurodegeneration.  Moreover, there are a number of host 
factors that can provide neuroprotective benefits.  For example, smoking reduces the 
likelihood of PD, with its therapeutic benefit largely attributed to stimulation of nicotinic 
receptors in nigrostriatal pathways (Quik, 2004).  Moderate alcohol intake may also be 
associated with lower PD risk, although this relationship is stronger for reducing AD risk 
((Campdelacreu, 2014; Wirdefeldt, Adami, Cole, Trichopoulos, & Mandel, 2011).  Exercise 
is another valuable host strategy for reducing PD incidence and serves as an intervention 
strategy, due to its ability to stimulate neurotrophic factors that support the growth and 
survival of dopaminergic cells (Goodwin, Richards, Taylor, Taylor, & Campbell, 2008). 
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Cellular deficits of PD 
Parkinson’s disease is neuropathologically defined by the progressive loss of 
dopaminergic neurons in the substantia nigra, intracellular proteinaceous inclusions 
consisting of α-synuclein, a stochastic decrease in striatal dopaminergic terminals, and 
aberrant behavior of neuroinflammatory cells (Obeso et al., 2010; Sudhakar R Subramaniam 
& Howard J Federoff, 2017).  While the propagation and accumulation of α-synuclein in 
topographically-specific brain regions are considered the primary pathology responsible for 
the progressive death of dopaminergic cells, there are a myriad of homeostatic cell functions 
that become deranged and exacerbate these primary pathological events. 
Mitochondrial dysfunction 
Mitochondrial dysfunction is (rightfully so) one of the more well-recognized facets of 
disturbed cellular physiology in PD.  Given their role in oxidative phosphorylation, 
mitochondria are a potent source of free-radical mediated oxidative stress, producing 
superoxide radicals as a byproduct of electron transfer.  Four respiratory chain complexes (I-
IV) comprise oxidative phosphorylation. It has been observed that an approximate 35% 
complex I deficiency occurs exclusively in the substantia nigra of PD patients (Mann et al., 
1994) and that it does not even occur in related Parkinsonian syndromes (i.e., multiple 
systems atrophy) (Gu et al., 1997).  Additionally, a number of genes encoding mitochondrial-
associated proteins (DJ-1, Parkin, and PINK1) are associated with early-onset forms of PD 
when loss-of-function is observed (Canet-Avilés et al., 2004; Dodson & Guo, 2007). 
Oxidative stress 
Oxidative stress results from deranged mitochondrial function and contributes to the 
vicious cycle of PD pathogenesis.  Autosomal recessive mutations, such as the antioxidant 
protein DJ-1, exacerbate degeneration of dopaminergic neurons in murine knockout models 
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(Di Nottia et al., 2017; Guzman et al., 2010), thereby highlighting the notion that oxidative 
stress contributes to neuronal death.  When considering the oxidative burden these cells face 
in PD, one may naturally wonder why those neurons appear selectively vulnerable to stress.  
Anatomically, the cellular architecture of dopaminergic neurons in the substantia nigra is 
relatively large, with a high degree of arborization of its unmyelinated axon.  These size and 
signaling requirements place a heavy energy demand on the cell, that when imbalanced, 
potentiate premature cell death (Bolam & Pissadaki, 2012; Pissadaki & Bolam, 2013). 
Additionally, cytosolic metabolites of dopamine synthesis themselves become directly toxic 
and promote oxidative stress (Lotharius & Brundin, 2002; Mosharov et al., 2009).  This state 
of increased oxidative stress in PD does not remain pathologically inclusive, as it promotes 
lysosomal depletion, functionally impairing the lysosomal-autophagy system (Dehay et al., 
2010). 
Autophagy 
Proteolytic defense systems are an integral component of upholding intracellular 
homeostasis.  These processes consist of both the ubiquitin-proteasome system (UPS) and the 
lysosomal autophagy system (LAS).  The maintenance of these systems is particularly 
paramount in the context of neurodegeneration, as there is an age-related reduction in their 
function, which promotes intracellular accumulation of α-synuclein in neurons (Kaushik & 
Cuervo, 2015; Xilouri, Brekk, & Stefanis, 2013).  LAS has been suggested as being a more 
efficient removal process of α-synuclein oligomers (Xilouri et al., 2013) and the 
accumulation of these oligomers has been shown to inhibit UPS (Emmanouilidou, Stefanis, 
& Vekrellis, 2010), thereby leading to macro autophagy inhibition (Winslow et al., 2010) 
When dysfunctional, the relative contribution of each system to the pathogenic 
progression within a diseased neuron is unclear, as these processes are intimately associated 
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with one another.  What is more clear is that the inhibition of either process promotes α-
synuclein accumulation (Xilouri, Vogiatzi, Vekrellis, Park, & Stefanis, 2009) and the 
derangement of these processes is inherently linked with the disruption of other cellular 
processes believed to be central to cellular dysfunction in PD.  For example, oxidative stress 
resulting from mitochondrial dysfunction has been shown to deplete lysosomes (Dehay et al., 
2010). Together, the collective disruption of these proteolytic processes imposes a vicious 
cycle that impairs α-synuclein degradation and its subsequent accumulation within the cell. 
Neuroinflammation 
Neuroinflammation is yet another well-recognized facet of PD pathogenesis.  
Originally recognized as a secondary event to proteinopathies in neurodegenerative disease, 
recent developments have shifted that paradigm to support the notion that neuroinflammation 
occurs as a priming event that exacerbates the development of pathogenic processes.  
 Historically, the field of neuroimmunology has largely failed to collectively and 
systematically define “neuroinflammation”. Despite the ambiguity of defining 
neuroinflammation, a well-recognized facet of this process has been the chronic activation of 
microglia, the brain’s resident macrophage. While the immune system is vital for repair and 
regeneration of damaged tissues, chronic activation of the innate immune system in 
neurodegenerative disease is representative of an unresolved state of injury. This unresolved 
state potentiates a negative feedback loop, creating aberrant microglial behavior, leading to 
chronic activation and subsequent production of inflammatory molecules called cytokines. 
Cytokines are small-protein, intracellular messengers that mediate a multitude of cell-cell 
signaling interactions involved in cell activation and proliferation, antibody production, and 
are an integral component of inflammation. Having both pro- and anti-inflammatory 
functions, these cytokines influence neuronal homeostasis, and have a potent capacity to 
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influence behavioral and cognitive functioning (C. Cunningham et al., 2009; Dantzer & 
Kelley, 2007; Perry & Teeling, 2013). This evidence suggests that immune system 
modulation could have therapeutic benefit in neurodegenerative diseases.  Furthermore, 
epidemiological studies have shown reduced risk between long-term non-steroidal anti-
inflammatory drug (NSAID) use and PD incidence (Gagne & Power, 2010). 
As for the temporal kinetics of neuroinflammatory processes, microglia and astrocyte 
activation has been shown to occur between 24-72 hours (depending on inflammatory 
stimulus) (Hoogland, Houbolt, van Westerloo, van Gool, & van de Beek, 2015). This cell 
activation subsequently produces an inflammatory milieu within the brain parenchyma. 
Additionally, blood-derived immune cells (lymphocytes and monocyte-derived 
macrophages) are recruited to and infiltrate the CNS. These events augment the relatively 
delayed disruption of blood-brain barrier (BBB) tight junction regulation, leading to 
increased BBB permeability (Obermeier, Daneman, & Ransohoff, 2013; Ransohoff, 2016a, 
2016b). Collectively, these events disrupt neuronal homeostasis and promote cell death 
processes that are relevant to neurodegenerative disease (Hirsch et al., 2016; Perry, 2004; 
Perry, Cunningham, & Holmes, 2007). 
The influence of the peripheral immune system on CNS function has been a relatively 
new development, with its bi-directional relationship only being appreciated within the past 
10-15 years.  Although there is intense research interest in this relationship, there are many 
basic questions that remain unanswered before viable drug targets could begin to emerge. 
Therefore, identifying, characterizing, and understanding the functions of various cell 
signaling pathways is an essential effort in the battle to develop disease-modifying therapies 
for the treatment of neurodegenerative diseases.  The scope of this dissertation is focused on 
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the role of neuroinflammation and whether a specific cell-signaling pathway has a role in 
Parkinsonian pathogenesis.  Therefore, the subsequent sections of this literature review will 
be dedicated to understanding the current state of innate immune system activation and the 
role it plays in Parkinson’s disease and related disease states. 
Peripheral Inflammation and CNS Infiltration 
The functional significance of the immune system can be most appreciated when one 
considers the vitality of an organism’s capacity to survey and appropriately respond to 
foreign, potentially lethal antigens.  The detection and subsequent clearance of these stimuli, 
while not compromising self-tissue, is vital for host survival and serves an essential 
evolutionary role.  This function is maintained by the innate immune system, as opposed to 
the adaptive immune system which responsible for conferring immunological memory.  
Innate immunity is operationally defined by inflammation, an immune response in which 
vascular changes deliver effector cells (both innate and adaptive cell types) to a site of host 
injury or illness (Parkin & Cohen, 2001). 
Evidence for a neuro-immune axis 
Central evidence for a relationship between the immune and central nervous systems 
has been through “sickness behavior”, a phenomena in which systemic inflammation 
produces behavioral and cognitive derangements (Dantzer & Kelley, 2007; Konsman et al., 
2002).  Best observed during periods of infection, this behavior is characterized by lethargy, 
reduced locomotor activity, reduced appetite, malaise, and fatigue.  It’s largely supported that 
these collective behaviors exist as an adaptive response to limit host energy consumption 
and/or allow for increased energy consumption required for an immune reponse (Hart, 1988; 
Kluger, 1991).  Importantly, the clinical presentation of these symptoms is non-specific, as is 
the inherent nature of the innate immune system; an eclectic array of clinical conditions is 
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capable of inducing an array of sickness-like behaviors.  Historically, this rivaled the notion 
that the immune system operated autonomously of other physiological systems.  For if the 
immune system did influence host behavior to pathogens, it could not do so without a neuro-
immune feedback loop (Dantzer & Kelley, 1989; Kelley, Dantzer, Mormede, Salmon, & 
Aynaud, 1985).  This idea only recently gained widespread acceptance by neuroscientists and 
immunologists with Kipnis’ discovery of lymphatic vessels within the CNS (Louveau et al., 
2015).  So, if a neuro-immune axis does exist, what are the central mediators of this 
communication? 
Cytokines as mediators of sickness behavior 
Cytokines are inflammatory molecules produced by immune cells and tissue that are 
responsible for orchestrating a slew of cell-to-cell communications.  With regards to their 
role in the neuro-immune axis, cytokines in the brain were believed to be an artifact of a 
sickness response to immune challenge (Dantzer & Kelley, 1989).  Until interleukin (IL)-1, 
or “lymphocyte activating factor” as it had originally been designated, was cloned in 1984 
(Auron et al., 1984) there had not been direct evidence that a communicative surrogate even 
existed.  However, when both purified and recombinant IL-1 was systemically administered 
to rodents, it led to activation of the hypothalamic-pituitary-adrenal (HPA) axis by 
stimulating production of corticotropin-releasing factor in the paraventricular nucleus 
(Berkenbosch, Van Oers, Del Rey, Tilders, & Besedovsky, 1987; Besedovsky, Del Rey, 
Sorkin, & Dinarello, 1986). 
Early theories emerged that attempted to explain the effects of cytokine-induced 
sickness behavior.  Hart postulated that sickness behavior occurred as a by-product of a 
fever, leading to an adaptive conservation of energy (Hart, 1988).  However, it was later 
established that IL-1 can induce sickness behavior, independent of fever (Kent et al., 1992).  
23 
Others attempted to rectify cytokine-induced sickness behavior as an evolutionary attempt to 
cope with pain during inflammation (Maier, Wiertelak, Martin, & Watkins, 1993).  It has 
since been asserted that cytokine-induced sickness behavior exists as a host motivational 
state to maintain relative homeostasis; sickness behavior dominates an organism’s behavior 
so that organism can efficiently cope with and clear an infection.  Whatever those actions are, 
they are relative to that host, and will inherently vary (Bolles & Fanselow, 1980; Dantzer, 
2001a; Konsman et al., 2002). 
Sickness behavior and depression 
This basic research concept received merit in the late 1980s/early 1990s when recombinant 
IL-2 and interferon-α were developed and clinically used as adjunctive therapies in cancer 
and hepatitis C patients (Dantzer, O'Connor, Freund, Johnson, & Kelley, 2008).  Shortly after 
beginning immunotherapy, health care providers observed potent increases in major 
depressive disorders among patients (Denicoff et al., 1987; Renault et al., 1987).  While these 
neuropsychiatric changes were initially believed to be a mere side effect of immunotherapy, 
it became established that they were caused by chronic cytokine administration and produced 
clinically distinct depressive phenotypes (Capuron et al., 2002; Capuron et al., 2000; Dantzer 
et al., 2008).   
Clinical proponents began to emerge that implicated immune system dysfunction as 
the cause of depression, dubbing the macrophage theory of depression (Maes, 1993).  This 
theory postulated that the acute, pro-inflammatory response mounted by the innate immune 
system had the capacity to induce depression.  This observation that depression occurred 
under chronic cytokine administration was important evidence for the legitimacy of a neuro-
immune axis.  It was understood that an acute immune response would adaptively produce a 
milieu of pro-inflammatory factors that would act on the brain and influence behavior (i.e., 
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sickness behavior).  Conversely, depression represents a maladaptive immune response that 
occurred when an innate immune response was particularly vigorous, or its duration was 
prolonged (Dantzer et al., 2008).  Indeed, this concept has been validated through clinical 
observations that major depressive disorder (MDD) patients have elevated levels of 
circulating Tumor necrosis factor (TNF)-α and IL-6 (Dowlati et al., 2010).  Additionally, 
MDD patients often have a high degree of comorbidity with systemic inflammatory 
conditions, including diabetes, cancer, and cardiovascular disease (Iwata, Ota, & Duman, 
2013).  Collectively, chronic inflammatory diseases are seen as both a predisposing factor for 
depression, and a disease state that can exacerbate a depressive phenotype (Wohleb, 
Franklin, Iwata, & Duman, 2016).  
 The available repertoire of clinical inflammatory biomarkers is largely limited to IL-
6, TNF- α, and to a lesser degree IL-1β (Dowlati et al., 2010). Although elevated levels of 
these circulating cytokines can consistently be observed in MDD patients, there is often a 
difference in pathophysiology among clinical subtypes of MDD, making it a challenge to 
characterize neuro-immune dysfunction based on disease phenotype (Gold, 2015).  An 
additional facet that complicates the modeling, and subsequent study, of this relationship is 
the behavioral difference between sickness-like and depressive-like behavior.  While 
sickness-like behaviors are associated with rapid, intense expression of pro-inflammatory 
cytokines, this expression is transient and represents an adaptive immune response.  
Conversely, stress-induced inflammatory changes associated with depressive-like behaviors 
are less pronounced and represent a chronic, maladaptive immune profile (Wohleb et al., 
2016). An important and well-accepted paradigm for studying neuro-immune interactions is  
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through peripheral immune challenge with lipopolysaccharide (LPS), a bacterial endotoxin 
that potently stimulates a toll-like receptor (TLR) – 4 mediated immune response.  
Lessons from LPS studies 
The use of LPS in mechanistic neuro-immune studies has produced multiple seminal 
findings.  First, systemic administration of LPS in rodents produces robust pro-inflammatory 
gene and protein expression in the brain, primarily characterized by increased TNF-α, IL-1β, 
and IL-6 (Breder et al., 1994; Gatti & Bartfai, 1993; Quan, Stern, Whiteside, & Herkenham, 
1999; van Dam, Brouns, Louisse, & Berkenbosch, 1992).  This observation came nearly 30 
years after Neal Miller administered endotoxin to rats and studied motivational behavior 
changes. These animals were subjected to a forced wheel running paradigm, a volitional 
action negatively affected by sickness, and classically conditioned to press a lever for periods 
of rest.  Instead of conserving energy during a period of sickness, animals increased their 
lever pressing to earn more rest (N. E. Miller, 1964).  Secondly, this same degree of sickness 
behavior can be induced by either central or peripheral administration of recombinant TNF-α 
or IL-1β.  These behavioral alterations present as reduced psychomotor activity, decreased 
reward-seeking, social withdrawal, anhedonia, and even reduced amplitude of diurnal 
rhythms (Dantzer, 2001a).  Thirdly, these behavioral deficits can be abrogated following 
central administration of anti-inflammatory factors, such as IL-10 and IGF-I ((Bluthé et al., 
1999; Dantzer, Gheusi, Johnson, & Kelley, 1999).  Importantly, these changes clinically 
translate to humans.  When administered to healthy humans at a sub-septic dose (0.8 ng/kg), 
LPS has the capacity to negatively affect memory independent of sickness, and these changes 
inversely correlate circulating TNF-α (Reichenberg et al., 2001). 
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BBB regulates neuro-immune communication 
Given the observation that a peripheral immune challenge negatively influences 
behavior and that increased pro-inflammatory cytokine expression mediates this effect, one 
can reasonably begin to question how that inflammatory cascade is propagated into the CNS.  
The blood-brain barrier (BBB) is an important interface that mediates these central-
peripheral immune interactions.  Convention has taught generations of neuroscientists that 
the BBB is absolute in its restrictive abilities, thereby making the brain an immunologically 
“privileged” organ.  However, that convention has been challenged over recent years and we 
have come to understand that progressive loss of BBB integrity is integral to 
neuroinflammatory and subsequent neurodegenerative pathology (Lange, Storkebaum, De 
Almodóvar, Dewerchin, & Carmeliet, 2016; Obermeier et al., 2013). 
 Endothelial cells (ECs) constitute the anatomical foundation of the BBB.  Salient 
features of this brain vasculature include intracellular tight junctions, that combined with 
minimal fenestrations, strictly regulate transcytosis between the blood and brain (Abbott, 
Rönnbäck, & Hansson, 2006).  These features insulate the parenchyma from the blood, 
enabling the BBB to tightly regulate influx and efflux of various factors and nutrients.  
Beyond EC regulation of the BBB, pericytes sheath neural blood vessels and contribute to 
BBB integrity through vessel stabilization, vaso-regulation, and blood flow (Winkler, Bell, & 
Zlokovic, 2011).  The next layer of protection is provided by astrocytes, whose end-feet 
processes completely encircle the vessel.  Astrocytes are believed to contribute to BBB 
integrity via maintaining tight junctions, in addition to producing phospholipid transporter 
molecules (i.e., APOE) (Gee & Keller, 2005).  In conjunction with an interplay between 
neurons and microglia, these BBB components form the neurovascular unit (NVU).  In  
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relation to neurodegeneration, NVU breakdown has increasingly become recognized as a 
contributor to disease progression (Zlokovic, 2008). 
Routes of neuro-immune communication 
In addition to the rich cellular interplay within the neurovascular unit, systemic inflammation 
has four well-recognized routes of communicating with the CNS, either through neural or 
humoral modalities (Konsman et al., 2002; Perry, 2004).  Although each of these routes can 
independently propagate peripheral inflammation into the CNS, they are very likely 
redundant.  
 Neural routes of inflammatory transmission are largely delivered via efferent and 
afferent vagus sensory nerves.  This can serve as a direct central-to-peripheral route from the 
gastrointestinal tract and spleen, when systemic inflammatory challenges are administered to 
the peritoneal cavity (Goehler et al., 1999).  Humoral routes of transmission are a particularly 
important consideration for studying neuro-immune interactions because they rely on signals 
from blood-derived products to propagate inflammation into the CNS.  These interactions 
form the basis of neuro-immune interactions and will be discussed according to: BBB 
disruption, active cytokine transport across an intact BBB, and immune cell trafficking. 
 Historically, the notion that the brain is “immune privileged” has led to a perception 
that the BBB is static and impermeable to insult.  The basis of this early theory was rooted in 
the differentiated vascular anatomy of brain capillaries.  Within the vessels of the BBB, there 
is a distinct lack of intracellular fenestrations, endothelial cells sealed by tight junctions, and 
a subsequent reduction in pinocytosis (Reese & Karnovsky, 1967).  These studies arose from 
the observation that dyes injected into the bloodstream, such as Evan’s blue, did not stain the 
brain because they were bound by albumin in the blood and were prevented from barrier 
entry (Davson, 2012).  
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BBB disruption 
The BBB, as a component of the neurovascular unit, is the quintessential gatekeeper 
between the CNS and the peripheral immune system.  When the homeostatic balance of the 
BBB is lost, this system crosses the threshold into a disease state phenotype.  Therefore, 
disruption of the BBB is an important pathophysiological event, known to underlie numerous 
neurologic diseases, including neurodegenerative disease (Varatharaj & Galea, 2017).  BBB 
disruption is intimately linked with systemic inflammation, as exemplified by LPS studies in 
the 1980s that demonstrated BBB disruption after systemic bacterial challenge in rats 
(Wispelwey, Lesse, Hansen, & Scheld, 1988).  Follow-up studies confirmed that this 
disruption was cytokine-induced, largely mediated by TNF- α (Banks & Erickson, 2010).  
What remains to be determined about the role of BBB disruption in disease is the function 
and temporal kinetics of this disruption during disease progression.  This disruption may 
represent a terminal breakdown and inability of the BBB to regulate self-repair, as a result of 
septic insult.  Or, it may be that this disruption is not an end-stage process, but simply the by-
product of physiologic cytokine-signaling, induced by chronic inflammatory host states 
(Banks, 2015; Obermeier et al., 2013; Varatharaj & Galea, 2017; Zlokovic, 2008).  
Regardless of unanswered questions regarding the function of BBB disruption, it is 
undeniable that cytokine-mediated BBB disruption has major implications for a wide array of 
disease states. 
Cytokine transport across intact BBB 
Early evidence for the active transport of cytokines across the BBB came from IL-1 
studies.  Peripherally administered IL-1 induces sickness behavior, but when an IL-1 
neutralizing antibody is concomitantly administered to the brain, these behavioral detriments 
can be mitigated (Cremona et al., 1998; Pugh, Fleshner, Watkins, Maier, & Rudy, 2001).  
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This effect is not limited to IL-1, as LPS-induced TNF can be transported across the BBB 
where it can stimulate microglia to subsequently release TNF stores, which promote neuronal 
apoptosis (Qin et al., 2007).  To date, the recognized cytokine transport and signal 
propagation mechanisms into the CNS include 1) indirect entry via vagal nerve stimulation 
(Watkins, Maier, & Goehler, 1995), 2) the secretion of cytokines from blood-to-brain 
trafficked monocytes (Persidsky et al., 1997), 3) stimulated cytokine release from BBB 
endothelial cells (Verma, Nakaoke, Dohgu, & Banks, 2006), 4) uptake at circumventricular 
organs (Maness, Kastin, & Banks, 1998), and finally 5) receptor-mediated direct passage into 
the CNS (Banks, Farr, La Scola, & Morley, 2001). 
BBB trafficking of immune cells 
Uptake of immune cells across the BBB (i.e., diapedesis) and the subsequent increase in 
BBB permeability is linked to numerous neurologic and neurodegenerative diseases, 
including AD and PD (Obermeier et al., 2013).  The stereotypical neuroinflammatory disease 
in the CNS is multiple sclerosis (MS), which is pathologically characterized by T cell and 
macrophage extravasation, and serves as a prime model for studying immune cell infiltration.  
Increased T cell infiltration is believed to increase BBB permeability, allowing entry of other 
pro-inflammatory leukocytes that promote a feed-forward loop of inflammatory pathogenesis 
(Lassmann, 2008).  Regardless of the cells that do enter the CNS, the very recruitment of 
activated inflammatory immune cells produces a pro-inflammatory milieu within the 
neurovascular unit.  This leads to increased localized oxidative stress, alterations to matrix 
metalloproteases, and increased cytokine expression that synergistically drives this vicious 
cycle forward by disrupting tight junction regulation within the BBB (Larochelle, Alvarez, & 
Prat, 2011). 
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Microglia and astrocytes as inflammatory brain cells 
Deemed the brain’s “resident macrophage”, microglia are the primary inflammatory 
effector cells of the brain. However, developmentally unique from bone marrow-derived 
macrophages of the peripheral immune system, microglia originate from primitive yolk sac 
macrophages and colonize the embryonic murine CNS about E 9.5-10.5. Microglia are 
maintained through local proliferation; they are not replaced from circulating bone-marrow-
derived elements, indicating that they have very low cell turnover (DiSabato, Quan, & 
Godbout, 2016; Ransohoff, 2016b). What we have recently come to understand and 
appreciate about microglia is that they have enormous capacity to respond to changes in their 
local environment; single cells have extraordinary heterogeneity in their cell stress response 
profiles, the transcriptomic profiles appear highly consistent across disease states in both 
human and animal models, and it is generally well-accepted that microglia activity dictates 
disease state progression in the brain (Glass, Saijo, Winner, Marchetto, & Gage, 2010; 
Gosselin et al., 2017; Keren-Shaul et al., 2017). A major limitation of studying microglia and 
their role in various neuroinflammatory states is that there is no reliable method for isolating, 
purifying, and characterizing the function of these cells (Korzhevskii & Kirik, 2016). Ionized 
calcium-binding adaptor molecule 1 (IBA1) is a very widely-used marker for microglial 
“activation” (Walker & Lue, 2015). This protein localizes with cytoskeletal actin bundles and 
is functionally involved in membrane ruffling and phagocytosis (D. Ito et al., 1998). While a 
plethora of published studies characterize microglial activation through IBA1 gene and 
protein expression, immunohistochemical methods that allow for the examination of physical 
alterations to microglia remain the gold standard. However, pro-inflammatory cytokine-
producing microglia do not always exhibit morphological changes (Jeong, Ji, Min, & Joe, 
2013; Norden, Trojanowski, Villanueva, Navarro, & Godbout, 2016; Walker & Lue, 2015). 
31 
Only within the past two years has there been the identification of a resting marker for 
microglial populations (i.e., TMEM119) (M. L. Bennett et al., 2016). Any experimental 
method to characterize “microglial activation’ should be heavily critiqued. As for microglia’s 
(arguably) pathogenic role in neuroinflammation, they are considered the principle cytokine-
producing cell and are frequently implicated in the production of pro-inflammatory TNF-α, 
IL-6, and IL-1β (Perry, Nicoll, & Holmes, 2010; H. A. Silverman et al., 2015). The increased 
expression of these three pro-inflammatory cytokines have regularly been used to 
phenotypically define a neuroinflammatory signature. 
Astrocytes also have a role in neuroinflammation. As the brain’s most abundant glial 
cell type, astrocytes maintain BBB integrity, regulate immune cell trafficking, glutamate 
uptake, potassium uptake, and support metabolic activity of neurons (Farina, Aloisi, & 
Meinl, 2007). In animal models, the inactivation of NF-κB specifically in astrocytes, has 
been shown to reduce inflammatory burden in a number of injury and disease models 
(Colombo & Farina, 2016). Although these responses are context-dependent, astrocytes have 
also been shown to be the principle chemokine-producing cell in response to neurological 
insult, which augments T-cell mediated adaptive immune responses (Farina et al., 2007; 
Summers, Kangwantas, Nguyen, Kielty, & Pinteaux, 2010). It has also been shown that LPS-
induced neuroinflammation leads to a rapid microglial response, followed by delayed 
activation of astrocytes via up-regulation of glial fibrillary acidic protein (GFAP) (Norden et 
al., 2016). This suggests that microglial activation augments astrocyte activation in instances 
of systemic inflammation. 
Acute vs. chronic forms of neuroinflammation 
A variety of cellular stimuli have the capacity to produce acute or chronic 
neuroinflammation. The point at which a neuroinflammatory event (acute or chronic) 
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because maladaptive, compared to protective, is frequently unclear. LPS models are a nice 
context for studying acute neuroinflammation, while diet-induced obesity serves as a strong 
model for studying chronic neuroinflammation. In each context, the functional immune 
response and inflammatory pathways involved will inherently vary. 
As an acute neuroinflammatory challenge, LPS challenge is expected to elicit 
microglial activation that is reparative. Ultimately, this response functions to identify and 
remove toxic, aversive stimuli. Initially, this response remains local within tissue and can be 
characterized by a relatively high magnitude of pro-inflammatory cytokine production, often 
characterized by a robust induction of TNF-α production (Qin et al., 2007; Skelly, Hennessy, 
Dansereau, & Cunningham, 2013). If left unresolved over time, this will create a vicious 
cycle of local inflammation (Michelle L Block, Zecca, & Hong, 2007). Acute 
neuroinflammation will often produce some degree of parenchymal damage, cell death, and 
debris, followed by microglial and astrocyte activation, and recruitment of peripheral 
immune cells to the CNS to aid the inflammation resolution (Schwartz & Baruch, 2014). 
Microglial “activation” is often identified as the initial immune-reaction event followed acute 
neuroinflammatory insult (Shechter, London, & Schwartz, 2013).  
Conversely, chronic neuroinflammation resulting from diet-induced obesity can be 
characterized by a relatively lesser magnitude of pro-inflammatory production. Obesity 
produces a form of low-grade systemic neuroinflammation that will progressively precipitate 
neurodegeneration, that is frequently characterized by modestly increased levels of IL-1β 
(Johnson, 2015; Perry, 2004; Perry et al., 2010). Chronic microglial activation and its 
subsequent neuroinflammatory phenotype becomes maladaptive to neuronal health. 
Additionally, the unresolved nature of chronic neuroinflammation requires constant, low-
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grade CNS recruitment of peripheral immune cells (monocytes and lymphocytes) that 
promotes increased permeability of the BBB via cell entry into the parenchyma, which 
subsequently promotes more damage (Schwartz & Baruch, 2014). 
Summary 
Each of these events provides impressive evidence that the brain is not so much 
“immune privileged”, but rather immune specialized.  While cytokine signaling and cell 
trafficking within the neurovascular unit holds important homeostatic function, it is also an 
important pathogenic event to consider when studying neurological pathogenesis.  As we 
know that peripherally-derived inflammatory signals have the capacity to influence the brain 
and behavior, the study of how these signals are mechanistically transferred into the CNS is 
imperative to shed further light on the role of immune regulation in chronic CNS disease 
states.  Coupled with recent landmark discoveries, such as the existence of lymphatics within 
the CNS (Louveau et al., 2015), the field of neuroimmunology has been enabled to shed new 
light on immune system dysfunction in neurodegenerative disease. We are not only 
understanding how inflammatory signals are propagated to the brain and the behavioral 
detriments they produce, but how they create self-sustaining cascades that drive disease 
progression forward and potentiate additional pathogenic events. 
Chronic Inflammation and Host Factor Detriments 
Immunological dogma has long held that immune responses to foreign antigen are 
adaptive and they functionally exist to identify, initiate, and resolve an appropriate response 
to ensure host survival.  The basis of this innate immune response begins with inflammation, 
a collective cellular and vascular response intended to deliver immune cells to a site of injury 
or illness.  Classically, this response is associated with cardinal signs of inflammation: heat, 
pain, swelling, and redness (Serhan, Ward, & Gilroy, 2010).  The kinetics of a mild 
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inflammatory immune response detail a fast-acting, rigorous burst of cell signaling events 
that when temporally acute, often remain localized to the immediate site of injury.  However, 
this is not always case, as severe acute immune challenges have a large capacity to elicit 
systemic inflammation.  Conversely, a chronic, unresolved inflammatory response to either 
endogenous or exogenous stimuli will become maladaptive to the host.  
 Systemic inflammation has become increasingly recognized as a pathogenic factor 
capable of driving progressive neurodegeneration (C. Cunningham et al., 2009; Perry, 2004; 
Perry & Teeling, 2013).  The underlying basis for this theory is that the innate immune 
systemic is chronically activated, leading to sustained production of pro-inflammatory 
mediators (Michael T Heneka, Kummer, & Latz, 2014).  This phenotype is predominantly 
maintained by microglia, CNS-resident mononuclear phagocytes (Kreutzberg, 1996), and 
will be discussed in greater detail below.  This sustained inflammatory state primes microglia 
to mount an exaggerated immune response when a given host encounters additional immune 
challenges (i.e., respiratory infections) (Perry et al., 2007). In order to gain insight into the 
influence that systemic inflammation has on neurodegenerative pathogenesis, with particular 
emphasis on PD, we will discuss aging, obesity, and infection as they directly pertain to this 
body of work. However, there are a number of host conditions that promote 
neuroinflammation. Given that chronic neuroinflammation occurs early in the development 
of PD, these processes hold a high degree of therapeutic potential for developing effective 
diagnostic and therapeutic tools which may lead to disease-modifying approaches for treating 
these diseases. 
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Host risk factors for systemic inflammation 
Aging 
Aging remains the single greatest risk factor for neurodegenerative disease, including 
PD.  A dizzying array of cellular and molecular changes accompanies senescence.  
Immunologically, elderly individuals exhibit a diminished immune response to challenge, 
compared to young.  Often best exemplified by a weaker immune response to influenza 
vaccine and a subsequent increase in vulnerability to these environmental pathogens 
(Fleming & Elliot, 2005), these deficits in immune initiation and resolution are driven by 
both innate (Solana et al., 2012) and adaptive changes (Montecino-Rodriguez, Berent-Maoz, 
& Dorshkind, 2013).  As for the capacity of these changes to influence normal behavior, the 
cognitive impairments produced by an inflammatory challenge are often sustained in the 
elderly and drive dementia-like changes (Craft et al., 2012). 
 An important distinction to make when examining age-related changes in the brain is 
to differentiate “normal” aging from pathological events associated with neurodegeneration.  
For example, microglia isolated from aged murine brains display greater basal up-regulation 
of immune activation markers (MHCII, CD11b, and IBA-1) when controlling for cell number 
(Frank et al., 2006).  This implies that aged microglia are primed to produce an exaggerated 
phenotype against immune challenges, characterized by greater production of pro-
inflammatory cytokines.  This response correlates with long-lasting memory deficits 
(Barrientos, Frank, Watkins, & Maier, 2010).  While this immune behavior is restricted to the 
context of host immune challenges (i.e., aged microglia do not produce exaggerated 
responses without immune challenge), the more that an aged host experiences immune 
challenges via inflammatory insults, the greater the likelihood that the brain will cross the 
threshold for a disease state phenotype.  For PD, this aberrant neuroinflammatory phenotype 
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in the aged brain can synergistically augment the aggregation of primary pathological 
hallmarks, such as α-synuclein misfolding (L. Wang et al., 2014). While PD risk is associated 
with a number of environmental insults and host factor detriments, the following sections 
will focus i) on aging, obesity, and influenza infections, ii) how they lead to changes in the 
PD brain, and iii) how they can contribute to Parkinsonian pathogenesis.  
Obesity 
Initial animal studies in the early 1990s established a causative relationship between 
obesity and behavioral deficits. Rats fed a diet high in saturated fatty acids for 12 weeks 
displayed spatial and associative memory deficits (Greenwood & Winocur, 1990). In 
humans, obesity can negatively affect executive function, that becomes exacerbated with age 
(Gunstad et al., 2007). Additionally, mid-life obesity is a predictor of age-related mild 
cognitive impairment and serves as a common risk factor for neurodegenerative disease, 
including Parkinson’s disease (Freeman, Haley-Zitlin, Rosenberger, & Granholm, 2014; Xu 
et al., 2011). 
In addition to insulin resistance, oxidative stress, and altered vascularization (Gregor 
& Hotamisligil, 2011; C. N. Lumeng & Saltiel, 2011), obesity is a detrimental host state 
known to produce neuroinflammation (Freeman et al., 2014; A. A. Miller & Spencer, 2014). 
This pro-inflammatory signature in the brain is characterized by reactive astrocytes and 
microglia that produce increased cytokine expression of TNF-α, IL-6, and IL-1β, which can 
underlie behavioral and cognitive disturbances (Guillemot-Legris & Muccioli, 2017; Hao, 
Dey, Yu, & Stranahan, 2016; E. B. Kang et al., 2016; Pistell et al., 2010).  
As diet-induced obesity and chronic consumption of excess nutrients leads to the 
accumulation of visceral adipose (white adipose tissue), fat tissue itself becomes a hot-bed 
for the sustained production of inflammatory molecules. Acting in an endocrine-like fashion, 
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adipose cells secrete inflammatory cytokines and chemokines which promote the recruitment 
of peripheral inflammatory cells (Wellen & Hotamisligil, 2003). Animal studies of obesity 
have observed that 45-60% of cells in adipose tissue are F4/80+ macrophages, compared to 
15% in lean controls (Weisberg et al., 2003). The phenotype of these adipose tissue 
macrophages is largely pro-inflammatory, characterized by greater expression of TNF-α and 
nitric oxide synthase 2 (iNOS) (Carey N Lumeng, Bodzin, & Saltiel, 2007). As a key 
inflammatory mediator, both genetic deletion of IL-1 receptors and systemic administration 
of IL-1β neutralizing antibody has been shown to reduce neuroinflammation (Denes et al., 
2012). Attenuating these chronic, pro-inflammatory processes can rescue BBB integrity and 
reduced the pathogenic burden of host factor detriments and neuroinflammatory disease 
(Argaw, Gurfein, Zhang, Zameer, & John, 2009; Obermeier et al., 2013). 
Influenza 
Although relatively understudied, influenza infections have long been recognized to 
produce behavioral and cognitive deficits that are attributed to systemic inflammation 
(Dantzer, 2001b). Additionally, a direct relationship between Parkinsonism and influenza 
infection has been recognized for the past 40 years (Moore, 1977), and is historically 
exemplified by the 1918 H1N1 Spanish Flu pandemic. Following primary infection with the 
1918 H1N1, a secondary disease state referred to as encephalitic lethargica (EL) could be 
observed for up to a decade later and was characterized by lethargy, ophthalmoplegia, and 
delirium (Henry, Smeyne, Jang, Miller, & Okun, 2010). Approximately 80% of these patients 
went on to develop post-encephalitic Parkinsonism (PEP), which included bradykinesia and a 
resting tremor (Cunha, 2004; Maurizi, 2010). The notion that influenza infection can promote 
Parkinsonism is further supported by the observation that antivirals, like amantadine, have  
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therapeutic benefit for the clinical management of PD (Pahwa et al., 2015; Sadasivan, Sharp, 
Schultz-Cherry, & Smeyne, 2017). 
When the brain parenchyma is directly infected with strains of influenza that can 
cross the BBB, neuroinflammation and Parkinsonian pathology is aggravated. C57BL/6 mice 
intranasally inoculated with influenza A/Vietnam/1203/04 (H5N1), a neurotropic virus that 
invades the CNS, exhibited long-lasting microglial activation and aggregation of α-synuclein 
that promoted degeneration of dopaminergic neurons in the substantia nigra (H. Jang et al., 
2009).  
However, most influenza strains are non-neurotropic (G. F. Wang, Li, & Li, 2010) 
and are capable of producing long-lasting neurobehavioral deficits (Luyt et al., 2012). It has 
previously been demonstrated that influenza-induced systemic inflammation causes 
microglia to exhibit a neuroinflammatory phenotype than can compromise hippocampal-
mediated behaviors through architectural changes to dendritic branching and synaptic spine 
density (Jurgens, Amancherla, & Johnson, 2012). This phenotype consisted increased 
expression of the pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in the hippocampus of 
male BALB/c mice 7 days post-infection with influenza A/PR/8/34. Furthermore, influenza-
induced microglial activation is not limited to specific strains of influenza. Intranasal 
infection with non-neurotropic influenza A/California/04/2009 (H1N1) has been shown to 
produce chronic microglial activation in both the substantia nigra and hippocampus 
beginning 21 days post-infection (DPI) and persisting through 90 DPI (Sadasivan, Zanin, 
O'Brien, Schultz-Cherry, & Smeyne, 2015). Combining influenza infections with other 
inflammatory insults can precipitate a neurodegenerative cascade. Dual challenge with 
influenza A/California/04/2009 and the Parkinsonian toxin 1-methyl, 4-phenyl, 1,2,3,6-
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tetrahydropyridine (MPTP) in mice has been shown to have no additive effect on microglial 
activation, but produces substantial loss of dopaminergic neurons in the substantia nigra 
(Sadasivan et al., 2017). 
Double-Stranded RNA-Dependent Protein Kinase (PKR) in Cell Stress 
Double-stranded RNA-dependent protein kinase (PKR) is a serine/threonine kinase 
that characteristically serves an antiviral role, in response to dsRNA viral intermediates. 
Acting as a pattern recognition receptor (PRR) for the innate immune system, its activation 
leads to the phosphorylation of the α subunit of the eukaryotic initiation factor 2, thereby 
inhibiting viral translation and subsequent protein production within infected cells.  This 
response ultimately induces apoptosis (Garcia et al., 2006).  Upon binding dsRNA, free PKR 
undergoes a conformational change by dimerizing and exposing an activation loop which 
autophosphorylates, thereby activating PKR (Clemens, 1997).  Once activated, PKR is able 
to phosphorylate a number of substrates involved in translation regulation, or propagate 
IkB/NF-kB-mediated signal transduction, based on cellular stimuli. 
PKR activation mechanism 
In response to either cellular, viral, or synthetic dsRNA, PKR will autophosphorylate 
and activate via dual 70 amino acid, dsRNA-binding motifs in the N-terminus (CLEMENS & 
ELIA, 1997). In resting conditions, PKR exists in a latent state. The autoinhibition of PKR is 
regulated by two dsRNA-binding domains (dsRBD) that block catalytic activity of its kinase 
domain (M. A. Garcia et al., 2006). Each monomer of the dsRBD consists of two α-β folds, 
joined by a 20 amino acid linker with a random coil conformation (Nanduri, Carpick, Yang, 
Williams, & Qin, 1998). Both dsRBDs have been shown to be required for optimal dsRNA 
binding (H. M. Chen, Wang, & D'Mello, 2008). This linker is what affords PKR the 
flexibility to structurally wrap around dsRNA and optimally allow protein-RNA interactions, 
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while also providing an explanation for which length of dsRNA is required to activate PKR 
(Manche, Green, Schmedt, & Mathews, 1992).  Although PKR can be activated by dsRNA 
of at least 30 base pairs, dsRNA of 80 base pairs or longer will yield optimal activation, 
thereby representing a diverse window of dsRNA activators.  
As an inhibitor of translation, PKR is intracellularly localized to ribosomes. 
Ribosomal proteins have been shown to mediate PKR via the dsRBDs. Ribosomal 
localization affords PKR the functional flexibility to respond to activating stimuli (i.e., 
dsRNA), locally inhibit translation and protein synthesis, all the while not affecting global 
mRNA translation (M. Garcia et al., 2006). Once active, PKR will autophosphorylate and 
dimerize, exposing its catalytic domains. Within the activation loop, the amino acid residues 
Thr446 and Thr451 have been shown to be required for autophosphorylation. Substitution of 
Thr451 leads to PKR inactivation. Of particular note, PKR exhibits a bell curve pattern of 
activation in which high concentrations of dsRNA can actually inhibit PKR (B. R. Williams, 
1999). Conversely, this implies that a high level of PKR expression would be elicited by 
moderate levels of cell stress. 
Mechanism of PKR inhibition with imoxin 
The two commercially available small molecule inhibitors of PKR are 2-aminopurine 
(2-AP) and 8-(imidazol-4-ylmethylene)-6H-azolidino [5,4-g] benzothiazol-7-one. The latter 
was identified by Jammi et al. (2003) and is referred to as Imoxin, C16, and PKRi in the 
literature. While 2-AP does inhibit PKR kinase activity, it has been shown to inhibit other 
kinases (J. Huang & Schneider, 1990; Posti et al., 1999). The oxindole/imidazole inhibitor 
Imoxin inhibits PKR by serving as an ATP site-directed competitor which blocks PKR 
autophosphorylation, although pharmacokinetic data is largely absent from existing literature 
(Ingrand et al., 2007; Weintraub et al., 2016). The estimated IC50 for Imoxin, a metric that 
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graphically represents inhibition of a compound by plotting percentage of activity versus 
concentration, was 186 ± 20nM compared to the 2-AP with an IC50 of 10 mM (Jammi, 
Whitby, & Beal, 2003). In functional contrast, 2-AP inhibits PKR-independent kinases at 
higher (millimolar) concentrations (Y. Hu & Conway, 1993). In neurons in vitro and ex vivo, 
Imoxin has respectively been shown to modulate expression for Jun N-terminal kinases 
(JNKs), p38 MAP kinases, and others (H. M. Chen et al., 2008; Couturier et al., 2011). 
Nonetheless, PKR inhibition in vitro with Imoxin prevents stress-induced neuronal apoptosis 
in numerous experimental contexts and could serve as a neuroprotective strategy (Weintraub 
et al., 2016).  
Activators of PKR 
dsRNA 
Whether originating from cellular, viral, or a synthetic source (poly:IC), double-
stranded RNA (dsRNA) leads to PKR activation through displacing autoinhibitory 
interactions that allow for substrate recognition. Natural viral PKR activators occur during 
viral replication in an infected host cell. Although intermediates of both RNA and DNA 
viruses can activate PKR, RNA viruses produce dsRNA intermediates necessary for 
producing sister copies. No matter the source, dsRNA at high concentrations will lead to 
PKR inhibition. At high concentrations, 2 PKR monomers that would ordinarily dimerize and 
activate, will dissociate as they compete to bind different dsRNA. Just as high concentration 
of dsRNA inhibits PKR, minimal concentrations will elicit a greater magnitude of PKR 
expression (F. Zhang et al., 2001). 
Toll-like receptors (TLRs) 
The TLR family is a highly conserved innate immune mechanism for identifying 
antigen and the subsequent production of an adaptive immune response that produces 
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immunological memory and (ideally) confers lifelong protection against pathogenic antigen. 
From previous work where PKR-deficient mice were systemically challenged with the TLR4 
agonist, lipopolysaccharide (LPS), they exhibited reduced serum expression of 
proinflammatory IL-6 and IL-12 (Goh & Williams, 2000). While TLR3 does not directly 
activate PKR, extracellular dsRNA can activate TLR3 (Z. Jiang et al., 2003). 
Cytokines 
As a member of the interferon (IFN) response pathway, PKR is induced by the 
cytokines IFN-α, IFN-β, and IFN-γ. Interferons were one of the earliest identified classes of 
cytokines whose stereotypical function is to interfere with viral replication (Pindel & Sadler, 
2011). IFN-γ-induced PKR activation in vitro has been shown to activate downstream NF-κB 
through a Janus kinase-1 (JAK1) mechanism. From the same studies, there was no observed 
IFN-γ-mediated activation NF-κB in PKR-null fibroblasts (HeLa S3, 2fTGH, and NIH-3T3) 
(Deb, Haque, Mogensen, Silverman, & Williams, 2001). NF-κB is a transcription factor that 
regulates and controls the production of cytokines relevant for a cell survival response 
(Lawrence, 2009). 
 Additionally, PKR has shown to be activated following activation of the 
proinflammatory cytokines, tumor necrosis factor-alpha (TNF-α). Genetic deletion of PKR in 
vitro reduces the TNF-α-induced activation of NF-κB (Takada, Ichikawa, Pataer, Swisher, & 
Aggarwal, 2007). That is, PKR partially modulates TNF-NF-κB signaling, implying a signal 
transduction function, rather than a signal effector. 
Protein activator of PKR (PACT) 
Following stimulation by extracellular stresses, PKR can be activated through 
intracellular protein-protein interactions with PKR-associated activator (PACT; aka PKRA; 
aka Rax, mouse ortholog) (Peters, Dickerman, & Sen, 2009). Independent of dsRNA, PACT 
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has been shown to mediate cell responses to a multitude of stimuli, such as H2O2 and arsenic 
(Singh & Patel, 2012). Phosphorylation of PACT at Ser246 and/or Ser287 leads to a 
conformational change of inactive PKR within the dsRNA binding domain, thereby 
activating PKR in a mechanism distinct from activation by dsRNA, but one that produces 
similar cell stress responses (Li et al., 2006). This PACT-PKR relationship has previously 
been shown to mediate apoptotic cell stress responses (Peters, Li, & Sen, 2006). 
Mediators of PKR signaling 
Eukaryotic initiation factor 2-α (eIF2-α) 
The most well-characterized target and natural substrate for activated PKR is the α 
subunit of eukaryotic initiation factor 2 (eif2α).  While PKR is one of four kinases that 
phosphorylate eif2α and exert the similar action of general translation inhibition, PKR’s 
dsRNA-binding domain is a unique structural and functional feature of the kinase, allowing it 
to inhibit the translation of viral mRNA within infected cells (Balachandran et al., 2000).  
This action is attributed to PKR’s high substrate affinity for eif2α (M. A. Garcia et al., 2006).  
Once active, autophosphorylation of the Thr446 residue promotes recognition of substrate 
and further phosphorylation. Within the C lobe of the kinase domain lies the αG helix that 
promotes initial interaction between PKR and eif2α.  This interaction promotes a 
conformational change that allows the Ser51 residue to phosphorylate and unfold, allowing 
eif2α to fully access PKR’s catalytic cleft (Dar, Dever, & Sicheri, 2005). 
Interferon regulatory factors (IRF) and signal transducers and activators of 
transcription (STAT) 
As integral components of the Type I Interferon pathway, interferon regulatory 
factors (IRF) and signal transducers and activators of transcription (STAT) are two groups of 
transcription factors known to contribute to PKR signaling. The induction and activation of 
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these factors is often restricted to instances of viral infection, as the stereotypical function of 
interferon signaling is to interfere with viral replication (Lazear et al., 2013). IRF-1 has been 
implicated as a mediator of PKR-induced apoptosis following IFN-γ or poly:IC treatment 
(Kumar et al., 1997). As for PKR’s regulation of STAT1 signaling, a signal transducing role 
has been proposed. PKR knockout has been shown to reduce STAT1 activation, although 
catalytically active PKR is not required (Ramana et al., 2000). This evidence highlights that 
PKR has both direct and indirect cell signaling functions. 
p53 
As a tumor suppressor gene, p53 is frequently implicated as an essential mediator of 
tumor growth in numerous forms of cancer (Greenblatt, Bennett, Hollstein, & Harris, 1994). 
In TNF-α-treated lymphoma cells, PKR activation has been shown to induce p53 (Yeung, 
Liu, & Lau, 1996). Alternatively, p53 induction resulting from genotoxic insult activates 
PKR, leading to translation inhibition and induction of apoptosis via the eukaryotic initiation 
factor 2-α (eIF2-α) pathway (Yoon, Lee, Lim, & Bae, 2009). In PKR deficient MEF cells, 
p53-mediated arrest of the cell cycle is disrupted, but not completely abolished (Cuddihy, 
Wong, Tam, Li, & Koromilas, 1999). Thus, PKR and p53 have a bi-directional relationship 
where PKR is an important contributor to cell cycle regulation following stress. 
Mitogen-activated protein kinases (MAPKs) 
Of mammalian responses to cell stress, MAPKs are integral players in responding to a 
variety of insulting stimuli (Arimoto, Fukuda, Imajoh-Ohmi, Saito, & Takekawa, 2008). 
Consisting of the ERK, JNK, and p38 families, which regulate activation of stress-response 
transcription factors (NF-κB, ATF, STAT), many of these pathways also overlap with PKR. 
The involvement of PKR in these MAPK responses does not depend on its kinase function. 
For example, catalytically inactive PKR contributes to TNF-α-induced p38 expression (Deb, 
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Zamanian‐Daryoush, Xu, Kadereit, & Williams, 2001). PKR’s exact role and contribution to 
these signaling events is context-dependent, but occurs in response to stimuli ranging from 
thermal shock to inflammatory cytokines (M. Garcia et al., 2006). 
Activating transcription factors (ATF) 
Among additional transcription factors related to PKR signaling is Activating 
Transcription Factor 3 (ATF-3). ATF-3 has been shown to promote p53 activation following 
cell stress (Yan, Lu, Hai, & Boyd, 2005) and overexpression of ATF-3 increased caspase-3 
mediated apoptosis  (Syed et al., 2005). Although ATF-3 gene and protein expression are 
relatively low in both neurons and glial cells in the CNS, cell stress will promote its 
induction following a variety of stresses (Anderson, 2012). In particular, ATF-3 is induced 
following endoplasmic reticulum (ER) stress and its induction has been shown to be 
dependent on the eif2α (H.-Y. Jiang et al., 2004). Collectively, ATF-3 expression mediates 
cell stress responses and regulates cellular proliferation by acting through the eif2α, whose 
phosphorylation is maintained by PKR. 
Fas-associated death domain (FADD) and caspase-8 
Of key mediators involved in PKR-mediated stress responses and apoptosis, the fas-
associated death domain (FADD) and the initiator caspase, caspase-8 are key signaling 
events. FADD is an intracellular adaptor protein that can consequently activate the initiator 
caspase, caspase-8, in response to extracellular stress signals (Balachandran et al., 1998). 
FADD-activated caspase-8 can go on to either directly activate the executioner caspase-3, or 
promote Bcl-2 activation that leads to mitochondrial release of cytochrome c (Xiao-Ming, 
2000). In HeLa CCL-2 cells treated with staurosporine, an apoptosis-inducing bacterial 
alkaloid, PKR was shown to induce apoptosis through FADD/caspase-8 signaling. This 
activation was not dependent on PKR phosphorylation, nor eIF2-α phosphorylation (von 
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Roretz & Gallouzi, 2010). Additionally, the PKR/FADD apoptotic pathway has been shown 
to mediate Aβ-induced cell death in SH-SY5Y neurons (Couturier et al., 2010). Fas-FADD 
are not the only pathways involved in caspase-8/PKR-mediated apoptosis, but also involve 
TNF-TNFR1 interactions (Gil & Esteban, 2000).  
NF-κB 
The NF-κB signaling pathway is master transcriptional regulator involved in a broad 
range of neuroinflammation and inflammatory processes. In unstimulated cells, NF-κB is 
sequestered in the cytoplasm by the inhibitory IκBs. Upon detection of cell stress, the IκB 
dimer  dissociates and promotes nuclear translocation that leads to the transcription of 
inflammatory genes (Liu, Zhang, Joo, & Sun, 2017). PKR-mediated activation of the NF-κB 
pathway occurs either from direct activation from FADD via TNFR1 or Fas-induced 
apoptosis (W.-H. Hu, Johnson, & Shu, 2000; Ranjan & Pathak, 2016), or through PKR itself 
(Zamanian-Daryoush, Mogensen, DiDonato, & Williams, 2000). Furthermore, PKR-
mediated activation of NF-κB does not require catalytically active PKR (Bonnet, Weil, Dam, 
Hovanessian, & Meurs, 2000). Additional evidence for PKR’s role in inflammatory signaling 
comes from in vitro studies (discussed in greater detail below). When murine macrophages 
are treated with known NLRP3 agonists, pharmacological PKR inhibition with Imoxin 
significantly reduces production of caspase-1 and subsequent IL-1β (Lu et al., 2012). What 
can be unclear from studies investigating NF-κB and PKR is whether NF-κB is activating as 
an anti-apoptotic response to limit PKR-mediated apoptosis, or if it is activating apoptosis to 
promote cell death following inflammation. 
NLRP3 inflammasome 
Inflammasomes are multimeric signaling platforms for caspase-1 that have been 
shown to be required for the production of IL-1β and IL-18, two pro-inflammatory cytokines 
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implicated in a number of disease states (Bauernfeind et al., 2009; Dagenais, Skeldon, & 
Saleh, 2012; Leemans, Cassel, & Sutterwala, 2011). A report by Lu et al. (2012) had 
implicated a direct relationship between PKR and NLRP3. Peritoneal macrophages were 
isolated from PKR+/+ and PKR-/- mice and stimulated with a variety of stress-inducing stimuli 
that serve as danger-associated molecular patterns (DAMPs) for recognition by the innate 
immune system: synthetic dsRNA (poly:IC), ATP, monosodium urate (MSU), adjuvant 
aluminum, lipopolysaccharide (LPS). Activation and expression of caspase-1 and IL-1β was 
diminished in response to ATP, MSU, and Alum in PKR knockout samples. Pharmacological 
inhibition of PKR in ATP- and MSU- treated macrophages had similar effects, indicating that 
the anti-inflammatory action of PKR inhibition is not limited to genetic deletion. 
Additionally, immunoprecipitation of stimulated mouse macrophages indicated that PKR 
uniquely associated with NLRP3 and no other members of the NLR-family (Lu et al., 2012). 
This seminal paper provided the first evidence suggesting that PKR was a novel authorizing 
factor for the production of NLRP3.  
However, subsequent reports went on to imply this interaction with NLRP3 was 
independent of PKR’s kinase action (Hett et al., 2013), while others have observed that PKR 
activity does not modulate the inflammasome at all (He, Franchi, & Nunez, 2013), or that 
PKR actually suppresses inflammasome activity (Yim et al., 2016). Others have reported that 
inhibiting PKR autophosphorylation with the flavonoid luteolin actually increases NLRP3 
activation in macrophages and microglia (Dabo et al., 2017). In the context of obesity, 
NLRP3 has been identified as a critical mediator that regulates metabolic inflammation (i.e., 
‘metainflammation’). However, there was no difference in the IL-1β phenotype of nigericin 
or ATP-treated bone marrow-derived macrophages (BMDMs) from obese wildtype or PKR 
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knockout mice (Lancaster et al., 2016). These results imply that NLRP3 activity is not 
dependent on PKR. 
Evidence of CNS PKR Expression 
Clinical relevancy of PKR to neurodegeneration 
The first neuropathological report that PKR was expressed in the human brain came 
from 2002 findings that phosphorylated-PKR and eIf2α was expressed in degenerating 
hippocampal and cortical neurons of Alzheimer’s disease patients (Chang RC, 2002). In 
addition to AD, phosphophorylated PKR has been found in hippocampal neurons of PD and 
Huntington’s disease patients, suggesting that PKR expression is not limited to a single 
disease state, but could serve as a general marker of cell stress in neurodegeneration. 
Furthermore, these authors proposed that increased PKR expression could serve as a cell 
stress signal that precedes a bona fide disease state (Bando et al., 2005). Multiple groups 
have gone on to confirm that PKR expression localizes with degenerating neurons and it 
functions as a signaling transducing node in response to inflammation, autophagy, and 
apoptosis association with neurodegenerative disease progression (Hugon, Mouton-Liger, 
Dumurgier, & Paquet, 2017). 
CNS expression of PKR 
Animal studies have extended our understanding of PKR by showing that genetic 
deletion of PKR leads to attenuated neuroinflammation and that pharmacological inhibition 
can produce similar effects. Repeated systemic administration of LPS (1 mg/kg I.P., 
O111:B4, daily for 3 days) led to increased TNF-α and IL-6 cytokine release, IBA1 
microglial activation, and increased production of Aβ in the hippocampus of C57BL/6 mice. 
None of these changes were observed in PKR knockout mice (Carret-Rebillat et al., 2015). 
Directly relevant to PKR signaling, no changes were detected to eIf2α phosphorylation. 
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Either signaling changes had dissipated by the 24 hour post-LPS timepoint, or it alternatively 
suggests that PKR activation does not act downstream on its canonical substrate. Alternative 
evidence for involvement of the eIf2α pathway with PKR signaling comes from transgenic 
Alzheimer’s models (APP/PS1) and oxidative stress assays on immortalized human neurons 
(SH-SY5Y). This report found a positive correlation between phosphorylated PKR, 
phosphorylated eIf2α, and the Aβ peptide-producing enzyme BACE1 (Mouton-Liger et al., 
2012). Similar results have been observed in thiamine-deficiency models of 
neurodegeneration, once again highlighting PKR’s broad potential to indicate neurological 
cell stress in a variety of disease states (Mouton-Liger et al., 2015). 
Given the observation that PKR is induced following a variety of neurodegenerative-
related cell stresses, it is reasonable to postulate that the inhibition of PKR could alleviate 
disease state burden. Others have shown that PKR inhibition can attenuate peripheral 
inflammation in white adipose tissue, both in vivo and in vitro (Nakamura, Arduini, Baccaro, 
Furuhashi, & Hotamisligil, 2014; Nakamura et al., 2010). Two commercial PKR inhibitors 
are available, 2-aminopurine (2-AP) and imoxin (aka C16 & PKRi) (Jammi et al., 2003; 
Weintraub et al., 2016). Imoxin is an ATP-site-directed competitor that blocks PKR 
autophosphorylation. In vitro studies using Aβ-induced oxidative stress in SH-SY5Y neurons 
have shown that treatment with imoxin can prevent PKR phosphorylation and activation. 
Additionally, PKR inhibition with imoxin prevented caspase-3-mediated cell death in these 
studies (Page et al., 2006). In age-related animal studies of PKR expression, inhibition with 
imoxin has been shown to reduce PKR and eIf2α expression, while not stimulating the pro-
survival mTOR pathway (Ingrand et al., 2007). In an in vivo 3-nitropropionic acid (3-NP) 
model of Huntington’s disease, imoxin reduced neuronal apoptosis and modulated cell cycle 
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progression. 3-NP is a neurotoxin that selectively caused neuronal cell death. When 
administered at the time of 3-NP, imoxin reduced the extent of striatal neurodegeneration and 
improved behavioral deficits (H. M. Chen et al., 2008). Additionally, imoxin attenuated 3-
NP-induced expression of cyclin-dependent kinases (CDK) and the pro-apoptotic ATF-3, 
while not modulating eIf2α expression. These results implied that PKR inhibition with 
imoxin is modifying stressed neurons’ attempt to re-enter the cell cycle, which could lead to 
apoptosis. The therapeutic potential of PKR inhibition is not just limited to neurons. Primary 
co-cultures of mouse neurons, microglia, and astrocytes treated with Aβ exhibited decreased 
expression of pro-inflammatory cytokines TNF-α and IL-1β, reduced NF-κB activation, and 
caspase-3 activation was abolished, following treatment with imoxin (Couturier et al., 2010). 
PKR as a mediator of neuroinflammation 
Outside of its stereotypical antiviral function, PKR has proven to be a stress-induced 
cell signal that uniquely has crossover function in inflammation, autophagy, and apoptosis 
(M. A. Garcia et al., 2006). Thus, PKR can uniquely orchestrate cell stress responses to a 
variety of stimuli. While PKR relationship with NLRP3 is debatable (He et al., 2013; Lu et 
al., 2012; Yim et al., 2016), catalytically inactive forms of PKR are capable of activating NF-
κB and promoting TNF-α production, thereby negating the role of PKR/eIF2-α signaling 
(Bonnet et al., 2000). Activated by inflammatory cytokines, both bacterial and viral infection, 
genotoxic stress, and additional forms of cell stress, PKR goes on to mediate the expression 
of MAPKs, Nf-κB, IRFs, and ATF’s.  
Stress-induced PKR expression in the brain has regularly been shown to co-localize 
with neurons (Hugon et al., 2017). This increased expression has been shown to occur as 
both cytoplasmic and/or nuclear fractions of PKR (Marchal et al., 2014; X. Wang, Fan, 
Wang, Luo, & Ke, 2007). Additionally, PKR has been shown to co-localize with neuronal 
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expression of phosphorylated tau (Bose et al., 2011). As for non-neuronal expression of 
PKR, LPS-induced PKR expression has been shown in both primary rat microglia and 
astrocytes (J. H. Lee et al., 2005; Ong et al., 2005). In animal models of Gaucher disease, a 
lysosomal storage disease caused by a mutation to glucocerebrosidase (GBA1), PKR has 
been shown to co-localize with GFAP-positive astrocytes and MAC2-positive microglia 
(Vitner et al., 2016). While highly expressed throughout all major brain structures (isocortex, 
olfactory bulb, hippocampal formation, cortical subplate, striatum, pallidum, thalamus, 
hypothalamus, midbrain and cerebellum), basal mRNA PKR is not differentially expressed 
throughout the brain (Lein et al., 2007). The pons and medulla have the lowest relative 
mRNA expression in the mouse brain.  
The inherent challenge in studying inflammatory processes is that this complex 
crosstalk of cell signaling produces both adaptive and maladaptive responses, which are 
highly context-dependent. Ideally, our work and the work of others can posit PKR as a 
molecular entity that is capable of predicting disease state progression and responding to 
therapeutic intervention for Parkinson’s disease and other neurodegenerative conditions. 
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Abstract 
Inflammation has readily become recognized as an early pathogenic event that can drive the 
progression and development of neurodegenerative disease. Peripheral inflammatory signals 
have been shown to produce chronic, aberrant activation of microglial cells, which 
compromises neuronal homeostasis, promotes astrocyte activation, and progressively 
contributes to the pathogenesis of neurodegenerative disease. Our lab had previously 
identified increased expression of RNA-dependent Protein Kinase (PKR) in murine brains of 
a chronic model of systemic inflammation and sought to understand its role in an acute 
model of systemic inflammation. Functionally, PKR has diverse antiviral, apoptotic, and 
inflammatory responses that can occur independently of one another. Collectively, we sought 
to examine hippocampal and striatal CNS PKR expression in male C57/BL6 mice brains 
following a systemic immune challenge with LPS, the neuroinflammatory phenotype that 
coincided with PKR expression, the concurrent microglial and astrocyte phenotype, the 
therapeutic potential of the PKR inhibitor imoxin (IMX) to attenuate acute LPS-mediated 
neuroinflammation, and the cell signaling pathway modulated by PKR inhibition. We 
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observed a considerable degree of overlap in inflammatory and apoptotic signaling events, 
with PKR and NLRP3 expression appearing to be negatively regulated by FADD/Caspase-8. 
Together, this work suggests that PKR does not function as an effector molecule in systemic 
inflammation, but rather acts as a node whose functions are dependent on the availability of 
players in the response network and the context of the inflammatory challenge.  
Introduction 
In an ever-aging population, neurodegenerative diseases have irrefutably become 
established as one of the greater public health burdens among modern society. Current 
therapeutic options for the treatment of Alzheimer’s (AD) and Parkinson’s disease (PD), the 
two most prevalent neurodegenerative diseases, do not modify disease progression (Erkkinen 
et al., 2018). Of the deranged cellular processes implicated in neurodegeneration, 
inflammation has readily become recognized as an early pathogenic event that can drive the 
progression and development of neurodegenerative disease (Perry et al., 2010).  
While neuroscientific dogma had previously postulated the brain as an 
immunologically “privileged” organ, we now appreciate that the blood brain interface is 
highly dynamic and capable of propagating peripheral inflammatory signals into the CNS 
(Erickson, Nicolazzo, & Banks, 2018; Obermeier et al., 2013; Zlokovic, 2008). These 
signaling events have largely been shown to produce chronic, aberrant activation of 
microglial cells, the brain’s resident innate immune cell. Chronic microglial activation 
becomes a pathogenic event that compromises neuronal homeostasis, promotes astrocyte 
activation (Liddelow et al., 2017), and progressively contributes to the pathogenesis of 
neurodegenerative disease (Colm Cunningham, 2013). 
PKR is constitutively expressed in mammalian cells and stereotypically functions as 
an anti-viral kinase, phosphorylating its canonical substrate eukaryotic translation initiation 
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factor-2α (eIF-2α), thereby inhibiting protein synthesis within virally-infected cells (Berry, 
Knutson, Lasky, Munemitsu, & Samuel, 1985; Clemens, 1997; M. A. Garcia et al., 2006). 
While dsRNA species produced during viral synthesis activate PKR via autophosphorylation, 
PACT (RAX mouse ortholog) is recognized as a cytosolic protein activator of PKR in 
response to a multitude of extracellular stresses (T. Ito, Yang, & May, 1999; Li et al., 2006). 
Several knockout studies have eloquently implicated PKR’s role in neurodegenerative 
pathogenesis (Carret-Rebillat et al., 2015; Hugon et al., 2017; Mouton-Liger et al., 2015). 
Additionally, its neuropathological expression occurs in human brain regions relevant to 
Alzheimer’s, Parkinson’s, and Huntingtin’s disease pathogeneses (Bando et al., 2005; Chang 
et al., 2002; A. L. Peel et al., 2001). Functionally, PKR has diverse antiviral, apoptotic, and 
inflammatory responses that can occur independently of one another. This collective 
response synergistically contributes to a cell stress response that could either be detrimental 
or protective. Pharmacological inhibition of PKR has been shown to produce a myriad of 
diverse biological effects, including PKR-independent changes (M. A. Garcia et al., 2006).  
Inflammation is notoriously fickle, producing both adaptive and maladaptive 
responses that are highly context-dependent. This complex crosstalk of cell signaling has 
made it a challenge to identify molecular entities that are capable of predicting disease state 
progression and responding to therapeutic intervention. PKR has a well-accepted role in 
inflammatory signaling, across a variety of host cell types (R. Kang & Tang, 2012). Using 
LPS as a model to stimulate peripheral-to-CNS inflammation, we hypothesized that LPS-
induced PKR activation would regulate neuroinflammation, and the pharmacologic inhibition 
of PKR with Imoxin (IMX), would attenuate this neuroinflammatory phenotype. Given the 
pathophysiological involvement of these regions in AD and PD, we characterized the kinetics 
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of PKR expression across the hippocampus and striatum in male C57/BL6 mice, the 
neuroinflammatory phenotype that coincided with PKR expression, the therapeutic potential 
of IMX to attenuate acute LPS-mediated neuroinflammation, and the involvement of cell 
death signaling pathways modulated by PKR inhibition. 
Materials and Methods 
2.1 Study Design 
This work consisted of two studies. Study #1 was an initial LPS dose response and 
timeline study to define LPS-induced PKR expression in the brain. Male C57BL/6 mice were 
randomly assigned to either: saline (n = 5), a single dose of 5 mg/kg LPS I.P. and brains 
collected 3 hours later (n = 5), a single dose of 1 mg/kg LPS I.P. and collected 3 hours later 
(n = 5), or a single dose of 1 mg/kg LPS I.P. and brains collected 24 hours later (n = 3-4). 
Samples were processed for gene expression via qPCR to determine the dose at which 
transcriptional PKR expression in the striatum and hippocampus was the greatest, for follow-
up studies using a PKR inhibitor. 
From Study #1, the 1 mg/kg LPS I.P. dose at 24 hours post-LPS was selected and 
used in Study #2. This dose of LPS was selected for the PKR inhibitor study because it 
elicited the same magnitude of PKR gene expression in the brain, while producing a modest 
pro-inflammatory profile that would not mask a potential drug effect in Study #2.  
Study #2 utilized the same paradigm as the LPS dose response study, with the 
exception that two doses of the PKR inhibitor imoxin were administered prior to LPS 
challenge. The objective of this study was to test the role of PKR in modifying downstream 
stress responses to LPS. Animals were randomly assigned to one of five groups: Saline (n = 
7), Saline + 2 S.C. doses of 1 mg/kg IMX (n = 5), one I.P. injection of LPS at 1 mg/kg and 
brains collected 24 hours later (n = 6), pretreated with two S.C. doses of 0.5 mg/kg IMX + 
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LPS (n = 7), or pretreated with two S.C. doses of 1.0 mg/kg IMX + LPS (n = 7). As a 
positive control, imoxin alone did not modulate gene expression for any of our markers of 
interest, compared to saline. While not graphically represented, these data were included in 
analyses.  
Doses of imoxin were administered 24 hours pre-LPS (hour 0) and again at 2-hours pre-
LPS (hour 22). 1 mg/kg O111:B4 LPS was administered at hour 24, with animals sacrificed 
24 hours later (hour 48). Samples from Study #2 were processed for gene expression via 
qPCR and protein expression via Western Blotting. 
2.2 Animals 
Male C57BL/6 mice (Charles River) were maintained in group housing (n = 5/cage) and 
kept on a 12-hour reverse light cycle in ventilated Innovive racks (Innovive, San Diego), with 
ad libitum food and water access. All experimental protocols were approved by the 
Institutional Animal Care and Use Committee of Iowa State University. In Study #1, animals 
were I.P. challenged with Lipopolysaccharide (LPS) at 6 weeks of age, sacrificed via 
asphyxiation (CO2), brains removed and micro-dissected for the hippocampus and striatum, 
then snap-frozen in liquid nitrogen for subsequent processing. Study #2 utilized the same 
overall design, with the exception that mice were only given one dose of LPS, and two pre-
LPS doses of PKR inhibitor were administered. 
2.3 Treatment 
2.3.1 LPS Challenge 
In Study #1, animals were administered 2 different doses of O111:B4 LPS I.P. 
(Sigma-Aldrich, St. Louis; L4391) with 2 post-LPS collection times to survey the difference 
in neuroimmune phenotype across different dose intensity and challenge duration: 5 mg/kg 
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LPS at 3 hours post-LPS, 1 mg/kg LPS at 3 hours post-LPS, and 1 mg/kg LPS at 24 hours 
post-LPS. Control mice were administered saline intraperitoneally. LPS was dissolved in 
saline at room temperature and given at a volume of 8 µl/kg (~200 µl per 25 g mouse). Body 
weights were recorded pre- and post-LPS challenge. The percent of weight loss from 
challenge in Study #1 and Study #2 is available in Table 1.  
2.3.2 Imoxin Administration 
Using a separate cohort of mice for Study #2, PKR inhibitor studies were performed 
using Imidazolo-oxindole PKR inhibitor Imoxin (Calbiochem; #527450). Imoxin was 
prepared by dissolving the stock powder in 100% ethanol (soluble at 20 mM) and further 
diluting doses in saline. Mice received either 0.5 mg/kg or 1.0 mg/kg IMX S.C. at a volume 
of 4 µl/kg (~100 µl per 25 g mouse). 1 mg/kg LPS was administered at hour 24, with animals 
sacrificed 24 hours later (hour 48). Injection times were appropriately staggered to ensure an 
accurate tissue collection schedule.  
2.4 Gene Expression 
At the time of processing, samples were kept frozen on liquid nitrogen and RNA isolation 
was performed using an RNA binding-column method (Qiagen RNeasy Micro Plus Kit; 
#74034). Total RNA was isolated from one hemisphere and reverse transcribed to cDNA 
(Qiagen RT2 First Stand Kit; #330404) to be used in SYBR green assays for relative gene 
expression (Qiagen RT2 SYBR Green Fluor qPCR Mastermix; 330513). qPCR was 
performed on a Bio-Rad MyIQ PCR system for 40 cycles of amplification, with a subsequent 
melt curve to validate the purity of amplified product. The primer sequences used are 
available in Table 2. Relative difference of gene expression between groups was analyzed  
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using the Pfaffl Method (Pfaffl, 2001), where threshold cycle (Ct) values were normalized to 
both β-actin and GAPDH, and expressed relative to control groups.  
2.5 Protein Expression 
Protein lysates from one hemisphere of each animal were homogenized with a motorized 
pestle in 150 µl of custom Lysis Buffer A containing: 30 mM NaHEPES, 5 mM EGTA, 3 
mM EDTA, 20 mM KCL, 32% glycerol, phosphatase inhibitor cocktail 3 (Sigma-Aldrich; 
P0044), and HALT protease inhibitor cocktail (Thermo Fisher; 78425). Homogenates were 
centrifuged for 15 minutes at 15,000 g (4 ͦC), and supernatant collected. Total protein was 
quantified using the bicinchoninic acid method (BCA; Pierce Biotechnology, Inc.; #23227) 
with bovine serum albumin standards. Western blot protein samples (10-30 μg) were run on 
8-16% Criterion TGX Precast Gels (Bio-Rad) at 150V for 1.5 hours, transferred to 
polyvinylidene fluoride membranes (PVDF; EMD Millipore), and blocked in Tris-buffered 
saline (TBS; pH 8.0) containing 0.05% Tween-20 and 5% non-fat dry milk (LabScientific; 
#M0841) for 1 hour at room temperature. Membranes were incubated overnight at 4 ͦC with 
primary antibody at the manufacturer recommended dilution. Primary antibody solutions 
were prepared in 1x TBST, 0.05% Na Azide, and 3% BSA and markers included: NLRP3 
(Adipogen; cryo-2), p-PKR (Thr 451; EMB Millipore; #07-886), p-eIF2α (Ser 51; CST; 
#3398) and β-actin (CST; #4970). Primary mouse monoclonal antibodies from Santa Cruz 
Biotechnology included: PKR (sc-6282), p-PACT (sc-53524), PACT (sc-377103), CDK2 
(sc-6248), ATF3 (sc-518032), FADD (sc-271748), Caspase-8 (sc-81656), NF-κB p65 (sc-
8008), and RIP1K (sc-133102). Cut membranes were washed with 1x TBST (0.1% Tween), 
probed at room temperature for 1 hour with respective secondary antibody, treated with 
SuperSignal ELISA Femto Maximum Sensitivity Substrate (Thermo; #970740), and images 
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captured on a Bio-Rad Universal Hood II gel imager. Densitometry was performed using 
ImageJ software (NIH), normalizing all values to β-actin, and expressed relative to control 
groups. Cropped Western Blot images show group representative samples run from the same 
gel, with corresponding housekeeping control. 
2.6 Analysis 
Data were analyzed in GraphPad Prism (version 6 for Windows) using one-way analysis 
of variance (ANOVA) on both gene and protein expression values. Post-hoc multiple 
comparisons were performed using Sidak correction, with an α-level of 0.05. Figures were 
generated in GraphPad, reporting data as mean fold change with error propagated as 95% 
Confidence Intervals. Gene data were represented on a Log2 scale, with protein data on a 
linear scale. Significance above bar denotes difference from control, with between group 
differences denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-way 
ANOVA. Additional images were generated using PowerPoint 2016 (Microsoft).  
Results 
3.1 LPS challenge produced a stereotypical neuroinflammatory phenotype 
To assess the capacity for systemic inflammation to induce CNS PKR expression, we 
administered two doses of LPS (5 mg/kg & 1 mg/kg), with 2 post-LPS collection timepoints 
(3 hours & 24 hours), to the cohort of animals used in Study #1. To characterize the pro-
inflammatory phenotype of our model, we used qPCR to describe the gene expression 
patterns of IL-6, TNF-α, and IL-1β. These are three well-validated pro-inflammatory markers 
of neuroinflammation (Harold A Silverman et al., 2014; Skelly et al., 2013).  
A one-way ANOVA between Control, 5 mg/kg LPS at 3 hr Post-LPS, 1 mg/kg LPS 
at 3 hr Post-LPS, and 1 mg/kg LPS at 24 hr Post-LPS revealed that striatal IL-1β (F (3, 14) = 
40.26, p < 0.0001), TNF-α (F (3, 14) = 39.57, p < 0.0001), and IL-6 mRNA (F (3, 14) = 
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39.57, p < 0.0001) were significantly upregulated from control in all groups receiving LPS 
(Figure 1A). Additionally, hippocampal mRNA was significantly up-regulated for IL-1β (F 
(3, 13) = 9.869, p = 0.0012), TNF-α (F (3, 13) = 56.38, p < 0.0001), and IL-6 (F (3, 13) = 
89.34, p < 0.0001) compared to control for all three LPS groups. The only non-significant 
change was that 1 mg/kg LPS did not induce IL-6 mRNA expression at 24 hours post-LPS. 
5 mg/kg LPS at 3 hours Post-LPS produced the greatest magnitude of change 
compared to Control for IL-1β, TNF-α, and IL-6 across all LPS groups in both the striatum 
(181-fold, 187-fold, & 64-fold, respectively) and hippocampus (3-fold, 47-fold, & 211-fold, 
respectively). Across the three pro-inflammatory genes surveyed, IL-1β appeared to exhibit a 
greater degree of IL-1β induction in the striatum over the hippocampus. 
In addition to cytokine expression, we examined markers pertaining to NLRP3 
inflammasome gene induction. NLRP3 gene expression was significantly up-regulated from 
control in the striatum (F (3, 14) = 14.43, p = 0.0001). Post hoc comparisons revealed that 
this was primarily driven from a difference between controls and 5 mg/kg LPS dose at 3 
hours Post-LPS (M = 10.22, SD = 1.48), t(14) = 6.042, p = 0.0002) (Figure 1B). 
Hippocampal NLRP3 mRNA expression exhibited the same pattern of up-regulation, with 
NLRP3 significantly different in 5 mg/kg LPS dose at 3 hours Post-LPS, compared to 
Control (M = 9.43, SD = 1.089), t(13) = 7.142, p < 0.0001). Post hoc comparisons revealed 
that the NLRP3 adaptor molecule ASC was significantly up-regulated in the 1 mg/kg LPS 
dose at 24 hours Post-LPS in both the striatum (M = 2.57, SD = 0.42), t(14) = 5.01, p = 
0.0011) and hippocampus (M = 2.33, SD = 0.67), t(13) = 3.578, p = 0.0201), compared to 
controls (Figure 1B).  
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As PKR was our mechanism of interest, we sought to determine whether its 
expression would vary based upon LPS dose and if its level of expression changed over time. 
Striatal PKR mRNA was  significantly upregulated in all 3 LPS groups: 5 mg/kg at 3-hours 
Post-LPS (M = 1.80, SD = 0.195), t(14) = 5.320, p = 0.0006, 1 mg/kg at 3-hours Post-LPS (M 
= 1.712, SD = 0.222), t(14) = 4.889, p = 0.0014, and 1 mg/kg at 24-hours Post-LPS (M = 
1.83, SD = 0.368), t(14) = 5.174, p < 0.0008. There was no significant difference in mean 
fold change between treatment groups in the striatum. Hippocampal PKR mRNA was 
significantly upregulated in all 3 treatment groups: 5 mg/kg at 3-hours Post-LPS (M = 2.79, 
SD = 0.211), t(13) = 6.119, p = 0.0001, 1 mg/kg at 3-hours Post-LPS (M = 2.65, SD = 0.226), 
t(13) = 5.799, p = 0.0002, and 1 mg/kg at 24-hours Post-LPS (M = 1.80, SD = 0.532), t(13) = 
3.058, p = 0.0272. There was no significant difference in mean fold change between 
treatment groups in the hippocampus (Figure 1C). 
3.2 PKR inhibition changed neuroinflammatory phenotype and attenuated NLRP3 
inflammasome expression  
Following the LPS dose study (Study #1), the 1 mg/kg LPS dose at 24 hours Post-
LPS was selected and used in Study #2. Two doses of PKR inhibitor imoxin (0.5 mg/kg or 
1.0 mg/kg) were administered 2 and 24 hours prior to LPS.  
A one-way ANOVA between Control, 1 mg/kg LPS, 0.5 mg/kg IMX + LPS, and 1.0 
mg/kg IMX + LPS revealed that gene expression for striatal IL-1β (F (4, 27) = 157.8, p < 
0.0001) and TNF-α (F (4, 26) = 90.24, p < 0.0001) were significantly upregulated. 
Hippocampal mRNA was also significantly upregulated for IL-1β (F (4, 27) = 15.53, p < 
0.0001) and TNF-α (F (4, 27) = 12.35, p < 0.0001). As observed for the 1 mg/kg LPS dose at  
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24 hours in Study #1, IL-6 gene expression in the striatum and hippocampus did not 
significantly change (Figure 2A).  
Striatal NLRP3 gene expression was significantly up-regulated by LPS (M = 3.04, SD 
= 0.559), t(27) = 6.614, p < 0.0001. Although attenuated, striatal NLRP3 gene expression 
was also significantly up-regulated with 0.5 mg/kg IMX + LPS (M = 2.27, SD = 0.289), t(27) 
= 4.326, p = 0.0019, as well as 1.0 mg/kg IMX +LPS (M = 2.00, SD = 0.826), t(27) = 3.392, 
p < 0.0213. Compared to LPS alone, 1.0 mg/kg IMX + LPS significantly decreased NLRP3 
gene expression in the striatum (t(27) = 3.355, p = 0.0234). 1 mg/kg LPS at 24 hours led to 
significant gene up-regulation of NLRP3 in the hippocampus (M = 2.34, SD = 0.377), t(27) = 
6.461, p < 0.0001. Hippocampal NLRP3 expression was significantly increased with 0.5 
mg/kg IMX + LPS (M = 1.64, SD = 0.244), t(27) = 6.461, p < 0.0001, compared to control, 
but not significantly different from LPS alone. Additionally, 1.0 mg/kg IMX significantly 
increased hippocampal NLRP3 gene expression to a comparable magnitude of LPS alone (M 
= 2.18, SD = 0.469), t(27) = 6.461, p < 0.0001. ASC gene expression was not significantly 
upregulated in the striatum or hippocampus by LPS alone, however, hippocampal ASC was 
significantly upregulated from Control in the 0.5 mg/kg IMX + LPS (M = 1.53, SD = 0.333), 
t(27) = 3.044, p = 0.0455 and 1.0 mg/kg IMX + LPS (M = 1.63, SD = 0.235), t(27) = 3.468, p 
= 0.0157 groups (Figure 2A). 
Gene data mirrored protein analysis (Figure 2B), which found striatal NLRP3 protein 
to be significantly up-regulated by LPS (M = 2.15, SD = 0.773), t(20) = 3.047, p = 0.0376, as 
well as 1.0 mg/kg IMX + LPS (M = 2.44, SD = 0.632), t(20) = 3.836, p = 0.0062. 
Hippocampal NLRP3 protein expression was significantly up-regulated by LPS (M = 2.43, 
SD = 1.256), t(19) = 3.025, p = 0.041. As seen in the striatum, hippocampal NLPR3 
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expression was also significantly increased in the 1 mg/kg IMX + LPS group (M = 2.41, SD 
= 0.930), t(19) = 3.136, p = 0.0322. In both regions, NLRP3 protein expression in 0.5 mg/kg 
IMX + LPS was not significantly different from control.  
Consistent with results from Study #1, striatal PKR gene expression was significantly 
upregulated by LPS (M = 2.46, SD = 0.491), t(20) = 7.657, p < 0.0001. Although 
significantly increased by 0.5 mg/kg IMX + LPS (M = 1.91, SD = 0.370), t(20) = 4.931, p = 
0.0004 and also 1.0 mg/kg IMX + LPS (M = 2.11, SD = 0.273), t(20) = 6.052, p < 0.0001, 
striatal PKR gene expression appeared to be decreased by 0.5 mg/kg IMX in a similar pattern 
to pro-inflammatory cytokine and inflammasome expression (Figure 2A). Just as with the 
striatum, hippocampal PKR gene expression was significantly upregulated by LPS (M = 
2.48, SD = 0.271), t(27) = 5.946, p < 0.0001, 0.5 mg/kg IMX + LPS (M = 1.68, SD = 0.407), 
t(27) = 3.525, p = 0.0137, and 1.0 mg/kg IMX + LPS (M = 2.22, SD = 0.235), t(27) = 5.416, 
p < 0.0001, although hippocampal PKR expression was decreased by 0.5 mg/kg IMX. 
3.3 The effects of PKR inhibition with imoxin may not produce changes that are dependent 
on its kinase activity  
Striatal PKR protein expression was significantly increased with LPS (M = 1.62, SD 
= 0.419), t(20) = 3.374, p = 0.018 and 1.0 mg/kg IMX + LPS (M = 1.82, SD = 0.385), t(20) = 
4.487, p = 0.0014. As for protein expression of phosphorylated PKR (p-PKR; Thr451) in the 
striatum, LPS significantly decreased p-PKR (M = 0.413, SD = 0.103), t(20) = 5.815, p < 
0.0001, as did 0.5 mg/kg IMX + LPS (M = 519, SD = 0.123), t(20) = 4.762, p = 0.0007, and 
1.0 mg/kg IMX + LPS (M = 0.635, SD = 0.181), t(20) = 3.616, p = 0.0103.  
Conversely, pairwise comparisons revealed that hippocampal PKR protein was 
significantly increased by LPS (M = 1.66, SD = 0.474), t(20) = 4.129, p = 0.0031. 
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Hippocampal p-PKR protein expression was only significantly different between 0.5 mg/kg 
IMX and 1.0 mg/kg IMX under LPS (t(20) = 4.946, p = 0.0005). Collectively, PKR protein 
expression was increased by LPS in both the striatum and hippocampus, while the 0.5 mg/kg 
dose of IMX appeared to attenuate striatal PKR expression. While LPS would have been 
expected to increase p-PKR, we observed a decrease in the striatum (Figure 3). The 
magnitude of p-PKR protein expression did not vary when data were analyzed as p-PKR 
alone, compared to p-PKR/total PKR. 
3.4 LPS-induced PKR gene expression coincided with time-dependent astrocyte activation, 
not microglial activation  
In Study #1, striatal GFAP gene expression was significantly upregulated with 5 
mg/kg LPS at 3-hours Post-LPS group (M = 1.52, SD = 0.297), t(14) = 3.129, p = 0.0435 and 
1 mg/kg LPS at 24-hours Post-LPS group (M = 3.24, SD = 0.368), t(14) = 8.340, p < 0.0001. 
Given the significant up-regulation of GFAP in the 1 mg/kg LPS at 24-hours Post-LPS group 
compared to the 3-hour post-LPS timepoint using 1 mg/kg LPS (t(14) = 8.566, p < 0.0001), it 
is reasonable to conclude that the magnitude of GFAP gene expression is temporally-
dependent on longer time points. While the hippocampus did up-regulate GFAP gene 
expression 1 mg/kg LPS at 24-hours Post-LPS group (M = 2.09, SD = 0.414), t(13) = 3.653, 
p = 0.0174, the magnitude of its expression was not as great as in the striatum (Figure 4A). 
Under our paradigm, we saw no significant change in IBA1 gene expression in either the 
hippocampus or striatum.   
In Study #2, LPS significantly upregulated striatal GFAP gene expression (M = 5.77, 
SD = 0.716), t(27) = 15.73, p < 0.0001, 0.5 mg/kg IMX + LPS (M = 3.52, SD = 0.333), t(27) 
= 8.66, p < 0.0001, and 1.0 mg/kg IMX + LPS (M = 5.56, SD = 0.723), t(27) = 15.65, p < 
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0.0001. Furthermore, pairwise comparisons revealed that 0.5 mg/kg IMX +LPS significantly 
decreased striatal GFAP expression from LPS alone (t(27) = 7.411, p < 0.0001) and 1.0 
mg/kg IMX + LPS (t(27) = 14.43, p < 0.0001). Similar to Study #1, the only significant 
change we observed for IBA1 gene expression was upregulation in the striatum with 0.5 
mg/kg IMX + LPS (M = 2.17, SD = 0.392), t(27) = 3.589, p = 0.0129. However, this 
difference is likely attributed to a smaller standard deviation. We observed no significant 
change for IBA1 gene expression in the hippocampus (Figure 4B). 
3.5 PKR inhibition changes protein expression of PKR activator and canonical downstream 
substrate 
Western blotting revealed a significant decrease of phosphorylated PACT (p-PACT) 
the striatum with 1 mg/kg IMX + LPS, (M = 0.648, SD = 0.086), t(20) = 3.743, p = 0.0077. 
Hippocampal p-PACT was significantly decreased with 0.5 mg/kg IMX + LPS, (M = 0.529 
SD = 0.152), t(19) = 4.038, p = 0.0042 and with 1.0 mg/kg IMX + LPS, (M = 0.305, SD = 
0.117), t(19) = 5.966, p < 0.0001. Furthermore, 1.0 mg/kg IMX + LPS significantly 
decreased p-PACT, when compared to LPS alone (t(27) = 4.779, p = 0.0008) (Figure 5A). 
These data suggests that while treatment with imoxin under LPS challenge reduces 
expression for PKR and other inflammatory mediators, this PKR inhibitor appears to 
decrease the better-characterized protein activator of PKR (M. A. Garcia et al., 2006).  
As PKR’s cognate substrate, we examined whether LPS induced a change in 
phosphorylated eIF-2α (p-eIF-2α) and if imoxin was capable of modulating its expression. 
While previous reports have shown that repeated injections of systemic LPS do not modulate 
p-eIF-2α (Carret-Rebillat et al., 2015), we observed a significant decrease in striatal p-eIF-2α 
protein with a single dose of LPS (M = 0.538, SD = 0.129), t(19) = 5.973, p < 0.0001 (Figure 
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5B). Striatal p-eIF-2α was significantly decreased with 0.5 mg/kg IMX + LPS (M = 0.589, 
SD = 0.115), t(19) = 5.211, p = 0.0003 and 1.0 mg/kg IMX + LPS (M = 0.703, SD = 0.120), 
t(19) = 3.493, p = 0.0145. 
Hippocampal p-eIF-2α protein expression was significantly decreased by LPS alone 
(M = 0.597, SD = 0.051), t(19) = 5.973, p < 0.0001 and with 0.5 mg/kg IMX + LPS (M = 
0.6942, SD = 0.054), t(19) = 5.973, p < 0.0001, but was restored to baseline by 1.0 mg/kg 
IMX + LPS. This recovery in LPS-induced p-eIF-2α by imoxin was significantly different 
from LPS alone in both 0.5 mg/kg IMX + LPS (t(20) = 6.396, p < 0.0001) and 1.0 mg/kg 
IMX + LPS (t(20) = 4.735, p = 0.0008) (Figure 5B). These results suggest that inhibition of 
PKR in LPS-induced neuroinflammation can restore phosphorylation of eIF-2α in the 
hippocampus.  
3.6 PKR inhibition modulated downstream effectors related to cell proliferation  
Striatal ATF3 protein expression was not significantly different in any of the 3 
treatment groups alone, compared to control. However, ATF3 was significantly increased 
between LPS and 1.0 mg/kg IMX + LPS (t(20) = 4.067, p = 0.0036), and between 0.5 mg/kg 
IMX + LPS and 1.0 mg/kg IMX +LPS (t(20) = 3.178, p = 0.0280). Similar to the striatum, 
hippocampal ATF3 protein expression was significantly different between LPS and 1.0 
mg/kg IMX + LPS (t(20) = 3.571, p = 0.011) (Figure 6A). These results suggest that 1.0 
mg/kg IMX can increased striatal and hippocampal ATF3 from LPS alone, and that this dose 
is more effective than 0.5 mg/kg IMX. 
There were no significant differences in hippocampal CDK2 protein expression, 
however LPS alone led to a significant decrease of CDK2 in the striatum (M = 0.858, SD = 
0.037), t(20) = 3.117, p = 0.0321 (Figure 6B). While we only observed modest LPS-induced 
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changes to cell proliferation events via ATF-3 and CDK2, others have reported that cyclin-
dependent kinases more strongly mediate this relationship in an acute model rodent model of 
Huntingtin’s disease (H. M. Chen et al., 2008).  
3.7 Administration of IMX may function through upregulating apoptotic markers early in the 
downstream signaling pathway, while downregulating others 
LPS did not significantly change FADD or procaspase-8 protein expression in the 
striatum, but 0.5 mg/kg IMX + LPS did significantly increase both FADD (M = 1.76, SD = 
0.336), t(15) = 5.089, p = 0.0008 and procaspase-8 (M = 2.35, SD = 0.490), t(16) = 6.795, p < 
0.0001. This increase to striatal FADD with 0.5 mg/kg IMX + LPS was significantly 
different from LPS alone (t(15) = 3.836, p = 0.0097) and from 1.0 mg/kg IMX + LPS (t(15) 
= 3.334, p = 0.0269).  Similarly, the increase to striatal procaspase-8 with 0.5 mg/kg IMX + 
LPS was significantly different from LPS alone (t(16) = 5.519, p = 0.0003) and from 1.0 
mg/kg IMX + LPS (t(16) = 3.501, p = 0.0176). Striatal procaspase-8 was also significantly 
increased from control with 1.0 mg/kg IMX + LPS (M = 1.95, SD = 0.174), t(16) = 4.777, p 
= 0.0012. There were no changes to hippocampal FADD expression, but hippocampal 
procaspase-8 was significantly decreased with LPS (M = 0.772, SD = 0.096), t(20) = 5.47, p 
= 0.0001, with 0.5 mg/kg IMX + LPS (M = 0.806, SD = 0.053), t(20) = 4.672, p = 0.0009, 
and with 1.0 mg/kg IMX + LPS (M = 0.768, SD = 0.044), t(20) = 5.572, p = 0.0001.  
LPS significantly decreased RIP1K in the striatum (M = 0.694, SD = 0.213), t(20) = 
3.777, p = 0.0071, along with 0.5 mg/kg IMX + LPS (M = 0.595, SD = 0.075), t(20) = 4.993, 
p = 0.0004 and 1.0 mg/kg IMX + LPS (M = 0.519, SD = 0.063), t(20) = 5.931, p < 0.0001. 
The hippocampus displayed an opposite RIP1K expression pattern. RIPK1 protein 
expression was significantly increased with 1.0 mg/kg IMX + LPS (M = 1.319, SD = 0.137), 
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t(23) = 3.991, p = 0.0035. This increase was also significantly different from LPS alone 
(t(23) = 6.06, p < 0.0001) and from 0.5 mg/kg IMX + LPS (t(23) = 3.90, p = 0.0043). In the 
striatum we observed an LPS-induced decrease in RIPK1 protein expression that was not 
changed by imoxin, while 1.0 mg/kg IMX + LPS increased hippocampal RIPK1, compared 
to control, LPS alone, and 0.5 mg IMX + LPS. 
RIP1 kinase has previously been shown to serve as a regulator of cell-death which 
authorizes NF-κB (Kawai & Akira, 2006). LPS significantly decreased striatal p65 protein 
expression (M = 0.731, SD = 0.118), t(20) = 3.705, p = 0.0084, as well as 0.5 mg/kg IMX + 
LPS (M = 0.756, SD = 0.147), t(20) = 3.354, p = 0.0188, although to a lesser extent. The 
hippocampus did not reveal any p65 changes.  
Discussion 
Our studies assessed CNS PKR expression following an acute systemic immune 
challenge and observed a severe degree of overlap in inflammatory and apoptotic signaling 
pathways. The is the first evidence of CNS PKR expression following a single, low-grade 
LPS challenge, in addition to showing that PKR is not dose- or duration-dependent, and that 
PKR’s function may not depend on its kinase action. Others have reported CNS PKR 
expression following repeated LPS (Carret-Rebillat et al., 2015) and subcutaneous boluses of 
cultured E. coli (Poon et al., 2015). Transcriptionally, this activation occurs by at least 3 
hours post-challenge and remains elevated through 24 hours, suggesting that PKR is not an 
acute phase stress signal in the brain. Post-mortem observations of increased p-PKR and 
PKR in the brain of neurodegenerative patients supports the notion that this signal is 
enduring throughout disease progression (Bando et al., 2005; Chang et al., 2002; A. L. Peel 
et al., 2001). Furthermore, the relative magnitude of PKR gene expression was not largely 
69 
different between the hippocampus and striatum, suggesting that neither region has a greater 
proclivity over one another to express LPS-induced PKR. This could be meaningful if PKR 
became a therapeutic molecule of interest, because its expression may be relatively global 
and drug action would not be anatomically restricted to one region of interest. 
Despite a highly selective substrate-recognition mechanism, PKR activates in 
response to a multitude of cellular stresses across various disease states. Pharmacological 
inhibition with the PKR inhibitor imoxin (aka C16 and PKRi) has previously been shown to 
protect against tunicamycin-induced apoptosis in SH-SY5Y neurons (Shimazawa & Hara, 
2006). Additionally, pretreatment of SH-SY5Y neuronal cells with imoxin in an in vitro 
model of Alzheimer’s disease ameliorated Aβ42-induced increases in PKR phosphorylation 
(Thr451) (Couturier et al., 2010). While this ATP binding site-directed inhibitor blocks 
autophosphorylation of PKR (Jammi et al., 2003), it has also been shown to promiscuously 
produce a number of PKR-independent effects (Nakamura et al., 2014; Naz et al., 2015; 
Weintraub et al., 2016). 
4.1 LPS decreased PKR phosphorylation in the striatum recovered with Imoxin 
Challenge with LPS is known to influence a myriad of synergistic cell signaling 
processes related to proliferation, cell death (apoptotic and necrotic), and inflammation (C. 
Cunningham, Wilcockson, Campion, Lunnon, & Perry, 2005; Godbout et al., 2005; 
Hoogland et al., 2015; Qin et al., 2007). As an inflammatory insult, LPS was hypothesized to 
increase p-PKR, and subsequently total PKR protein expression. We observed increased total 
PKR with decreased p-PKR/PKR in the striatum. Imoxin did appear to recover this LPS-
induced decrease in p-PKR/PKR, although non-significantly. In an effort to clarify these 
mixed findings, we performed protein analysis on excess tissue from samples taken in Study 
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#1 (cerebellum). We hypothesized that p-PKR, while downregulated in the striatum at 24 
hours post-LPS with 1.0 mg/kg LPS, would be upregulated with 1.0 mg/kg LPS at 3 hours 
post-LPS in the cerebellum. Following a one-way ANOVA between control, 1 mg/kg LPS at 
3 hours, and 1 mg/kg LPS at 24 hours, we observed that p-PKR/PKR was significantly 
increased with 1.0 mg/kg LPS at 3 hours post-LPS (M = 1.36, SD = 0.117), t(11) = 2.835, p = 
0.0479. There were no LPS-induced changes in total PKR expression in the cerebellum 
(Supplementary Figure 1). We can conclude that PKR phosphorylation (Thr451) increases 
early and decreases by 24 hours, implying that our post-LPS collection time used in Study #2 
did not accurately capture the kinetics of PKR phosphorylation. 
4.2 LPS-induced decrease of eIF2-α phosphorylation in the striatum and hippocampus was 
recovered with 1.0 mg/kg IMX in striatum 
Phosphorylation of PKR has been shown to directly correspond to the 
phosphorylation of eukaryotic translation initiation factor 2 (p-eIF2-α) and subsequent 
regulation of apoptosis in AD cell models (Chang et al., 2002), AD rodent models (A. Peel, 
2003), and human AD lymphocytes (Paccalin et al., 2006). Furthermore, the inhibition of the 
PKR/ eIF2-α pathway in neonatal rat brains has been shown to reduce apoptosis, while not 
stimulating the mTOR survival pathway (Ingrand et al., 2007). Conversely, inhibiting eIF2-α 
phosphorylation does not fully protect cells from TNF-α-induced apoptosis (S. P. Srivastava, 
Kumar, & Kaufman, 1998). We observed LPS-induced decreases in p-eIF2-α in the striatum 
and hippocampus, with imoxin appearing to recover this decrease. Similarly, treatment of 
primary rat cortical neurons with either apoptotic-inducing homocysteic acid or camptothecin 
has been shown to decrease p-eIF2-α, with imoxin treatment recovering its expression (H. M. 
Chen et al., 2008).  
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4.3 LPS did not significantly change PACT phosphorylation in the striatum or hippocampus, 
but treatment with 1.0 mg/kg IMX significantly reduced PACT phosphorylation 
As the primary non-viral protein activator of PKR, PACT activation has been deemed 
necessary for PKR activation in non-viral forms of cell stress (Li et al., 2006; Singh, 
Fowlkes, Handy, Patel, & Patel, 2009). Phosphorylation of PACT (p-PACT) has previously 
been shown to directly correspond with p-eIF2-α activation (T. Ito et al., 1999; Marchal et 
al., 2014), although we observed LPS+imoxin-induced decreases of p-PACT with concurrent 
striatal and hippocampal increases in p-eIF2-α expression. While LPS did not significantly 
change p-PACT expression, the combination of imoxin with LPS led to a decrease in its 
protein expression within the striatum and hippocampus. Based on our protein analysis, we 
saw no changes in striatal or hippocampal total PACT levels following LPS. This finding is 
in line with previous reports that stress in human and mouse cells does not cause total 
PACT/RAX levels to vary, but that stressful stimuli lead to the phosphorylation of PACT (R. 
L. Bennett, Blalock, & May, 2004). Knowing that PKR signaling exhibits diverse responses 
under various conditions of host stress (M. A. Garcia et al., 2006), we can simply posit that 
the therapeutic action of imoxin likely influences cell signaling that is dependent and 
independent of direct PKR signaling following a single dose of LPS.  
4.4 LPS significantly reduced striatal CK2 expression, but there were no other LPS-induced 
changes to cell proliferation activity 
There were largely no changes to ATF-3 or CDK2 protein expression, except the 
novel observation that acute LPS decreased striatal CDK2 expression. This observation is 
consistent with in vitro and in vivo reports that CDK2 is downregulated by LPS in models of 
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diabetic nephropathy (Saurus et al., 2016). In an acute 3-nitropropionic acid (3-NP) model of 
Huntingtin’s disease, which causes selective death to striatal neurons, PKR inhibition with 
imoxin has been shown to be neuroprotective by acting through cyclin-dependent kinase 2 
(CDK2) (H. M. Chen et al., 2008). These authors also conclude that IMX inhibits expression 
of pro-apoptotic activating transcription factor 3 (ATF-3) in primary neuronal cultures and in 
vivo, which they conclude functions as an apoptosis-regulated protein that contributes to cell 
cycle activation during stress. ATF-3 upregulation is associated with a host of cell stresses 
(Hai, Wolfgang, Marsee, Allen, & Sivaprasad, 1999), is selectively induced by PKR (Guerra, 
López-Fernández, García, Zaballos, & Esteban, 2006) and has been implicated as a key 
signaling event in the eIF-2 cell stress response (H.-Y. Jiang et al., 2004).  
4.5 FADD and Caspase-8 apoptotic signaling increased with 0.5 mg/kg IMX + LPS 
PKR has been shown to be required for interferon-induced receptor interacting kinase 
1 (RIP1K) necrosis, which is negatively regulated by FADD and caspase-8 (Thapa et al., 
2013). Following cell surface binding of the FAS and tumor necrosis factor receptor-1 
(TNFR-1) death receptors, Fas-associated death domain (FADD) activation leads to a pro-
apoptotic cascade (Chinnaiyan, O'Rourke, Tewari, & Dixit, 1995) that recruits caspase-8 and 
activates downstream effector caspases (e.g., caspase-3) (Kreuz et al., 2004). Overexpression 
of FADD in vitro has been shown to protect SH-SY5Y neurons from TNF- and Aβ-induced 
apoptosis (Cantarella et al., 2003).  PKR inhibition with imoxin in Aβ-treated neurons has 
been shown to reduce p-PKR/FADD nuclear translocation and to protect against capase-8 
and -3 induction (Couturier et al., 2010). PKR localizes to both the cytoplasm and nucleus 
(Jeffrey et al., 1995). Although poorly understood, nuclear accumulation of PKR may be 
indicative of neuronal stress (Couturier et al., 2010). Moreover, LPS challenge of bone 
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marrow-derived macrophages (BMDMs) has been shown to activate the NLRP3 
inflammasome and that FADD and caspase-8 are upstream mediators of this expression 
(Gurung et al., 2014). NLRP3 activation has also been shown to be regulated by upstream 
RIP1K (Tao et al., 2018; Zhou et al., 2017). These findings suggest that in our studies, 
FADD/Caspase-8 may be a signaling platform through which we observed LPS-induced 
increased in PKR and NLRP3 expression.  The increases in striatal FADD and Caspase-8 
protein expression with 0.5 mg/kg IMX + LPS may arguably account for the observed 
decreases in striatal PKR and NLRP3 with this treatment. Additionally, this relationship has 
previously been observed to not be dependent on PKR phosphorylation (von Roretz & 
Gallouzi, 2010). 
4.6 Striatal RIP1K and NF-κB p65 were significantly reduced with LPS and PKR inhibition 
did not recover these decreases 
FADD-mediated apoptosis has also been shown be regulated by RIP1K in adaptive 
lymphocytes and to mediate NF-κB activation (H. Zhang et al., 2011). In models of 
interferon-induced cell death, PKR-RIP1K signaling has been shown to be regulated by 
FADD (Thapa et al., 2013). RIP1K has recently been identified as a critical mediator of 
promoting a disease-associated microglial (DAM) phenotype in an APP/PS1 model of 
Alzheimer’s disease (Ofengeim et al., 2017) and has been shown to be critical for TNF-α-
induced apoptosis in vitro and in vivo (Meng et al., 2018). As systemic LPS has been 
consistently observed to produce aberrant microglial activation (C. Cunningham et al., 2005; 
Godbout et al., 2005; Hoogland et al., 2015; Qin et al., 2007), increased apoptosis driven by 
increased RIP1K expression is expected with these changes. However, we did not observe a 
gene signature of microglial activation and observed an LPS-induced decrease in striatal and 
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hippocampal RIP1K. This RIP1K decrease could function to inhibit cell death (Ma, Temkin, 
Liu, & Pope, 2005). These events are also influenced by NF-κB, which has been shown to be 
protective against cell death following interferon-induced RIP1K activation (Ma et al., 2005). 
In our studies, LPS decreased NF-κB p65 expression in the striatum, with IMX appearing to 
restore that decrease. Furthermore, catalytically inactive forms of PKR alone are capable of 
activating NF-κB, thereby mitigating consideration of PKR/eIF2-α signaling in this 
experimental context (Bonnet et al., 2000).  
4.7 LPS did not induce microglial activation in the striatum or hippocampus, but LPS did 
induce astrocyte activation, which was significantly reduced with 0.5 mg/kg imoxin 
Microglia are believed to be the primary harbingers of cytokine production under 
neuroinflammatory contexts (Colm Cunningham, 2013; DiSabato et al., 2016; Jeong et al., 
2013). They are also indicated as the primary neuro-effectors of NLRP3 (Gustin et al., 2015), 
although astrocytes are indeed capable of NLRP3 production (Song, Pei, Yao, Wu, & Shang, 
2017). Initial reports had implicated PKR and its kinase function to be a key regulator in 
inflammasome activation (Lu et al., 2012). Subsequent reports went on to dispute this role 
was independent of PKR’s kinase action (Hett et al., 2013), while others have observed that 
PKR activity does not modulate the inflammasome at all (He et al., 2013), or that PKR 
actually suppresses inflammasome activity (Yim et al., 2016). We observed significantly 
increased gene and protein expression of PKR in the hippocampus and striatum in both the 
LPS dose study (Study #1) and PKR inhibitor study (Study #2). This expression coincided 
with significant upregulation of gene and protein NLRP3, as well as, significant gene 
induction of TNF-α and IL-1β. Conversely, IL-6 exhibited a transient, acute phase response 
that appeared to dissipate by 24 hours with 1 mg/kg LPS. From our inhibitor study, we 
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observed concurrent LPS-induction of PKR and NLRP3, both of which were attenuated by 
0.5 mg/kg imoxin. This PKR and NLRP3 decrease with 0.5 mg/kg IMX + LPS may be 
negatively regulated by FADD/Caspase-8, which to our knowledge, would be a novel finding 
in acute LPS models of neuroinflammation. Our studies did not explore the functional 
implications of this observation and it could merely be coincidental. Others have reported 
that inhibiting PKR autophosphorylation with the flavonoid luteolin actually increases 
NLRP3 activation in macrophages and microglia (Dabo et al., 2017). 
Although, previous reports have shown amelioration of IBA1 microglial activity in 
PKR KO mice (Carret-Rebillat et al., 2015), we observed an absence of IBA1 gene 
expression in both the striatum and hippocampus, under all LPS doses. Lack of IBA1 gene 
expression may likely be a by-product of our 3 and/or 24-hour post-LPS collection. Mixed 
reports in mice have cited IBA1 gene down-regulation at 4 hours post-LPS (single dose; 8 
mg/kg IP) (Hoogland et al., 2015; Harold A Silverman et al., 2014) and increased IBA1 
protein expression via immunohistochemistry at 3 hours post-LPS (single dose; 5 mg/kg IP) 
(Qin et al., 2007). However, the phenotype of pro-inflammatory cytokine expression 
observed in our studies has been suggested to precede IBA1 changes following LPS in mice 
(Norden et al., 2016). Therefore, microglia would very reasonably be expected to mediate 
our observed LPS-induced neuroinflammation, but we did not capture their involvement at 
our timepoint. 
Alternatively, peak GFAP astrocyte expression has appeared to indicate the resolution 
of microglial activation (Norden et al., 2016). We observed robust GFAP gene induction in 
our model and it responded to PKR inhibition, similar as PKR, NLRP3, and IL-1β. Thus, the 
induction of our pro-inflammatory signature could very well be microglial-derived and our 
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observed astrocyte activation could be secondary. Conversely, reactive astrocytes are induced 
by nitric oxide (Brahmachari, Fung, & Pahan, 2006) and PKR has been implicated as an 
essential component of this mechanism (He et al., 2013). Given our observation of robust 
GFAP gene induction and that glial expression of receptors for IFN-γ are most abundant on 
astrocytes (Hashioka, Klegeris, Schwab, Yu, & McGeer, 2010), we hypothesized that the 
pro-inflammatory cytokine IFN-γ promoted astrocyte activation and subsequent PKR 
expression. However, we observed no difference in IFN-γ protein expression in either the 
hippocampus or striatum (data not shown). Overall, the exact contribution of microglia and 
astrocytes to our observed neuroinflammatory signature is unclear, due to temporal 
limitations. We can conclude that PKR expression is not dependent on timing or LPS dose 
and that it appears to coincide with astrocyte activation. 
While characterizing differential CNS PKR expression and its concurrent 
inflammatory phenotype was a primary objective of this study, one limitation of the current 
study is that our immunophenotyping of astrocytes and microglia was limited solely to gene 
expression. These cells have only recently become identified for their enormous capacity for 
disease-state heterogeneity (Gosselin et al., 2017; Keren-Shaul et al., 2017; Mathys et al., 
2017; Norden et al., 2016; Ransohoff, 2016b). As cytokines mediate sickness behavior 
(Dantzer, 2001a; Dantzer et al., 2008), it would also be helpful to include behavioral 
measurements to assess the extent that cytokines may mediate CNS PKR expression and 
whether imoxin can recover LPS-induced behavioral detriments. Finally, the current study 
utilized a well-established model of immune challenge to interrogate peripheral-CNS 
communication. Future studies should expand upon PKR’s exact role in individual disease 
states by examining its expression in specific neurodegenerative disease models.  
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4.8 Conclusion 
These data add to the increasingly staggering body of literature implicating a role for 
systemic inflammation in neurological disease, which is shown to precede the clinical 
manifestation of neurodegeneration. The present study provides in vivo evidence that CNS 
RNA-dependent protein kinase (PKR) expression is induced following a single, systemic 
administration of LPS and appears to function outside if its canonical anti-viral role (Berry et 
al., 1985; Clemens, 1997). Although further studies are needed to clarify the therapeutic 
potential of PKR inhibition in individual neurodegenerative disease models, we believe PKR 
could be used an indicator of disturbed CNS homeostasis following systemic inflammation 
and that inhibition of PKR could likely produce therapeutic benefit by modulating apoptotic 
pathways. Collectively, this work suggests that PKR does not function as an effector 
molecule in systemic inflammation, but rather acts as a node whose functions are dependent 
on the availability of players in the response network and the context of the inflammatory 
challenge.  
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A. 
B. C. 
Figure 2.1 A single, systemic injection of LPS produces a pro-neuroinflammatory gene 
signature in the hippocampus and striatum. 
Animals received single I.P. injections of either saline, 5 mg/kg LPS and tissue collected 3 hours later, 1 
mg/kg LPS and tissue collected 3 hours later, or 1 mg/kg LPS and tissue collected 24 hours later. (A) Gene 
induction for IL-1β, TNF-α, IL-6 was greatest with 5 mg/kg LPS. (B) NLRP3 inflammasome gene expression 
was significantly increased with 5 mg/kg LPS at 3 hours post-LPS. ASC gene expression was opposite of 
NLRP3, with significant up-regulation with 1 mg/kg LPS at 24 hours post-LPS. (C) Striatal and hippocampal 
PKR gene expression was significantly upregulated by LPS in all three treatment groups and the magnitude of 
its expression did not significantly vary between groups. Data represented as mean fold change ± 95% CI on a 
Log2 scale. Significance above bar denotes difference from control, with between group differences denoted 
by line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA (n = 3-5 per group). 
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Figure 2.2 Pharmacological inhibition of PKR with imoxin (IMX) reduces LPS-induced 
neuroinflammation. 
(A) 1 mg/kg LPS at 24 hours post-LPS reproduced the neuroinflammatory phenotype observed in Study #1 and 
pre-LPS treatment with 2 S.C. doses of 0.5 mg/kg IMX + LPS appeared to reduce gene induction the greatest 
for IL-1β, TNF-α, NLRP3, and PKR. (B) LPS-induced NLRP3 protein expression was attenuated with 0.5 
mg/kg IMX. Data represented as mean fold change ± 95% CI on a Log2 scale, or linear scale for protein data. 
Cropped Western Blot images show group representative samples run from the same gel, with corresponding 
housekeeping control. Significance above bar denotes difference from control, with between group differences 
denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA. (n = 6-7 per group)  
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Figure 2.3 LPS downregulates PKR phosphorylation (p-PKR) in the striatum, while 
upregulating total PKR protein expression in the striatum and hippocampus. 
(A) p-PKR is downregulated in the striatum and the hippocampus had no significant differences from control. 
Total PKR protein expression was upregulated by LPS in both the striatum and hippocampus. Data represented 
as mean fold change ± 95% CI on a linear scale. Cropped Western Blot images show group representative 
samples run from the same gel, with corresponding housekeeping control. Significance above bar denotes 
difference from control, with between group differences denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 
0.01, * p < 0.05 by 1-way ANOVA. (n = 6-7 per group) 
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Figure 2.4 LPS induces astrocyte activation that is significantly reduced by 0.5 mg/kg 
imoxin, while producing no changes to microglial activation. 
(A) In Study #1, GFAP gene induction was greatest with 1 mg/kg LPS at 24 hours post-LPS in the striatum and 
hippocampus. There were no significant differences in IBA1 gene expression. (B) In Study #2, striatal GFAP 
expression was significantly decreased by 0.5 mg/kg imoxin + LPS, while still remaining significantly elevated 
from control. Hippocampal GFAP gene expression was significantly increased from control in all treatment 
groups. Consistent with Study #1, LPS did not induce IBA1 gene expression. Data represented as mean fold 
change ± 95% CI on a Log2 scale. Cropped Western Blot images show group representative samples run from 
the same gel, with corresponding housekeeping control. Significance above bar denotes difference from control, 
with between group differences denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-
way ANOVA. (n = 4-7 per group) 
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Figure 2.5 . PKR inhibition reduced PKR protein activator (p-PACT) expression, while LPS 
reduced protein expression for stereotypical PKR substrate (p-eIF2-α). 
(A) PACT phosphorylation was significantly decreased with 1.0 mg/kg imoxin + LPS in the striatum and 
hippocampus, although not by LPS alone. (B) LPS significantly down-regulated phosphorylation of eukaryotic 
translation initiation factor 2 (p-eIF2-α). Pre-treatment with imoxin recovered this LPS-induced decrease and 
these differences were significant in the hippocampus. Data represented as mean fold change ± 95% CI on a 
linear scale. Cropped Western Blot images show group representative samples run from the same gel, with 
corresponding housekeeping control. Significance above bar denotes difference from control, with between 
group differences denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA. 
(n = 6-7 per group) 
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Figure 2.6 Neither LPS or Imoxin caused major change in cell proliferation markers. 
(A) 1.0 mg/kg imoxin + LPS significantly increased ATF3 from LPS alone in the striatum and hippocampus. 
(B) LPS significantly decreased striatal CDK2 protein expression. Data represented as mean fold change ± 95% 
CI on a linear scale. Cropped Western Blot images show group representative samples run from the same gel, 
with corresponding housekeeping control. Significance above bar denotes difference from control, with between 
group differences denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA. 
(n = 6-7 per group) 
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Figure 2.7 Downstream signaling suggests an apoptotic function for PKR following acute 
LPS challenge. 
(A) LPS alone did not change FADD or Procaspase-8 protein expression in the striatum, but both were 
significantly increased with 0.5 mg/kg IMX + LPS. Hippocampal procaspase-8 was significantly decreased 
from control in all groups. (B) LPS significantly decreased striatal RIP1K expression and imoxin did not change 
this. Hippocampal RIP1K expression was significantly increased with 1.0 mg/kg imoxin +LPS, compared to 
LPS alone. Protein expression of proinflammatory NF-κB p65 was decreased with LPS in the striatum, with no 
changes occurring in the hippocampus. Data represented as mean fold change ± 95% CI on a linear scale. 
Cropped Western Blot images show group representative samples run from the same gel, with corresponding 
housekeeping control. Significance above bar denotes difference from control, with between group differences 
denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA. (n = 6-7 per group) 
A. 
B. 
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Figure 2.8 PKR signaling scheme. 
The diverse response by PKR suggest that it signaling events are cell type-specific and context-dependent. A 
number of detrimental cell stresses have been shown to induce PKR expression, including inflammation, 
ER/oxidative stress, and dsRNA viral intermediates (Guerra et al., 2006; Marchal et al., 2014).  Noxious cellular 
stimuli produced by these events leads to surface receptor binding that triggers a signaling cascade that can 
either activate PKR directly, or via phosphorylation of the PKR protein activator PACT (R. L. Bennett et al., 
2004). PACT has high activation potential, given that a multitude of factors can lead to it phosphorylation, 
including IL-3 deprivation, H2O2, and TNF-a, among others (Gilbert, Duance, & Mason, 2002; T. Ito et al., 
1999). Once activated, PKR has been shown to regulate translation though numerous regulatory pathways, 
including IRF, STAT, p53, MAPKs, ATF3, and NF-κB (M. A. Garcia et al., 2006). Identified as being largely 
localized to the cytoplasm, p-PKR fragments have been shown to accumulate in the nucleus following 
tunicamycin-induced apoptosis (Onuki et al., 2004). From our studies, we observed LPS-induced protein 
changes relating to cell growth and proliferation (ATF-3 and CDK2), and inflammation (RIP1K and p65). 
Moreover, we observed a negative relationship between FADD and Procaspase-8 with PKR in the striatum; 
inhibiting PKR with 0.5 mg/kg imoxin decreased PKR, while increasing FADD. PKR associates with RIP1K, 
which has been shown to be negatively regulated by FADD (Thapa et al., 2013). Therefore, FADD may 
negatively PKR and could represent a novel effect of imoxin. Neither of these pathways would be expected to 
function autonomously, but synergistically contribute to apoptosis. Furthermore, we observed changes to most 
of these proteins following PKR inhibition with imoxin, suggesting that the therapeutic potential of inhibiting 
PKR will likely exert PKR-dependent and PKR-independent effects on cell signaling. While we examined CNS 
PKR expression following a single, systemic injection of LPS, sustained inflammatory cell stress and 
subsequent PKR activation would be expected to promote pro-apoptotic processes and contribute to the 
neurodegenerative cascade associated with chronic neuroinflammation (C. Cunningham et al., 2009; Murray, 
Skelly, & Cunningham, 2011; Perry, 2004; Skelly et al., 2013). 
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A. 
B. 
Table 2.1 LPS-induced weight loss and was not changed by imoxin. 
(A) The greatest amount of weight loss in the LPS dose study (Study #1) occurred in mice receiving 1 mg/kg 
LPS with collection 24 hours post-LPS. (B) The selected 1.0 mg/kg LPS dose reproducibly caused an equal 
amount of weight loss in the PKR inhibitor study (Study #2). Administration of imoxin itself did not produce 
weight loss. Data represented as mean fold change ± 95% CI (n = 3-5 per group). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group 
Avg. Pre-LPS 
Weight (g) 
Avg. Post-LPS 
Weight (g) 
% Weight Loss 
of Original 
Control 25.60 ± 1.24 25.18 ± 1.18 98.34 
5 mg/kg LPS – 3 hr 26.87 ± 1.64 25.95 ± 1.30 96.45 
1 mg/kg LPS – 3 hr 26.02 ± 1.52 24.93 ± 1.48 95.83 
1 mg/kg LPS – 24 hr 27.31 ± 0.88 24.38 ± 1.17 89.26 
Group 
Avg. Pre-LPS 
Weight (g) 
Avg. Post-LPS 
Weight (g) 
% Weight Loss 
of Original 
Control 22.98 ± 1.22 23.34 ± 1.35 101.53 
Saline + 1.0 mg/kg IMX 21.91 ± 1.53 22.74 ± 1.38 103.78 
LPS + Saline 24.00 ± 0.98 21.42 ± 1.28 89.24 
LPS + 0.5 mg/kg IMX 21.89 ± 0.67 19.54 ± 0.57 89.26 
LPS + 1.0 mg/kg IMX 22.04 ± 1.02 19.96 ± 0.67 90.53 
87 
Table 2.2 Primer sequence information for qPCR assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Forward (5’ → 3’) Reverse (5’ → 3’) 
IL-1β GCTTCAGGCAGGCAGTATC AGGATGGGCTCTTCTTCAAAG 
TNF-α AGCCGATGGGTTGTACCTTG ATAGCAAATCGGCTGACGGT 
IL-6 ACCGCTATGAAGTTCCTCTC CTCTGTGAAGTCTCCTCTCC 
NLRP3 GCTCCAACCATTCTCTGACC AAGTAAGGCCGGAATTCACC 
ASC AGGAGTGGAGGGGAAAGC AGAAGACGCAGGAAGATGG 
PKR GATGGAAAATCCCGAACAAGG
AG 
AGGCCCAAAGCAAAGATGTCC
AC 
GFAP GGTTGAATCGCTGGAGGAG CTGTGAGGTCTGGCTTGG 
IBA1 CTTGAAGCGAATGCTGGAGAA GGCAGCTCGGAGATAGCTTT 
β-Actin GTGACGTTGACATCCGTAAAG
A 
GCCGGACTCATCGTACTCC 
GAPDH AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGT
CA 
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Supplementary Figure 2.1 Phosphorylated PKR (p-PKR) is significantly increased in the 
cerebellum, compared to control, at 3 hours Post-LPS. 
From the initial LPS dose study, p-PKR is up-regulated at 3 hours post-challenge with 1 mg/kg LPS, with 
expression decreasing by 24 hours post-challenge with 1 mg/kg LPS. Data represented as mean fold change ± 
95% CI on a linear scale. Significance above bar denotes difference from control. ****p < 0.0001, *** p < 
0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA (n = 3-5 per group). 
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Abstract 
Neuroinflammation resulting from various host and environmental factor detriments has 
emerged as a well-recognized component of Parkinsonian pathogenesis. Respiratory 
infection with non-neurotropic strains of influenza are capable of producing Parkinsonian 
sequelae, exemplified best by historic epidemiology of pandemic influenza outbreaks, and 
neuroinflammation has been implicated as the pathogenic mechanism mediating this 
relationship. However, the challenge of identifying neuroinflammatory preclinical drug 
candidates is understanding whether their cell signaling behavior is protective or pathogenic. 
Our lab has implicated the expression of double-stranded RNA-dependent protein kinase 
(PKR) as an intracellular danger-sensing mechanism that activates in response to influenza-
induced neuroinflammation. To determine its potential relevancy to Parkinsonian 
pathogenesis, we used an intranasal mouse model of influenza infection to induce systemic 
inflammation, followed by an acute MPTP challenge (4x, 18 mg/kg i.p.). Under this multi-hit 
model of dual influenza + MPTP-mediated neurotoxicity, we anticipated synergistic 
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expression of CNS PKR. Although we demonstrated that influenza infection in the peripheral 
immune system can directly produce a proinflammatory microglial phenotype our evidence 
does not suggest that influenza-induced PKR expression in the brain is a direct a 
neuroinflammatory effector, but more likely a delayed signal transducer that promotes 
apoptotic and inflammatory signaling. Whether this PKR-mediated cell stress response is 
pro-survival or pro-death is unclear. Given that influenza infections result in 3-5 million 
global cases of severe illness annually, it is pertinent to identify novel mechanisms of how 
peripheral sickness may impact the brain and precipitate neurodegenerative cascades.   
Introduction 
Clinically described as a neurodegenerative movement disorder, Parkinson’s disease 
(PD) is pathologically defined by the progressive degeneration of dopaminergic neurons in 
the nigrostriatal pathway that produces bradykinesia, muscle rigidity, postural instability, gait 
freezing, and a resting tremor (Mosley, Hutter-Saunders, Stone, & Gendelman, 2012; Poewe 
et al., 2017). As for its etiology, we have come to recognize that the clinical manifestation of 
PD largely results from a combination of environmental neuroinflammatory insults that 
accumulate over the course of one’s lifetime and precipitously disrupt homeostasis within the 
central nervous system (CNS) (Amor et al., 2014; Chao, Wong, & Tan, 2014; Colm 
Cunningham, 2013). 
Of implicated risk factors, influenza infections-alone have long been recognized to 
produce behavioral and cognitive deficits that are attributed to systemic inflammation 
(Dantzer, 2001b). Additionally, the relationship between Parkinsonism and influenza 
infection has been readily recognized for the past 40 years (Moore, 1977), epidemiologically 
exemplified by the 1918 H1N1 Spanish Flu pandemic. Following primary respiratory 
infection, a secondary disease state referred to as encephalitic lethargica (EL) was observed 
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for up to a decade later and was characterized by lethargy, ophthalmoplegia, and delirium 
(Henry et al., 2010). Approximately 80% of these patients went on to develop post-
encephalitic Parkinsonism (PEP), which included bradykinesia and a resting tremor (Cunha, 
2004; Maurizi, 2010). The notion that influenza infection can promote Parkinsonism is 
further supported by the observation that antivirals have therapeutic benefit for the clinical 
management of PD (Pahwa et al., 2015; Sadasivan et al., 2017). 
Intracerebral administration of neurotropic strains of influenza A in animal models 
have previously shown preferential localization to the substantia nigra (Yamada, 1996), 
which could provide direct evidence of how influenza may produce a Parkinsonian sequelae. 
Additionally, C57BL/6 mice intranasally inoculated with influenza A/Vietnam/1203/04 
(H5N1), a neurotropic virus that invades the CNS, produced long-lasting microglial 
activation and aggregation of α-synuclein that promoted degeneration of dopaminergic 
neurons in the substantia nigra (H. Jang et al., 2009). However, most influenza strains are 
non-neurotropic (G. F. Wang et al., 2010) and are still capable of producing long-lasting 
neurobehavioral deficits (Luyt et al., 2012), suggesting that the neuropathological effect of 
seasonal influenza on CNS function is through an indirect route. 
Systemic inflammation has recently emerged as a primary pathological mechanism in 
which influenza infection can disrupt CNS homeostasis (C. Cunningham, Campion, Teeling, 
Felton, & Perry, 2007; Perry, 2004; Perry & Teeling, 2013). Infection with non-neurotropic 
influenza produces activation of the peripheral innate immune system, which leads to 
increased expression of the pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in the 
hippocampus of male BALB/c mice 7 days post-infection with influenza A/PR/8/34 (Jurgens 
et al., 2012). This increased pro-inflammatory expression was met with increases in MHC-II 
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and IBA1 expression, implicating microglia as the primary harbingers of this 
neuroinflammatory response.  
As it relates to Parkinsonian pathogenesis, intranasal infection of mice with non-
neurotropic influenza A/California/04/2009 (H1N1) has been shown to produce chronic 
microglial activation in both the substantia nigra and hippocampus beginning 21 days post-
infection (DPI) and persisting through 90 DPI (Sadasivan et al., 2015). In this study, 
influenza-induced neuroinflammation was not met with breakdown of the blood-brain 
barrier, or increased T cell extravasation; two events suggested to contribute to systemic 
inflammation in neurodegeneration (Lyck & Engelhardt, 2012; Obermeier et al., 2013). Dual 
challenge with influenza A/California/04/2009 30 days post-infection and the Parkinsonian 
toxin 1-methyl, 4-phenyl, 1,2,3,6-tetrahydropyridine (MPTP) in mice has been shown to have 
no additive effect on microglial activation, but produces substantial loss of dopaminergic 
neurons in the substantia nigra (Sadasivan et al., 2017), suggesting that multiple 
inflammatory challenges can have detrimental effects relevant to the development of 
Parkinsonism. However, a challenge in identifying preclinical inflammatory markers that 
reliably indicate PD onset is that these signals are highly context-dependent and often exhibit 
both adaptive and maladaptive functions (Clark & Kodadek, 2016; Postuma & Berg, 2016). 
The current study investigated the in vivo and in vitro role of influenza-induced 
double-stranded RNA-dependent protein kinase (PKR) expression in brain and assessed its 
role in Parkinsonian pathogenesis. PKR is an antiviral kinase that has been shown to mediate 
cell stress responses to a variety of stimuli, both viral and non-viral (M. A. Garcia et al., 
2006). We hypothesized that influenza would time-dependently induce PKR expression in 
the CNS and that upon dual challenge with influenza + MPTP, CNS PKR expression would 
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be additive. Following intranasal infection with influenza A/PR/8/34 for either 3- or 15-days 
post-infection, animals were acutely challenged with MPTP (4x I.P., 18 mg/kg) and the 
striatum and hippocampus were analyzed for PKR expression, the coinciding 
neuroinflammatory phenotype, and downstream cell signaling pathways that may mediate 
PKR’s expression. 
Materials and Methods 
2.1 Study Design 
This study utilized in vivo and in vitro paradigms to model influenza infection. Three 
independent cohorts of mice were intranasally inoculated with 2 different influenza doses 
from the same batch of virus and brain tissue collected at either 3, 4, or 15 Days Post-
Infection (DPI): i) male BALB/c mice infected with 0.5 HAU (256 HAU batch total) and 
samples collected 4 or 15 DPI (n = 3-4 per group), ii) male C57BL/6 infected with 0.1 HAU 
and samples collected 3 DPI (n = 3-4), and iii) male C57BL/6 infected with 0.1 HAU and 
samples collected 15 DPI (n = 3-6). The day of infection was counted as Day 0. Standard 
influenza modeling for our lab utilizes BALB/c strains (N. Huang et al., 2013) as they are 
deemed more susceptible to respiratory challenge (Bouvier & Lowen, 2010). However, a 
strain change to C57BL/6 mice was warranted for infection studies utilizing 1-methyl, 4-
phenyl, 1,2,3,6-tetrahydropyridine (MPTP), as these animals are more susceptible to MPTP-
toxicity (Sedelis et al., 2000). Respective tissues were processed for gene and protein 
expression. 
In order to assess the direct effect of peripheral infection on dopaminergic neurons 
and microglia in vitro, conditioned media experiments were performed. RAW 264.7 
macrophages were infected with influenza, and both cell lysates and conditioned supernatant 
were collected. Cell lysates were processed for protein expression and the supernatants were 
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used to treat N27 dopaminergic neurons, along with BV2 microglia. Gene expression and 
cell viability experiments were performed on microglia and neurons, respectively. 
2.2 Animals and health monitoring 
Male BALB/c and C57BL/6 mice (Charles River) were maintained in group housing 
(n = 5/cage) and maintained on a 12-hour reverse light cycle in ventilated Innovive racks 
(Innovive, San Diego), with ad libitum food (Harlan Teklad 2014) and water access. Prior to 
any treatment, mice were environmentally acclimated for at least 1 week. Six to eight-week-
old mice were used in all studies. All studies were approved by the Institutional Animal Care 
and Use Committee of Iowa State University.  
Following either influenza infection or MPTP challenge, animals were individually-
housed and well-being was monitored twice daily. Body weight was recorded daily, with 
food and water monitored. In order to maintain wellness, mice too weak from infection were 
supplied with food and water combined in petri dishes for better access. Animals whose body 
weight loss exceeded 20% were removed from the study and sacrificed.  
At the end of a study’s respective duration, animals were sacrificed via asphyxiation 
(CO2), brains removed and micro-dissected for the hippocampus and striatum, then snap-
frozen in liquid nitrogen for subsequent processing. 
2.3 Treatment 
2.3.1 Virus and immunizations  
Influenza A/PR/8/34 H1N1 was grown in the amniotic-allantoic sac of embryonated 
eggs. For influenza virus used in all in vivo and in vitro studies, the hemagglutination unit 
(HAU) of stock virus was 256 HAU/0.05 ml. For all in vivo infections, mice were subjected  
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to light anesthesia with isoflurane (VAD Anesthetic Machine, Vetamac, Rossville, IN) and 
intranasally inoculated with 50 ul of chilled, serially-diluted virus prepared in saline.  
2.3.2 MPTP Formulation  
Following primary infection with influenza, animals were subjected to an acute 
MPTP paradigm to establish neuroinflammation and rapid dopamine degeneration. Mice 
received four intraperitoneal (I.P.) injections of 18 mg/kg MPTP-HCl dissolved in saline 
(free-base; Axon Medchem 1075) at 2-hour intervals. Animals were sacrificed either 1-day 
post-MPTP or 3 days post-MPTP. 
2.4 Gene Expression 
RNA isolation was performed on snap-frozen brain tissue using an RNA binding-
column method (Qiagen RNeasy Micro Plus Kit; #74034). Total RNA was isolated from one 
hemisphere and reverse transcribed to cDNA (Qiagen RT2 First Stand Kit; #330404) to be 
used in SYBR green assays for relative gene expression (Qiagen RT2 SYBR Green Fluor 
qPCR Mastermix; 330513). Qualitative Polymerase Chain Reaction (qPCR) was performed 
on a Bio-Rad MyIQ PCR system for 40 cycles of amplification, with a subsequent melt curve 
to validate the purity of amplified product. The primer sequences used are available in 
Supplementary Table 1. Relative difference of gene expression between groups was analyzed 
using the Pfaffl Method (Pfaffl, 2001), where threshold cycle (Ct) values were normalized to 
both β-actin and GAPDH, and expressed relative to control groups. 
2.5 Protein Expression  
Protein lysates from one hemisphere of each animal were homogenized with a 
motorized pestle in 150 µl of custom Lysis Buffer A (30 mM NaHEPES, 5 mM EGTA, 3 
mM EDTA, 20 mM KCL, 32% glycerol, phosphatase inhibitor cocktail 3 (Sigma-Aldrich; 
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P0044), and HALT protease inhibitor cocktail (Thermo Fisher; 78425)). Homogenates were 
centrifuged for 15 minutes at 15,000 g (4 ͦC), and supernatant collected. Total protein was 
quantified using the bicinchoninic acid method (BCA; Pierce Biotechnology, Inc.; #23227) 
with bovine serum albumin standards. Western blot protein samples (10-30 μg) were run on 
8-16% Criterion TGX Precast Gels (Bio-Rad) at 150V for 1.5 hours, transferred to 
polyvinylidene fluoride membranes (PVDF; EMD Millipore), and blocked in Tris-buffered 
saline (TBS; pH 8.0) containing 0.05% Tween-20 and 5% non-fat dry milk (LabScientific; 
#M0841) for 1 hour at room temperature. Membranes were incubated overnight at 4 ͦC with 
primary antibody at the manufacturer recommended dilution. Primary antibody solutions 
were prepared in 1x TBST, 0.05% Na Azide, and 3% BSA and markers included: NLRP3 
(Adipogen; cryo-2), p-PKR (Thr 451; EMB Millipore; #07-886), and β-actin (CST; #4970). 
Primary mouse monoclonal antibodies from Santa Cruz Biotechnology included: PKR (sc-
6282), p-PACT (sc-53524), PACT (sc-377103), FADD (sc-271748), Caspase-8 (sc-81656), 
and NF-κB p65 (sc-8008). Cut membranes were washed with 1x TBST (0.1% Tween), 
probed at room temperature for 1 hour with respective secondary antibody, treated with 
SuperSignal ELISA Femto Maximum Sensitivity Substrate (Thermo; #970740), and images 
captured on a Bio-Rad Universal Hood II gel imager. Densitometry was performed using 
ImageJ software (NIH), normalizing all values to β-actin, and expressed relative to control 
groups. Cropped Western Blot images show group representative samples run from the same 
gel, with corresponding housekeeping control. 
2.6 Cell culture and treatment paradigm 
RAW 264.7 macrophages were grown in high glucose DMEM medium (Thermo, 
11995-065) containing 10% FBS (GE Healthcare HyClone™, SH3008803HI), 100 U/ml 
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penicillin, and 100 ug/ml streptomycin at 37°C. For in vitro infection, cells were plated in a 
6-well plate at a density of 500,000 cells/well and incubated overnight for 12-24 hours until 
~80% confluence was achieved. Prior to infection, growth media was aspirated, and cells 
washed twice with pre-warmed 1X PBS. Cells were infected with 10 HAU Influenza 
A/PR/8/34 for 2 hours in 500 µl serum-free medium (DMEM + 1% Pen/Strep + 1 ug/ml 
TPCK-Trypsin), with plates rocked every 15 minutes. Following infection, virus-containing 
media was aspirated, monolayers washed once with 1X PBS, and 2 ml of serum-free medium 
(DMEM + 1% Pen/Strep + 1 ug/ml TPCK-Trypsin + 0.3% BSA) was applied. Plates were 
incubated for 6 hours, conditioned media collected, cells washed once with 1x PBS, and 
lysed. Homogenized lysates were analyzed for p-PKR, PKR, and NLRP3 protein expression 
using Western blotting. Conditioned media was used to treat BV2 microglia for 6 hours, with 
cell lysates subsequently processed for IL-18, IL-1β, NLRP3, and PKR gene expression 
using qPCR. 
2.8 MTS Cell Viability Assay 
Influenza-conditioned medium from RAW 264.7 macrophages was additionally used 
to treat N27 rat dopaminergic neurons in a cell viability assay. This immortalized cell line are 
mesencephalic dopaminergic neurons that can be differentiated to produce tyrosine 
hydroxylase and dopamine (Adams et al., 1996). Undifferentiated cells were grown in RPMI 
1640 medium containing 10% FBS, 2 mM L-glutamine, 50 units penicillin, and 50 µg 
streptomycin. N27 cells were seeded in a 96-well plate at 2E4 cells/well and treated in 100 µl 
serum-free RPMI with either: control media, Influenza A/PR/8/34-conditioned media for 24 
hours, 0.5 µM rotenone for 24 hours (Sigma, St. Louis, MO), or 0.5 µM rotenone for 16 
hours + A/PR/8/34 for 8 hours. Rotenone is a well-characterized complex I inhibitor used to 
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model mitochondrial toxicity in PD models (Greenamyre, Cannon, Drolet, & 
Mastroberardino, 2010). Cell viability was measured using the CellTiter 96 Aqueous One 
Solution Cell Proliferation Kit (Promega). Following treatment, cells were incubated with 
MTS dye and incubated for one hour at 37°C. Post-incubation, spectrophotometry measured 
absorbance of the cell viability indicator, formazan, at 490 nm.  
2.9 Analysis 
Data were analyzed in GraphPad Prism (version 6 for Windows) using a Student’s T 
test for studies comparing infection to control, and a one-way analysis of variance (ANOVA) 
on both gene and protein expression values for combined influenza and MPTP studies. Post-
hoc multiple comparisons were performed using Sidak correction, with an α-level of 0.05. 
Figures were generated in GraphPad, reporting data as mean fold change with error 
propagated as 95% Confidence Intervals. Gene data were represented on a Log2 scale, with 
protein data on a linear scale. Significance above bar denotes difference from control, with 
between group differences denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p 
< 0.05 by 1-way ANOVA.  
Results 
3.1 Peripheral infection with Influenza A/PR/8/34 produces delayed PKR expression in the 
hippocampus and striatum  
Initial influenza studies infected male BALB/c mice with 0.5 HAU A/PR/8/34 and 
collected samples 4- and 15-days post-infection (DPI). A student’s t test between saline and 
infected mice revealed no significant difference in total PKR protein expression at 4 DPI, in 
either the striatum or hippocampus. However, PKR protein expression was significantly up-
regulated from control 15 DPI in the striatum (M = 6.75, SD = 1.08), t(6) = 10.36, p < .0001). 
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Additionally, PKR was significantly up-regulated in the hippocampus 15 DPI (M = 2.83, SD 
= 1.40), t(6) = 2.57, p = 0.0423) (Figure 1). 
3.2 PKR expression 15 days post-infection (DPI) coincides with apoptotic and inflammatory 
signaling 
As downstream targets of PKR, 15 DPI with 0.5 HAU A/PR/8/34 produced 
significant up-regulation of fas-associated death domain (FADD) in the striatum (M = 2.52, 
SD = 0.39), t(5) = 4.19, p = 0.0086) and the hippocampus (M = 3.94, SD = 0.81), t(5) = 6.86, 
p = 0.001). Additionally, NF-κB p65 protein expression was significantly increased in the 
striatum (M = 8.25, SD = 0.94), t(6) = 15.41, p < 0.0001) and the hippocampus (M = 2.95, SD 
= 0.95), t(6) = 4.09, p = 0.0064) of influenza-infected mice. A primary effector caspase of 
apoptosis, caspase-3, did not reveal any protein changes in either the striatum or 
hippocampus (Figure 2A).  
Upstream of PKR activation, phosphorylated protein activator of PKR (p-PACT), was 
significantly increased in striatum (M = 1.64, SD = 0.31), t(6) = 4.18, p = 0.0058) of infected 
mice, but not the hippocampus. As for expression of effector neuroinflammatory glial cells 
that may mediate striatal and hippocampal PKR expression, glial fibrillary acidic protein 
(GFAP) protein was significantly up-regulated in the striatum (M = 4.77, SD = 0.82), t(5) = 
8.64, p = 0.00034) and hippocampus (M = 4.33, SD = 0.44), t(5) = 14.81, p < 0.0001) 15 DPI 
with influenza (Figure 2B).  
3.3 Infection of peripheral macrophages in vitro directly produces neuroinflammatory 
expression and compromises neuronal integrity relevant to Parkinsonian pathology. 
Conditioned media experiments from influenza-infected macrophages were used to 
treat immortalized BV2 microglial cells. Student’s t-tests revealed that influenza treatment 
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led to significant gene induction for IL-1β (M = 7.05, SD = 1.29), t(9) = 10.35, p < 0.0001), 
NLRP3 (M = 2.65, SD = 0.52), t(9) = 6.91, p < 0.0001), and PKR (M = 2.42, SD = 0.58), 
t(10) = 5.92, p = 0.00015) (Figure 3B). 
The same infection-conditioned media was used to treat N27 dopaminergic neurons, 
and an MTS cell viability assay was performed to determine the direct effect of influenza, 
rotenone (ROT), or the combination of both influenza + ROT. A one-way ANOVA revealed 
a significant loss of viable neurons compared to control, resulting from Influenza A/PR/8/34 
(M = 86.05, SD = 2.031), t(20) = 7.005, p < 0.0001), ROT (M = 76.37, SD = 3.046), t(20) = 
11.87, p < 0.0001), and A/PR/8/34 + ROT (M = 18.55, SD = 4.402), t(20) = 4.18, p < 0.0001) 
(Figure 3A). Furthermore, pairwise comparisons revealed that the percentage of viable cells 
from ROT treatment was significantly lower than A/PR/8/34 treatment (t(20) = 4.861, p = 
0.0006). The percentage of viable neurons from the combined treatment of A/PR/8/34 + ROT 
was significantly lower than ROT-alone (t(20) = 6.686, p < 0.0001) and A/PR/8/34-alone 
(t(20) = 6.686, p < 0.0001). Additive treatment led to the lowest percentage of viable 
dopaminergic neurons, compared to each treatment-alone. 
Furthermore, protein analysis of influenza-infected macrophages did not reveal any 
significant differences in p-PKR/PKR (M = 1.06, SD = 0.14), total PKR (M = 1.02, SD = 
0.15), or NLRP3 (M = 0.99, SD = 0.12) expression. This suggests that our observed striatal 
and hippocampal PKR expression is not produced by peripheral immune cells, which then 
propagates into the CNS parenchyma, but rather a localized stress signal. 
3.4 Dual Influenza 3 DPI + MPTP challenge produces limited PKR and NLRP3 protein 
changes 
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As an initial in vivo experiment to assess CNS influenza-induced PKR expression and 
its role in a multi-hit model of Parkinson’s disease (PD), we performed a pilot experiment to 
identify a sub-lethal dose of combined influenza + MPTP. Male C57Bl/6 infected with 0.1 
HAU A/PR/8/34 were challenged with 18 mg/kg MPTP 3 DPI and samples were collected 24 
and 72 hours post-MPTP. 72 hour post-MPTP data is shown in Supplementary Figure 1.  
While qPCR (24 hour post-MPTP) indicated no significant gene changes in MPTP or MPTP 
+ A/PR/8/34 groups for PKR, NLRP3, or IL-1β expression (Figure 4B), MPTP-alone 
treatment significantly reduced p-PKR/PKR protein expression in the striatum (M = 0.51, SD 
= 0.12), t(7) = 3.946, p = 0.0166) and hippocampus (M = 0.29, SD = 0.089), t(7) = 5.091, p = 
0.0042) from control (Figure 4A). NLRP3 protein expression was significantly reduced in 
hippocampus by MPTP (M = 44.13, SD = 0.809), t(7) = 6.375, p = 0.0011) and combined 
MPTP + A/PR8/34 (M = 023.47, SD = 0.85), t(7) = 3.817, p = 0.0196) (Figure 4A). 
 3.5 Dual Influenza 15 DPI + MPTP challenge changes PKR protein expression 
As a follow-up to the pilot 3 DPI experiment, we infected male C57Bl/6 mice with 
0.1 HAU A/PR/8/34 and 15 DPI, challenged with 18 mg/kg MPTP and collected samples 24 
hours later for gene and protein analysis. qPCR did not reveal any significant differences for 
PKR, NLRP3, or IL-1β gene expression in the striatum or hippocampus resulting from 
treatment with either MPTP-alone, A/PR8/34-alone, or MPTP + A/PR/8/34. Striatal TNF-α 
gene expression was significantly increased by MPTP (M = 0.29, SD = 0.089), t(11) = 8.361, 
p < 0.0001) and by MPTP + A/PR/9/34 (M = 0.29, SD = 0.089), t(11) = 7.768, p < 0.0001). 
Pairwise comparisons revealed a significant difference between MPTP and A/PR/8/34-alone 
(t(11) = 9.646, p < 0.0001) and between A/PR/8/34-alone and MPTP + A/PR/8/34 (t(11) = 
8.865, p < 0.0001). Hippocampal TNF-α gene expression was not significantly different from 
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control in any group, but pairwise comparisons revealed TNF-α was significantly lower in 
MPTP-alone, compared to MPTP + A/PR/8/34 (t(18) = 3.014 p = 0.0439) and significantly 
lower in A/PR/8/34-alone, compared to MPTP + A/PR/8/34 (t(18) = 3.454 p = 0.0169). 
Hippocampal IL-6 gene expression was significantly increased from control with MPTP + 
A/PR/9/34 (M = 30.20, SD = 1.28), t(20) = 55.60, p < 0.0001). Pairwise comparisons 
revealed this expression was also significantly increased from MPTP-alone (t(20) = 54.47, p 
< 0.0001) and A/PR/8/34-alone (t(20) = 56.09, p < 0.0001).  
Striatal PKR protein expression was significantly down-regulated in MPTP + 
A/PR/8/34 treated mice (M = 0.639, SD = 0.03172), t(12) = 3.315, p = 0.0244) and this 
expression was significantly lower from MPTP-alone (t(12) = 4.937, p = 0.0021). Also, 
striatal PKR expression was significantly lower with A/PR/8/34-alone, compared to MPTP-
alone (t(12) = 4.295, p = 0.0052). Hippocampal PKR expression was conversely up-regulated 
with MPTP + A/PR/9/34 compared to control (M = 2.176, SD = 0.61), t(8) = 3.659, p = 
0.0378) and pairwise comparisons indicated this increase was significantly different between 
A/PR/8/34-alone and MPTP + A/PR/9/34 (t(8) = 3.505, p = 0.0394).  
When analyzed as p-PKR/PKR, phosphorylated PKR (p-PKR) protein expression was 
significantly different in the striatum between A/PR/8/34-alone and MPTP + A/PR/8/34 
(t(12) = 4.409, p = 0.0051). p-PKR was significantly decreased in the hippocampus of MPTP 
+ A/PR/8/34 mice (M = 0.659, SD = 0.027), t(8) = 4.53, p = 0.0115) and this was 
significantly lower from MPTP-alone (t(8) = 4.026, p = 0.0189) (Figure 5A). The magnitude 
of p-PKR protein expression did not vary when data were analyzed as p-PKR alone, 
compared to p-PKR/total PKR. 
3.6 Astrocyte and microglial glial induction appears to be MPTP-mediated  
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In an effort to assess potential involvement of astrocytes and microglia, qPCR was 
performed for GFAP and IBA1 gene expression, respectively. Striatal GFAP gene expression 
was only different between MPTP and A/PR/8/34-alone (t(11) = 3.364, p = 0.0312) and 
between A/PR/8/34-alone and MPTP + A/PR/8/34 (t(11) = 4.015, p = 0.0121). Hippocampal 
GFAP gene expression was significantly increased from control with MPTP-alone (M = 
2.242, SD = 0.105), t(20) = 4.94, p = 0.0005), and MPTP + A/PR/8/34 (M = 3.581, SD = 
0.262), t(20) = 10.27, p < 0.0001). Additionally, pairwise comparisons indicated that GFAP 
for MPTP-alone was significantly increased over A/PR/8/34-alone (t(20) = 4.264, p = 
0.0023), that MPTP + A/PR/8/34 expression was greater than A/PR/8/34-alone (t(20) = 
9.592, p < 0.0001), and finally that GFAP gene expression from MPTP + A/PR/8/34 was 
greater than MPTP-alone (t(20) = 5.328, p = 0.0002). 
Combined treatment MPTP + A/PR/8/34 led to significant down-regulation of IBA1 
gene expression in the striatum (M = 0.29, SD = 0.622), t(12) = 3.997, p = 0.0106) and this 
decrease was significantly difference from A/PR/8/34-alone (t(11) = 3.694, p = 0.0153). 
There were no observed changes to hippocampal IBA1 gene expression. 
Discussion 
Pandemic influenza outbreaks have long been observed to produce neurological 
deficits. Yet, the relationship between influenza infection and Parkinsonian-like symptoms 
remains relatively understudied. Despite historical (1918 Spanish flu) and modern day (Cali 
09) epidemiological evidence, few studies have addressed the mechanisms that mediate this 
relationship. 
Seminal studies by Jang et al (2009) provided evidence that direct CNS infection with 
a neurotropic strain of influenza can promote PD neuropathology by promoting long-lasting 
microglial activation and feed-forward loop of α-synuclein aggregation, the intracellular 
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proteinaceous inclusion that makes up Lewy bodies (H. Jang et al., 2009). Once activated, 
Jurgens et al (2012) demonstrated that influenza-induced systemic inflammation causes 
microglia to exhibit a neuroinflammatory phenotype than can compromise hippocampal-
mediated behaviors through architectural changes to dendritic branching and synaptic spine 
density (Jurgens et al., 2012). Additionally, we know that systemic inflammatory insults with 
influenza can have synergistic effects, in combination with the Parkinsonian neurotoxin 
MPTP (Sadasivan et al., 2017). In addition to reactive microgliosis in the hippocampus and 
substantia nigra (Sadasivan et al., 2015), the additive effect of influenza and MPTP results in 
a significant loss of dopaminergic neurons (Sadasivan et al., 2017). These studies have 
provided foundational evidence that implicates systemic inflammation as a pathological 
process that can sensitize the brain to secondary immune challenges and produce 
Parkinsonism. What has not been addressed in these studies to date are neuroinflammatory 
mechanisms that may serve as therapeutic targets of interest. 
This report provides the first evidence that peripheral infection with non-neurotropic 
influenza produces PKR expression in the CNS. As a canonical anti-viral protein in infected 
cells, PKR activation leads to the inhibition of protein synthesis as a host defense mechanism 
(M. A. Garcia et al., 2006; Marchal et al., 2014). In addition to this function, PKR is 
expressed by numerous inflammatory cell types (R. Kang & Tang, 2012), has been found 
post-mortem in brains of PD patients (Bando et al., 2005), and has been shown to activate in 
response to a diverse array of cellular stress in acute and chronic disease states (Hugon et al., 
2017; B. R. Williams, 1999). A specific aim of our studies was to determine the mechanism 
of PKR activation in the brain following a systemic inflammatory challenge with influenza 
and assess its role in an MPTP model of dopaminergic neuron death. 
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In our models, in vivo PKR expression appeared to be both time and dose-dependent 
on influenza. We observed protein expression in both the striatum and hippocampus at 15 
DPI in BALB/c mice infected with 0.5 HAU, but not at 4 DPI (Fig. 1). The expression of 
PKR protein does not appear to be mediated by its autophosphorylation (Thr451), as we 
observed MPTP-induced decreased to p-PKR expression 24 hours post-MPTP (Fig. 4) and an 
MPTP-induced increase to p-PKR 72 hours post-MPTP (Suppl. Fig. 1). Increases in PKR, 
and its downstream action, would be expected to positively correlate with PKR 
phosphorylation. At 15 DPI with 0.1 HAU A/PR/8/34 in C57BL/6 mice, we observed a 
significant increase in hippocampal PKR protein, while p-PKR was significantly decreased. 
However, the action of influenza-induced PKR expression in our model may not be 
dependent on its kinase activity, as this has previously been shown in models of pyroptosis 
(Hett et al., 2013). The seemingly disparate, latent expression of influenza-induced PKR 
protein at 15 DPI may suggest that PKR expression is not dependent on its activation through 
phosphorylation. This would suggest that PKR is acting as a signal transducing node that 
supports apoptotic cell response. Alternatively, if influenza-induced CNS PKR expression is 
functioning in an apoptotic capacity, perhaps its expression is dependent on cell death within 
the brain. However, we did not observe changes to caspase-3 mediated cell death in BALB/c 
mice infected with 0.5 HAU A/PR/8/34 15 DPI (Fig. 2A).  
During the typical course of infection, peak viral expression in the lungs occurs by 3-
4 DPI, maximal weight loss and sickness by 5-8 DPI, with body weight loss recovered by 12-
15 DPI (Kohut, Sim, Yu, Yoon, & Loiacono, 2009; Warren et al., 2015). This served as 
rationale for selecting early (3-4 DPI) timepoints. Weight loss is considered a reliable metric 
of diseases progression in animal influenza models (Matsuoka, Lamirande, & Subbarao, 
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2009). We observed more global expression of CNS PKR (i.e., both striatum and 
hippocampus) when infection was severe enough to produce ~20% loss of body weight. In 
follow-up studies that incorporated MPTP-challenged groups, we had changes to both animal 
strain used and dose of influenza. While arguably more susceptible to influenza infection 
(Bouvier & Lowen, 2010; B. Srivastava et al., 2009), BALB/c mice are resistant to MPTP-
challenge, which is attributed to a difference in endogenous levels of brain monoamine 
oxidase-B (MAO-B) (Meredith & Rademacher, 2011). MAO-B is the enzyme responsible for 
the catalytic conversion of MPTP to MPDP+, which is subsequently oxidized to the 
neurotoxin MPP+. Having established that influenza-induced PKR occurs 15 DPI, our dose 
of influenza used in dual immune challenge (influenza + MPTP) had to be moderate enough 
that it did not produce lethality by 15 DPI. Hence, we opted for a dose of influenza (0.1 HAU 
A/PR/8/34 in C57BL/6 mice) that produced a modest ~5% loss of body weight.  
Evidence from the past decade has irrefutably highlighted inflammation as a primary 
driver of neuropathology. It is now generally well-accepted that neuroinflammation precedes 
neurodegeneration (C. Cunningham et al., 2009; C. Cunningham et al., 2005; Glass et al., 
2010; Sparkman & Johnson, 2008; Q. Wang et al., 2015) and these inflammatory changes 
have been shown to occur prior to neuronal changes induced by influenza infection (Jurgens 
et al., 2012). All nucleated cell types have been shown to express PKR, including murine 
neurons (Alirezaei et al., 2007), astrocytes (Ong et al., 2005), and microglia (J. H. Lee et al., 
2005). Following inflammatory challenge with influenza, or in combination with MPTP, we 
postulated that microglia were expressing PKR as an inflammatory mediator. Although our 
data did not explicitly phenotype glial cell populations, we did not observe substantial 
changes to IBA1 microglia gene expression (Fig. 6). As we observed an influenza-induced 
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increased in FADD apoptotic signaling, a plausible conclusion may be that neurons are the 
primary source of stress-induced PKR. Much of the literature examining CNS PKR 
localization implicates the source as being neuronal (Carret-Rebillat et al., 2015; H. M. Chen 
et al., 2008; Mouton-Liger et al., 2012; Mouton-Liger et al., 2015; X. Wang et al., 2007). 
However, it also possible that microglia themselves could be undergoing apoptosis as a 
regulatory mechanism to limit neuroinflammatory damage (White, McCombe, & Pender, 
1998). Infection of mixed primary mouse astrocytes and microglia with either H1N1 
(A/Shantou/169/06) or H5N1 (A/Chicken/Guangdong/1/05) has been shown to induce a 
proinflammatory response, in addition to apoptosis of these cytokine-producing cells (G. 
Wang et al., 2008). Furthermore, PKR is activated and expressed in both astrocytes and 
microglia in genetic models of Gaucher’s disease (Vitner et al., 2016). Future studies should 
utilize cell-specific techniques to localize the cellular source of PKR. 
Functionally, PKR has been implicated in a multitude of stress responses resulting in 
antiviral responses, anti-proliferative actions, stress-induced apoptosis, and inflammation 
(Marchal et al., 2014). Fas-associated death domain (FADD) and caspase-8, which precedes 
executioner caspase-3, have previously been shown to be downstream effectors of PKR-
mediated apoptosis (Balachandran et al., 2000; Couturier et al., 2010; Gurung et al., 2014; 
Thapa et al., 2013; von Roretz & Gallouzi, 2010). Following infection with 0.5 HAU 
A/PR/8/34 in BALB/c mice, we observed significant upregulation of FADD in both the 
striatum and hippocampus following infection. Additionally, we saw increases in NF-κB p65, 
of which FADD has previously shown to be an activator (W.-H. Hu et al., 2000). 
Overexpression of FADD in SH-SY5Y neurons has previously been shown to be protective 
against TNF- and Aβ-induced neurotoxicity in in vitro models of Alzheimer’s disease 
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(Cantarella et al., 2003) and may represent a PKR-mediated target for therapeutic 
interventions.  
What remains to be determined from studies of systemic inflammation and 
neurodegeneration are the context-specific mechanisms for how peripheral inflammatory 
signals can propagate in to the CNS. Three primary routes of CNS entry have been proposed; 
neuronal) afferent vagal nerves express inflammatory cytokine receptors that can be activated 
by systemic inflammation, direct)  inflammatory cytokines and chemokines can propagate 
inflammatory signaling via immune cells in circumventricular organs (specialized regions of 
the BBB that do not tightly regulate CNS entry), and humoral) trans-epithelial signaling from 
cytokines in the blood to perivascular macrophages in cerebral endothelial layers which 
promote microglial activation (Perry & Teeling, 2013; Teeling & Asuni, 2017). From our in 
vitro studies, we did not observe influenza-induced PKR expression in peripheral 
macrophages, but the post-infection media produced proinflammatory gene expression in 
treated microglia. This suggested that a soluble factor in conditioned media was capable of 
activating PKR. Although stereotypically induced by dsRNA intermediates produced viral 
infection, PKR activation can occur in response to a number of extracellular signals (M. A. 
Garcia et al., 2006). As for what CNS PKR activation may mean for PD pathology, treatment 
of dopaminergic neurons with influenza-conditioned media produces cell loss. When 
combined with a secondary, PD-specific toxin (rotenone), this cell loss is additive. These 
changes mirror what has previously been shown with dual influenza + MPTP challenges; 
although there are no increases in microglial activation, there is a significantly greater degree 
of dopaminergic neuron loss (Sadasivan et al., 2017).  
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The inflammatory insults that accrue over the course of one’s lifetime can produce 
long-lasting changes that compromise neuronal function and precipitously contribute to 
neurodegenerative disease development. Previous work has fundamentally shown that 
influenza produces neuronal and inflammatory perturbations in the brain and that these 
changes promote a neurodegenerative cascade. Building off of that work, this study provides 
the first report of a novel neuroinflammatory marker that is induced by respiratory influenza 
infection and its resulting systemic inflammatory phenotype. Our study suggests that PKR 
functions as an inflammatory and apoptotic stress signal, and as opposed to acting as a 
terminal signal, PKR is most likely a transducing signal to a variety of downstream effectors. 
Future studies should continue to investigate influenza-induced neuroinflammatory signaling 
mechanisms and in particular, address how these signals are propagated from the periphery 
into the brain.    
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Figures and Tables 
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Figure 3.1 CNS PKR protein expression occurs by 15 DPI with Influenza A/PR/8/34. 
Following brief anesthesia, male BALB/c mice were intranasally inoculated with either 1) Saline (n = 8) or 2) 
0.5 HAU Influenza A/PR/8/34 (n = 8). Independent groups were monitored twice daily for either 4 days post-
infection (DPI) or 15 DPI (n = 4/group). Data represented as mean fold change ± 95% CI on a linear scale. 
Cropped Western Blot images show group representative samples run from the same gel, with corresponding 
housekeeping control. Significance above bar denotes difference from control, with between group differences 
denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA.  
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Figure 3.2 Striatal and hippocampal apoptotic and inflammatory induction precedes 
prototypical cell death, occurring in conjunction with astrocyte activation, in BALB/c mice at 
15 DPI with 0.5 HAU Influenza A/PR/8/34 (n = 4) compared to control (n = 4). 
A) FADD and NF-κB p65 protein expression are upregulated in the striatum and hippocampus 15 DPI.  B) 
Protein activator of PKR (PACT) protein is upregulated by influenza in the striatum, with evidence of astrocyte 
activation. Data represented as mean fold change ± 95% CI on a linear scale. Cropped Western Blot images 
show group representative samples run from the same gel, with corresponding housekeeping control. 
Significance above bar denotes difference from control, with between group differences denoted by line. ****p 
< 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA. 
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Figure 3.3 Neurons and microglia treated with influenza-conditioned media in vitro exhibit 
increased cell death and inflammation.  
RAW 264.7 macrophages were infected with 10 HAU Influenza A/PR/8/34 for 6 hours. A) Conditioned 
supernatant was collected and used to treat N27 dopaminergic neurons in an MTS cell viability assay, expressed 
as a percentage of controls (n = 6). B) Influenza-conditioned supernatant was also used to treat BV2 microglia 
for 6 hours and subsequent qPCR assays were performed for IL-18, IL-1β, NLRP3, and PKR gene expression (n 
= 6). Microglia significantly up-regulated PKR and inflammasome-mediated gene expression. C) Western 
blotting on influenza-infected RAW 264.7 macrophages reveal no significant differences in PKR or NLRP3 
protein expression (n = 3). Data represented as mean fold change ± 95% Confidence Interval on a Log2 scale. 
Significance above bar denotes difference from control, with between group differences denoted by line. ****p 
< 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA.  
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Figure 3.4 Striatal and hippocampal inflammatory expression 3 DPI with combined challenge 
of 0.1 HAU Influenza A/PR/8/34 and 18 /mg/kg MPTP. 
Male C57 mice were treated with either 1) saline (n = 4), 2) 4 separate doses of MPTP (I.P.) (n = 3), or dual 
challenge with intranasal 0.1 HAU Influenza A/PR/8/34 and MPTP (4x; I.P.) (n = 3). Influenza-treated mice 
were challenged with MPTP 3 DPI and sacrificed 24 hours later. A) Phosphorylated-PKR (pPKR) protein 
expression was significantly decreased by MPTP alone, with no changes to total PKR. B) PKR, NLRP3, and 
IL-1β gene expression revealed no transcriptional changes. Data represented as mean fold change ± 95% CI on 
a linear scale (protein) or log2 scale (gene). Cropped Western Blot images show group representative samples 
run from the same gel, with corresponding housekeeping control. Significance above bar denotes difference 
from control, with between group differences denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p 
< 0.05 by 1-way ANOVA. 
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Figure 3.5 Striatal and hippocampal inflammatory expression 15 DPI with combined 
challenge of 0.1 HAU Influenza A/PR/8/34 and 18 mg/kg MPTP.  
A separate cohort of male C57 mice were treated with either 1) saline (n = 6), 2) 4 separate doses of MPTP 
(I.P.) (n = 6), or dual challenge with intranasal 0.1 HAU Influenza A/PR/8/34 and MPTP (4x; I.P.) (n = 6). 
Influenza-treated mice were challenged with MPTP 15 DPI and sacrificed 24 hours later. A) Protein expression 
showed down-regulated of pPKR and total PKR, with no changes to NLRP3. B) Gene expression revealed no 
PKR or inflammasome changes, but provides evidence of pro-inflammatory cytokine induction. Data 
represented as mean fold change ± 95% CI on a linear scale (protein) or log2 scale (gene). Cropped Western 
Blot images show group representative samples run from the same gel, with corresponding housekeeping 
control. Significance above bar denotes difference from control, with between group differences denoted by 
line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA.  
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Figure 3.6 Gene expression data for GFAP and IBA1 at 15 DPI with 0.1 HAU Influenza 
A/PR/8/34 and MPTP challenge. 
A) Striatal and hippocampal GFAP gene induction appears to be largely mediated by MPTP challenge. B) 
Striatal IBA1 gene induction is significantly lower from controls in dual Influenza + MPTP mice. Data 
represented as mean fold change ± 95% Confidence Interval on a Log2 scale. Significance above bar denotes 
difference from control, with between group differences denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 
0.01, * p < 0.05 by 1-way ANOVA (n = 6 per group). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
122 
p P K R /P K R
F
o
ld
 C
h
a
n
g
e
R
e
la
ti
v
e
 t
o
 C
o
n
tr
o
l
C
o
n
tr
o
l
M
P
T
P
M
P
T
P
 +
 A
/P
R
/8
/3
4
C
o
n
tr
o
l
M
P
T
P
M
P
T
P
 +
 A
/P
R
/8
/3
4
0
2
4
6
S tria tu m
H ip p o c a m p u s
**
***
**
**
N L R P 3
F
o
ld
 C
h
a
n
g
e
R
e
la
ti
v
e
 t
o
 C
o
n
tr
o
l
C
o
n
tr
o
l
M
P
T
P
M
P
T
P
 +
 A
/P
R
/8
/3
4
C
o
n
tr
o
l
M
P
T
P
M
P
T
P
 +
 A
/P
R
/8
/3
4
0 .0
0 .5
1 .0
1 .5
2 .0
S tria tu m
H ip p o c a m p u s
*
 
Supplemental Figure 3.1 Striatal and hippocampal PKR phosphorylation subsequently 
increases 72 hours post-MPTP. 
Additionally, hippocampal NLRP3 protein expression dissipates in dual-treated mice at 72 hours post-MPTP, 
versus 24 hours post-MPTP. Male C57 mice were treated with either 1) saline (n = 4), 2) 4 separate doses of 
MPTP (I.P.) (n = 3), or dual challenge with intranasal 0.1 HAU Influenza A/PR/8/34 and MPTP (4x; I.P.) (n = 
3). Influenza-treated mice were challenged with MPTP 3 DPI and sacrificed 72 hours later. Data represented as 
mean fold change ± 95% CI on a linear scale. Cropped Western Blot images show group representative samples 
run from the same gel, with corresponding housekeeping control. Significance above bar denotes difference 
from control, with between group differences denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p 
< 0.05 by 1-way ANOVA. 
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Supplemental Figure 3.2 Dose and strain-dependent weight loss by Influenza A/PR/8/34 
across three independent studies. 
The initial study using 0.5 HAU A/PR/8/34 (256 total HAU batch) in BALB/c mice produced approximately 
20% weight loss. Follow-up studies using C57/BL6 mice, to model dual MPTP+Flu, tested 0.1 HAU A/PR/8/34 
(256 total HAU batch) and saw minor weight loss that did not coincide with CNS PKR expression. Additional 
dose studies infecting C57/BL6 with a more potent batch of 0.1 HAU A/PR/8/34 (1024 total HAU batch) did 
not see weight loss. CNS PKR expression induced by peripheral influenza infection appears dependent on 
observable sickness. Data represented as mean ± 95% CI (n = 3-8 per group). 
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Supplemental Table 3.1 Primer sequence information for qPCR assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Forward (5’ → 3’) Reverse (5’ → 3’) 
IL-1β GCTTCAGGCAGGCAGTATC AGGATGGGCTCTTCTTCAAAG 
TNF-α AGCCGATGGGTTGTACCTTG ATAGCAAATCGGCTGACGGT 
IL-6 ACCGCTATGAAGTTCCTCTC CTCTGTGAAGTCTCCTCTCC 
NLRP3 GCTCCAACCATTCTCTGACC AAGTAAGGCCGGAATTCACC 
ASC AGGAGTGGAGGGGAAAGC AGAAGACGCAGGAAGATGG 
PKR GATGGAAAATCCCGAACAAGGAG AGGCCCAAAGCAAAGATGTCCAC 
GFAP GGTTGAATCGCTGGAGGAG CTGTGAGGTCTGGCTTGG 
IBA1 CTTGAAGCGAATGCTGGAGAA GGCAGCTCGGAGATAGCTTT 
β-Actin GTGACGTTGACATCCGTAAAGA GCCGGACTCATCGTACTCC 
GAPDH AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
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Abstract 
Neuroinflammation resulting from host factor detriments, such as obesity, has emerged as a 
well-recognized component of Parkinsonian pathogenesis. While it’s understood that low-
grade, systemic inflammation from obesity is capable of perturbing CNS homeostasis, the 
characterization of these inflammatory pathways in the brain is enigmatic and highly context-
dependent. Our lab has previously identified the expression of double-stranded RNA-
dependent protein kinase (PKR) in murine brains fed a long-term high fat diet. PKR may 
potentially serve as a neuroinflammatory target for therapeutic intervention in obese 
populations at risk for Parkinson’s disease (PD). PKR activation has been suggested to serve 
as an intracellular danger-sensing mechanism and may precede NLRP3 inflammasome 
activation. To determine its clinical relevancy to Parkinsonian pathogenesis, we established a 
chronic model of diet-induced obesity in C57BL/6 mice over 14 weeks, followed by an acute 
MPTP challenge (5 mg/kg, i.p.). Brains were micro-dissected at 1 and 7 days post-MPTP 
challenge and surveyed for gene (qPCR) and protein (western blot) expression, revealing 
PKR up-regulation in the hippocampus at 1 day post-MPTP. Additionally, this expression 
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appears regionally selective to the hippocampus, does not correspond to NLRP3 expression, 
and produces downstream apoptotic and inflammatory expression. This suggests PKR acts as 
a cell stress response in the obese brain following Parkinsonian insult.  Given the current 
absence of disease-modifying therapies for PD, focusing on modifiable lifestyle factors such 
as obesity and their neuroinflammatory signature may yield meaningful preclinical insights 
into the progressive nature of this disease. 
Introduction 
Although clinically characterized by bradykinesia, muscle rigidity, postural instability, gait 
freezing, and a resting tremor (Poewe et al., 2017), the pathophysiology of Parkinson’s 
disease (PD) has been shown to develop decades prior to the onset of symptoms (Obeso et 
al., 2010; Postuma & Berg, 2016). While the primary pathology is defined by a progressive 
loss of dopaminergic neurons within the substantia nigra, intracellular proteinaceous 
inclusions composed of α-synuclein, and a stochastic decrease in striatal dopaminergic 
terminals (Obeso et al., 2010), there is also an observed increase in aberrant behavior of 
neuroinflammatory microglia and astrocytes (S. R. Subramaniam & H. J. Federoff, 2017). 
Moreover, this chronic neuroinflammatory phenotype underlies and drives the development 
of neurodegenerative cascades (C. Cunningham et al., 2009; Dantzer et al., 2008; Perry & 
Teeling, 2013). 
Characteristically distinct from stereotypical inflammation, neuroinflammation is 
defined by i) central nervous system (CNS) recruitment and infiltration of blood-derived 
lymphocytes and monocyte-derived macrophages, ii) a decrease in the regulation of blood 
brain barrier (BBB) tight junction regulation, iii) morphological alterations to microglia and 
astrocytes, and iv) an accompanying expression of prolonged, low-grade inflammatory 
factors in the parenchyma that is induced by systemic inflammatory insults (Buckman et al., 
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2014; Obermeier et al., 2013; Ransohoff, 2016a, 2016b). In addition to a flurry of metabolic 
changes (Gregor & Hotamisligil, 2011; C. N. Lumeng & Saltiel, 2011), obesity is a 
detrimental host state known to produce neuroinflammation (Freeman et al., 2014; A. A. 
Miller & Spencer, 2014). This proinflammatory signature is characterized by reactive 
astrocytes and microglia that produce increased cytokine expression of TNF-α, IL-6, and IL-
1β, which can underlie behavioral and cognitive disturbances (Guillemot-Legris & Muccioli, 
2017; Hao et al., 2016; E. B. Kang et al., 2016; Pistell et al., 2010).  
Considering the multifactorial etiology of PD and related neurodegenerative diseases, 
it is postulated that the obese brain is sensitive to additional inflammatory insults (Choi, Jang, 
Park, & Kang, 2005; Koprich, Reske-Nielsen, Mithal, & Isacson, 2008; Sulzer, 2007). In 
MPTP models of PD, obesity-induced systemic inflammation has previously been shown to 
synergistically promote loss of dopaminergic neurons, through enhanced decreases in 
tyrosine hydroxylase (TH) and elevated neuroinflammatory expression (M. Bousquet et al., 
2012; Y. Jang et al., 2017; Paul et al., 2017; L. Wang et al., 2014). What is less understood 
are the precise mechanisms that mediate obesity-induced neuroinflammation and 
subsequently underlie neuronal dysfunction in PD. 
The double-stranded RNA-dependent protein kinase (PKR) has historically served an 
antiviral function, as an innate immune response that inhibits translation of virus-infected 
cells (M. A. Garcia et al., 2006). In addition to reducing viral replication, PKR acts as a 
signal transducing node and has been shown to mediate apoptotic cell stress responses, 
antiviral host protection, and cell growth/differentiation behavior in cancer (Marchal et al., 
2014). Increased expression of hippocampal phosphorylated PKR has been identified post-
mortem in the brains of PD and Huntington’s disease patients (Bando et al., 2005). PKR has 
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also been shown to be elevated in circulating lymphocytes of Alzheimer’s disease patients 
and this increase negatively correlates with learning and memory scores (Paccalin et al., 
2006). In rodent models, PKR knockout has been shown to ameliorate LPS-induced IBA1 
microglial activation (Carret-Rebillat et al., 2015). Additionally, PKR was once implicated as 
a mediator of NLRP3 inflammasome expression (Lu et al., 2012), a multimeric protein 
complex required for the production of IL-1β-mediated inflammation (Latz, Xiao, & Stutz, 
2013). The genetic and/or pharmacologic inhibition of PKR has been shown to attenuate 
neuroinflammatory phenotypes (H. M. Chen et al., 2008; Couturier et al., 2011; Ingrand et 
al., 2007; Mouton-Liger et al., 2012; Mouton-Liger et al., 2015). 
Overall, we hypothesize that PKR is a novel mechanism linking obesity-induced 
neuroinflammation with Parkinsonian disease progression. Using a combined murine model 
of diet-induced obesity (DIO) and an acute challenge with the Parkinsonian neurotoxin, 1-
methyl, 4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP), we examined striatal and 
hippocampal PKR expression in male C57BL/6 mouse brains fed a high fat diet (HFD) for 
14 weeks, followed by MPTP challenge for 1 or 7 days. In the following studies, we sought 
to determine i) the impact of DIO-mediated neuroinflammation on CNS PKR and NLRP3 
expression, ii) PKR’s role in prototypical neuroinflammation, iii) the capacity in which DIO 
makes the brain susceptible to MPTP challenge through PKR signaling, and iv) whether PKR 
contributes to PD neuropathology by serving a pro-apoptotic function. 
Materials and Methods 
2.1 Study Design 
Two independent cohorts of male C57BL/6 mice were subjected to a diet-induced 
obesity (DIO) paradigm with either a high fat diet (HFD) or control diet (CD) (see 2.2). 
Cohort #1 was maintained on their respective diet for 12 weeks and grouped by either i) 
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Control Diet, or ii) High Fat Diet (n = 3-4 per group). In Cohort #2, mice were maintained on 
their respective diet for 14 weeks and grouped by: i) Control Diet (n = 3 -5), ii) High Fat Diet 
(n = 3 -5), iii) Control Diet + MPTP (n = 3 -5), and iv) High Fat Diet + MPTP (n = 3 -5). 
Following dietary intervention, animals were acutely challenged with MPTP to induce a 
transient Parkinsonism (see 2.3). Animals were sacrificed either 1 day or 7 days post-MPTP. 
Both 1 and 7 day post-MPTP groups included respective controls.  
2.2 Animals, Treatment, and Well-being 
Male C57BL/6 (Charles River) were kept in group housing (n = 5/cage) and 
maintained on a 12-hour reverse light cycle in ventilated Innovive racks (Innovive, San 
Diego), with ad libitum food (Envigo, 2014 Teklad; 13% kcal from fat) and water access. 
Animals assigned to a HFD were fed ad libitum for 12-14 weeks (Research Diets, Inc.; 60% 
kcal from fat). Prior to any treatment, mice were environmentally acclimated for at least 1 
week. Six to eight-week-old mice were used in all studies. All studies were approved by the 
Institutional Animal Care and Use Committee of Iowa State University.  
Body weight was recorded weekly during dietary treatment. Following MPTP 
challenge, animals were individually-housed and well-being was monitored twice daily for 
food and water intake. Once MPTP-challenged, pre- and post-MPTP body weights were 
recorded. In order to maintain wellness, mice too weak from infection were supplied with 
food and water combined in petri dishes for better access. Animals whose body weight loss 
exceeded 20% were removed from the study and sacrificed.  
At the end of a study’s respective duration, animals were sacrificed via asphyxiation 
(CO2), brains removed and micro-dissected for the hippocampus and striatum, then snap-
frozen in liquid nitrogen for subsequent processing. 
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2.3 MPTP Formulation and Administration 
Animals were subjected to an acute MPTP paradigm to establish neuroinflammation 
and rapid dopamine degeneration. Mice received four intraperitoneal (I.P.) injections of 
either 5 mg/kg MPTP-HCl dissolved in saline (free-base; Axon Medchem 1075) at 2-hour 
intervals, or saline-alone in non-MPTP groups. Animals were sacrificed either 1 day post-
MPTP or 7 days post-MPTP. To account for dosing differences, MPTP administration was 
based on Body Surface Area (BSA), as opposed to body weight (M Bousquet et al., 2012; 
Cheung et al., 2009).  
Of special note, the original study design intended to repeat the 12-week DIO 
paradigm used in the initial study. However, at the time of the original MPTP-administration 
with 18 mg/kg (4x I.P.; every 2 hours), unexpected animal death occurred to 100% HFD-
treated mice. This death occurred either before all 4 injections could be administered, or 
within 12 hours of the final injection. No other animals from any group experienced lethality 
with MPTP. A follow-up pilot MPTP dose response study tested the lethality of 10 mg/kg 
MPTP (4x I.P.; every 2 hours) and 5 mg/kg MPTP (4x I.P.; every 2 hours) in HFD-treated 
mice (n = 3 per group). The 10 mg/kg MPTP dose was lethal in 2/3 mice tested, while no 
mortality was observed following the 5 mg/kg MPTP dose. Hence, this dose was used in the 
remainder of the study and accounts for our limited sample size.  
2.4 Gene Expression 
RNA isolation was performed on snap-frozen brain tissue using an RNA binding-
column method (Qiagen RNeasy Micro Plus Kit; #74034). Total RNA was isolated from one 
hemisphere and reverse transcribed to cDNA (Qiagen RT2 First Stand Kit; #330404) to be 
used in SYBR green assays for relative gene expression (Qiagen RT2 SYBR Green Fluor 
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qPCR Mastermix; 330513). Qualitative Polymerase Chain Reaction (qPCR) was performed 
on a Bio-Rad MyIQ PCR system for 40 cycles of amplification, with a subsequent melt curve 
to validate the purity of amplified product. Gene data from the first cohort of obese mice was 
collected using RT2 Profiler PCR Arrays for Type I Interferon Response (Qiagen; cat. No. 
330231). Gene data from the second cohort of mice was collected with primers for: TNF-α, 
IL-6, IL-1β, NLRP3, ASC, PKR, IBA1, and GFAP. The primer sequences used are available 
in Supplementary Table 1. Relative difference of gene expression between groups was 
analyzed using the Pfaffl Method (Pfaffl, 2001), where threshold cycle (Ct) values were 
normalized to both β-actin and GAPDH, and expressed relative to control groups. 
2.5 Protein Expression  
Protein lysates from one hemisphere of each animal were homogenized with a 
motorized pestle in 150 µl of custom Lysis Buffer A (30 mM NaHEPES, 5 mM EGTA, 3 
mM EDTA, 20 mM KCL, 32% glycerol, phosphatase inhibitor cocktail 3 (Sigma-Aldrich; 
P0044), and HALT protease inhibitor cocktail (Thermo Fisher; 78425)). Homogenates were 
centrifuged for 15 minutes at 15,000 g (4 ͦC), and supernatant collected. Total protein was 
quantified using the bicinchoninic acid method (BCA; Pierce Biotechnology, Inc.; #23227) 
with bovine serum albumin standards. Western blot protein samples (10-30 μg) were run on 
8-16% Criterion TGX Precast Gels (Bio-Rad) at 150V for 1.5 hours, transferred to 
polyvinylidene fluoride membranes (PVDF; EMD Millipore), and blocked in Tris-buffered 
saline (TBS; pH 8.0) containing 0.05% Tween-20 and 5% non-fat dry milk (LabScientific; 
#M0841) for 1 hour at room temperature. Membranes were incubated overnight at 4 ͦC with 
primary antibody at the manufacturer recommended dilution. Primary antibody solutions 
were prepared in 1x TBST, 0.05% Na Azide, and 3% BSA and markers included: NLRP3 
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(Adipogen; cryo-2), p-PKR (Thr 451; EMB Millipore; #07-886), and β-actin (CST; #4970). 
Primary mouse monoclonal antibodies from Santa Cruz Biotechnology included: PKR (sc-
6282), p-PACT (sc-53524), PACT (sc-377103), FADD (sc-271748), Caspase-8 (sc-81656), 
and NF-κB p65 (sc-8008). Cut membranes were washed with 1x TBST (0.1% Tween), 
probed at room temperature for 1 hour with respective secondary antibody, treated with 
SuperSignal ELISA Femto Maximum Sensitivity Substrate (Thermo; #970740), and images 
captured on a Bio-Rad Universal Hood II gel imager. Densitometry was performed using 
ImageJ software (NIH), normalizing all values to β-actin, and expressed relative to control 
groups. Cropped Western Blot images show group representative samples run from the same 
gel, with corresponding housekeeping control. 
2.6 Analysis 
  Data were analyzed in GraphPad Prism (version 6 for Windows) using a Student’s T 
test for studies comparing high fat diet to control diet, and a 2-way analysis of variance 
(ANOVA) on both gene and protein expression values for combined DIO and MPTP studies. 
Post-hoc multiple comparisons were performed using a Tukey test, with an α-level of 0.05, 
and reported as (mean fold change ± SD, p-value). Figures were generated in GraphPad, 
reporting data as mean fold change with error propagated as 95% Confidence Intervals. Gene 
data were represented on a Log2 scale, with protein data on a linear scale. Significance above 
bar denotes difference from control, with between group differences denoted by line. ****p 
< 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA.  
Results 
3.1 Diet-induced obesity (DIO) modulates type I interferon gene expression in the 
hippocampus and striatum 
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To determine the effect that diet-induced obesity can have on the Type I Interferon 
gene expression profile in the murine brain, we performed a microarray analysis on the 
hippocampus and striatum of male C57BL/6 mice fed a high fat diet (60% kcal from fat) for 
12 weeks. This duration of diet has previously been shown to produce a neuroinflammatory 
phenotype in the hippocampus (Hao et al., 2016). Of 84 different genes analyzed, the 
expression of only 2 genes in the hippocampus were significantly changed by DIO (Table 1). 
PKR (3-fold), also referred to as eukaryotic initiation factor 2-alpha kinase, and met proto-
oncogene (19-fold) were significantly up-regulated.  
The striatum appeared to exhibit a greater number of DIO-induced genes changes 
(Table 2). The following genes were significantly up-regulated following DIO: PKR (5.6-
fold), IFIT3 (6.5-fold), IFITM1 (6.9-fold), NMI (8-fold), OAS1A (8.8-fold), PML (17-fold), 
PACT (37-fold), PSME2 (42-fold), SHFM1 (9-fold), and HSP90 (6-fold). As part of the 
interferon pathway, the general function of these genes pertains to the antiviral response of 
the innate immune system (Akira, Uematsu, & Takeuchi, 2006; Balachandran et al., 2000). 
As PKR was significantly up-regulated in both the hippocampus and striatum, a follow-up 
study was performed to prioritize the characterization of CNS PKR in a DIO + MPTP dual 
model of inflammatory challenge. 
3.2 Hippocampal PKR gene expression is not synergistic under dual DIO + MPTP 
inflammatory challenge 
After 14 weeks of DIO, male C57BL/6 mice were challenged with MPTP, and 
sacrificed 24 hours post-MPTP. At 1 day post-MPTP, the only significant gene changes in 
the striatum were for the pro-inflammatory cytokine TNF-α. A two-way ANOVA between 
Diet and MPTP treatment revealed a significant main effect for MPTP, F(1, 12) = 69.03, p < 
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0.0001. Post-hoc comparisons using a Tukey test revealed that when compared to control 
diet-alone, striatal TNF-α was significantly increased by MPTP-alone treatment (9.7±0.73, p 
= 0.0006), and by HFD + MPTP (10.72±1.57, p = 0.0009). Multiple comparisons were also 
significant between HFD and MPTP-alone (p = 0.0002) and between HFD and HFD + MPTP 
(p = 0.0002). There were no significant main effects for Diet and/or MPTP for striatal gene 
expression of IL-6, IL-1β, NLRP3, ASC, or PKR. 
Hippocampal gene expression for IL-1β was significantly increased from control diet 
in both the MPTP-alone and HFD+MPTP groups at 1 day post-MPTP. A two-way ANOVA 
between Diet and MPTP treatment revealed a significant main effect for MPTP, F(1, 9) = 
57.18, p < 0.0001. When compared to control diet-alone, post-hoc comparisons using a 
Tukey test revealed a significant increase in IL-1β by MPTP-alone (3.71±0.31, p = 0.0173) 
and with HFD + MPTP (6.21±0.28, p = 0.0022). There was also a significant difference 
between HFD and MPTP-alone (p = 0.0021) and between HFD and HFD + MPTP (p = 
0.0003).  
Also, in the hippocampus at 1 day post-MPTP, there was a significant interaction 
between MPTP and Diet for PKR gene expression, F(1, 11) = 6.498, p = 0.027. Post-hoc 
comparisons using a Tukey test revealed that when compared to control diet-alone, PKR 
gene expression was significantly increased by HFD-alone (2.28±0.40, p = 0.0113), MPTP-
alone (2.48±0.25, p = 0.0059), and with HFD + MPTP (2.71±0.21, p = 0.003). The relative 
magnitude of gene expression did not vary between treatment groups, suggesting that the 
level of CNS PKR induction does vary between systemic inflammation from DIO, acute 
neurotoxicity from MPTP, or the combined inflammatory challenge of HFD + MPTP. 
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There were no hippocampal gene changes 1 day post-MPTP for TNF-α, IL-6, 
NLRP3, or ASC. 
3.3 Hippocampal PKR gene expression is time-dependent, following MPTP 
In addition to the 1 day post-MPTP timepoint, an additional cohort of animals were 
sacrificed 7 days post-MPTP and striatal and hippocampal samples were assessed for TNF-α, 
IL-6, IL-1β, NLRP3, ASC, and PKR. Neither HFD nor MPTP caused gene expression 
changes to any gene of interest. However, there was no detection for any of the assessed 
genes in the HFD + MPTP group at this timepoint. No follow-up experiments were 
performed to investigate this phenomenon, but a tempting conclusion would be that dual 
HFD + MPTP treatment lead to a decrease in viable, signal-producing cells. 
At 7 days post-MPTP in the hippocampus, there were significant gene expression 
changes for IL-1β and NLRP3. Compared to control, a two-way ANOVA between Diet and 
MPTP treatment revealed that hippocampal IL-1β was significantly decreased by MPTP, 
F(1, 11) = 35.05, p = 0.0001. Post-hoc analysis revealed a significant difference between 
control diet and MPTP-alone (0.41±0.98, p = 0.0227), between control diet and HFD + 
MPTP (0.30±0.26, p = 0.0045), between HFD and MPTP-alone (p = 0.0114), and between 
HFD and HFD + MPTP (p = 0.0021).  
Hippocampal NLRP3 gene expression at 7 days post-MPTP exhibited a similar 
pattern of down-regulation as IL-1β. MPTP treatment produced a significant main effect, 
F(1, 12) = 42.02, p < 0.0001. Post-hoc analysis indicated that group difference was 
significant between control diet and MPTP (0.51±0.12, p = 0.0071), control diet and HFD + 
MPTP (0.46±0.33, p = 0.0023), HFD and MPTP-alone (p = 0.0040), and HFD and HFD + 
MPTP (p = 0.0013). 
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There were no observed changes to hippocampal TNF-α, IL-6, or ASC gene 
expression 7 days post-MPTP. The only gene that exhibited changes at both the 1 and 7 day 
post-MPTP timepoints was IL-1β, increasing at 1 day with MPTP and decreasing by 7 days 
post-MPTP. Hippocampal gene expression of PKR 7-days post-MPTP had a significant main 
effect of MPTP, F(1, 10) = 9.86, p = 0.011. Post-hoc analysis with a Tukey test revealed this 
effect was mediated by a significant different between HFD and MPTP-alone (p = 0.0394). 
This attenuation of HFD-induced PKR signal could also be attributed to loss of PKR-
expressing cells at this time point, similar to what was observed for gene expression in the 
striatum. However, protein analysis for caspase-3 in the hippocampus at 7 days post-MPTP 
did not reveal any significant differences in expression of this executioner caspase (data not 
shown). 
3.4 No detectable expression of microglial activation 
In an effort to survey the involvement of astrocytes and microglia in our models, we 
performed gene expression for GFAP and IBA1 at 1 and 7 days post-MPTP. The only 
significant changes in glial cell activation markers were to GFAP in the striatum at 1 day 
post-MPTP. A two-way ANOVA revealed that MPTP treatment had a significant main 
effect, F(1, 12) = 58.48, p < 0.0001. Post-hoc analysis with a Tukey test indicated GFAP 
gene expression was significantly increased by MPTP-alone (6.57±1.21, p = 0.0023), and by 
HFD + MPTP (10.71±0.50, p = 0.0007), when compared to control diet. Additionally, there 
was a significant difference between HFD and MPTP-alone (p = 0.0009), and between HFD 
and HFD + MPTP (p = 0.0003).   
There was no significant gene induction for IBA1 in either the striatum or 
hippocampus, at either 1 or 7 days post-MPTP. 
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3.5 Expression of phosphorylated PKR is inverse of total 
Having only observed hippocampal PKR gene induction at 1 day post-MPTP, our 
protein analysis using Western blotting only examined these tissues. For PKR changes, we 
observed a significant decrease to phosphorylated PKR, when taken as a ratio over total PKR 
changes. A two-way ANOVA revealed a significant main effect of MPTP treatment, F(1, 12) 
= 17.8, p = 0.0012. Post-hoc analysis with a Tukey test indicated that hippocampal p-PKR 
protein was significant decreased from control with dual HFD + MPTP treatment (0.56±0.14, 
p = 0.0059) and that this difference was also significant between HFD and HFD + MPTP (p 
= 0.0056) (Figure 5A). As for changes to total PKR, there were significant main effects for 
MPTP treatment, F(1, 12) = 18.0, p = 0.0011 and also for Diet, F(1, 12) = 8.07, p = 0.0149. 
However, there was no significant interaction. Post-hoc analysis indicated that MPTP 
produced a significant increase in PKR protein (1.56±0.21, p = 0.0311), and in HFD + MPTP 
animals (1.81±0.28, p = 0.0017), when compared to control (Figure 5A). 
As for central PKR signaling events we observed a significant interaction to upstream 
protein activator of PKR (PACT) between Diet and MPTP, F(1, 12) = 7.07, p = 0.021. 
However, post-hoc analysis revealed no group differences. Also, two-way ANOVA revealed 
a significant main effect of MPTP, F(1, 11) = 5.44, p = 0.0397 for phosphorylated-eukaryotic 
initiation factor 2α (p-eIF2α) (Figure 5B). As with PACT, post-hoc analysis did not reveal 
any significant differences between groups (Figure 5B). This suggest that PKR’s downstream 
actions is likely mediated through other signaling pathways. The magnitude of p-PKR 
protein expression did not vary when data were analyzed as p-PKR alone, compared to p-
PKR/total PKR. 
3.6 Dual DIO + MPTP challenge produces synergistic changes to pro-inflammatory cytokine 
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Of expected inflammatory changes, diet-induced obesity was expected to produce a 
neuroinflammatory signature. Additionally, MPTP paradigms have previously been shown to 
produce a myriad of inflammatory changes, both systemically and centrally. A two-way 
ANOVA revealed a significant interaction between Diet and MPTP for hippocampal IL-1β 
protein, F(1, 8) = 6.65, p = 0.0327, with post-hoc analysis indicating a significant increase in 
IL-1β by MPTP-alone (2.97±0.64, p = 0.0149), compared to control.  
There was a significant interaction between Diet and MPTP for hippocampal NLRP3 
protein, F(1, 12) = 18.0, p = 0.0012. Post-hoc analysis indicated that NLRP3 was significant 
decreased by HFD + MPTP (p = 0.0026), compared to HFD, and also between MPTP-alone 
and HFD + MPTP (p = 0.0365). 
A two-way ANOVA of TNF-α protein expression indicated a significant interaction 
between Diet and MPTP, F(1, 11) = 5.54, p = 0.0382. Post-hoc analysis indicated this 
significant difference was between control diet and an increase with HFD + MPTP (3.0±0.71, 
p = 0.0005). Additional differences were between HFD and HFD + MPTP (p = 0.0057) and 
between MPTP-alone and HFD + MPTP (p = 0.0004) (Figure 6). 
3.7 DIO increases hippocampal expression of proapoptotic and proinflammatory markers  
As for hippocampal protein expression of PKR downstream effectors, Diet produced 
a significant difference in FADD protein expression, F(1, 10) = 17.6, p = 0.0018. Post-hoc 
analysis indicated that this apoptotic marker was significantly increased by HFD (2.07±0.44, 
p = 0.0085), compared to control, and significantly different between HFD and MPTP (p = 
0.0424).  
For caspase-8 expression, an initiator caspase that forms a death signaling complex 
with FADD, a two-way ANOVE produced a significant main effect of Diet and MPTP that 
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led to a significant interaction, F(1, 11) = 14.4, p = 0.0030. Post-hoc analyses indicated that 
caspase-8 was significantly increased by HFD + MPTP (2.68±0.60, p = 0.0004), compared to 
control diet. There was also a significant difference between HFD and HFD + MPTP (p = 
0.0045), and between MPTP-alone and HFD + MPTP (p = 0.0004). Elevated expression of 
caspase-8 appeared to depend on dual HFD + MPTP challenge. 
Downstream of FADD/Caspase-8 signaling, NF-κB p65 was significantly changed by 
both Diet and MPTP, yielding a significant interaction, F(1, 12) = 6.29, p = 0.027. Post-hoc 
analysis indicated that p65 was significantly increased from control diet by HFD-alone, 
(2.22±0.37, p = 0.0009). Additionally, there was a significant difference between HFD and 
MPTP-alone (p = 0.0013), and between HFD and HFD + MPTP (p = 0.027). These 
differences were mediated by the HFD-induced increase in p65 (Figure 7).  
Discussion 
The present study proposes a novel neuroinflammatory mechanism, double-stranded 
RNA-dependent protein kinase (PKR), that mediates the effect of diet-induced obesity (DIO) 
on the brain and the capacity in which DIO predisposes the brain to Parkinsonian insult. 
Collectively, this report is the first to show that DIO elicits PKR expression in the brain, PKR 
does not regulate NLRP3 in the brain following dual DIO + MPTP challenge, and that DIO-
induced PKR activation mediates the expression of apoptotic FADD/caspase-8 in the brain. 
4.1 Diet-induced obesity (DIO) through a high fat diet elicits PKR gene activation 
In an initial study characterizing the gene expression profile of the Type I Interferon 
pathway in the brains of mice fed a HFD for 12 weeks, we observed increased expression of 
double-stranded RNA-dependent protein kinase (PKR) in the striatum and hippocampus. 
Reports to-date of PKR expression in the brain have come from observations that elevated 
phosphorylated PKR (p-PKR) can be found accumulating in neurons, circulating 
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lymphocytes, and cerebrospinal fluid of Alzheimer’s, Huntington’s, and Parkinson’s disease 
patients, as well as in animal disease models of neurodegeneration (Bando et al., 2005; 
Hugon et al., 2017; A. Peel, 2003). Under the context of beta-amyloid (Aβ)-mediated 
neurodegeneration, the primary neuropathology in Alzheimer’s disease, PKR has been 
implicated as a pro-apoptotic kinase that exacerbates neuronal death and accumulation of 
proteinopathy (Mouton-Liger et al., 2012; Mouton-Liger et al., 2015). As it relates to 
Parkinson’s disease, PKR has recently been shown to phosphorylate and promote α-
synuclein pathology, the protein that comprises “Lewy bodies” (Reimer et al., 2018). 
Although a pro-apoptotic function of PKR has been well-established, PKR has also been 
implicated as a key inflammatory mediator capable of producing innate immune responses to 
a variety of extracellular stressors (R. Kang & Tang, 2012; Marsollier, Ferré, & Foufelle, 
2011). 
4.2 PKR does not appear to contribute to DIO-induced NLRP3 CNS expression 
In an effort to capture the mechanism through which inflammatory PKR expression is 
induced in the obese brain and how this signal is impacted by Parkinsonian insult, we 
examined gene and protein expression of the NLRP3 inflammasome. NLRP3 has been 
implicated as a key neuroinflammatory player in neurodegeneration (De Nardo & Latz, 2011; 
Gustin et al., 2015; M. T. Heneka et al., 2013; Jha et al., 2010; Song et al., 2017). We did not 
observe any gene changes to NLRP3 expression at 1 day post-MPTP in either the striatum or 
hippocampus. This timepoint is when we observed upregulation of hippocampal PKR by 
HFD, MPTP, and HFD + MPTP. We did however observe NLRP3 downregulation in the 
hippocampus at 7 days post-MPTP, following MPTP and HFD + MPTP. This expression was  
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driven by MPTP, which is consistent with previous reports (E. Lee et al., 2018), and did not 
appear to be influenced by DIO.  
While PKR had previously been suggested to function as an upstream authorizing 
event prior to NLRP3 expression (Lu et al., 2012), our observations do not support this 
relationship. Others have supported this by observing that PKR does not modulate the 
inflammasome at all (He et al., 2013; Lancaster et al., 2016) or have suggested that PKR 
actually suppresses inflammasome activity (Yim et al., 2016). Additional evidence that 
challenges a PKR-NLRP3 relationship in the brain is that astrocytes do not express NLRP3 
(Gustin et al., 2015), despite expressing PKR (Farina et al., 2007)  
4.3 PKR expression does not appear dependent on prototypical neuroinflammation 
We hypothesized that PKR induction would occur as a response to increased 
expression of pro-inflammatory TNF-α, IL-6, and IL-1β. As a triad of pro-inflammatory 
cytokines that are induced in the hippocampus following obesity (Guillemot-Legris & 
Muccioli, 2017), we expected their expression to coincide with PKR activation. The only 
cytokine up-regulated at the time of hippocampal PKR was interleukin-1β. PKR expression 
has previously been shown to occur independent of IL-1β in virus-infected epithelial cells, 
but to be dependent on TNF-α (Meusel, Kehoe, & Imani, 2002). This is further supported by 
the observation that PKR knockout in bone marrow-derived macrophages (BMDMs) of 
HFD-induced obese mice does not suppress IL-1β secretion (Lancaster et al., 2016). High fat 
feeding has been shown to produce an early transient spike in CNS TNF-α that recedes, but 
will return if HFD feeding is sustained (Spencer et al., 2017; Thaler et al., 2012; Waise et al., 
2015). As for the peripheral source of this inflammatory signal, white adipose tissue exhibits 
increased production of TNF-α and IL-6. When treated with a PKR inhibitor in a genetic 
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model of obesity, this cytokine expression is reduced (Nakamura et al., 2014; Nakamura et 
al., 2010). 
As for the CNS cell type mediating neuroinflammation and contributing to disease 
progression, astrocytes and microglia are implicated as the primary neuroinflammatory 
effectors (Teismann & Schulz, 2004). We hypothesized that PKR expression would be 
derived from activated microglia, yet we did not observe IBA1 gene expression in either the 
striatum or hippocampus. Ionized calcium-binding adaptor molecule 1 (IBA1) is a well-
validated marker of microglial expression that corresponds to actin-mediated morphological 
changes of activation (Hoogland et al., 2015; Sasaki, Ohsawa, Kanazawa, Kohsaka, & Imai, 
2001). Obesity-induced microglial activation, characterized by IBA1 expression (Hao et al., 
2016), has regularly been implicated as a neuropathogenic event (Johnson, 2015; A. A. 
Miller & Spencer, 2014). Both astrocytes and microglia have been shown to express PKR in 
animal models of Gaucher’s disease, a form of Parkinsonism that occurs from 
glucocerebrosidase (GBA) mutation (Vitner et al., 2016). Based on previous work in human 
and animal tissues, neurons are the most likely source of PKR signal in our model (Carret-
Rebillat et al., 2015; Hugon et al., 2017; Mouton-Liger et al., 2015). Even more so, 
hippocampal neurons in human PD brains have been shown to express PKR (Bando et al., 
2005). 
4.4 PKR expression is not additive under dual DIO + MPTP challenge 
The pathogenic potential of inflammation, as a disease driver in neurodegeneration, is 
predicated on the basis that multiple inflammatory “hits” amass in an additive fashion and 
can disrupt cellular homeostasis (Colm Cunningham, 2013). As such, we hypothesized that 
CNS PKR expression would be greater is dual challenged mice (HFD + MPTP), compared to 
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HFD-alone, or MPTP-alone. While we observed significant PKR gene induction in the 
hippocampus by HFD-alone, MPTP-alone, and HFD + MPTP, there was no difference in the 
magnitude of its expression between groups. This transcriptional expression would suggest 
that PKR is functioning as a stress response node, as opposed to a terminal effector. 
Hippocampal protein expression of PKR was significantly increased by MPTP and HFD + 
MPTP, which was mediated by MPTP and not obesity. Conversely, phosphorylated PKR 
protein was significantly down-regulated in the hippocampus with HFD + MPTP. Although 
HFD + MPTP does not induce a synergistic effect on PKR gene expression, it does for PKR 
protein expression. It would be expected that p-PKR and total PKR expression would 
positively correlate, as PKR phosphorylation has previously been shown to correspond to the 
phosphorylation of PKR’s canonical substrate in in vitro models of Alzheimer’s disease, 
eukaryotic initiation factor 2-α (eIF2-α) (Chang et al., 2002; M. A. Garcia et al., 2006). 
However, previous work by our lab has shown that PKR phosphorylation increases in the 
brain following systemic inflammation with LPS at 3 hours post-challenge, but dissipates by 
24 hours post-challenge (Jefferson et al., in preparation). In the current studies, the observed 
decrease in hippocampal p-PKR could either be a limitation of our collection timepoint post-
MPTP, or a compensatory decrease to cell stress that yields a total increase.  
MPTP has a known capacity to induce neuroinflammation beyond the basal ganglia 
(Machado, Zoller, Attaai, & Spittau, 2016; Sriram et al., 2006), but we had to administer a 
dose much lower than what standard models utilize (5 mg/kg vs 15-20 mg/kg). This may 
have resulted in a reduced neuropathological insult. Additionally, our analyses are limited to 
smaller sample sizes, as we unexpectedly experienced attrition in our HFD + MPTP animals. 
In a neurodegenerative context, PKR-induced expression of p-eIF2-α has been shown to 
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regulate an apoptotic response (Ingrand et al., 2007; A. Peel, 2003). Our results do not 
support a PKR-eIF2-α pathway as a regulator of apoptosis in the brain following systemic 
inflammatory challenges with DIO and MPTP.  
4.5 Increased pro-apoptotic FADD and inflammatory NF-κB are activated downstream of 
DIO-induced PKR expression  
Chronic inflammatory states are known to precipitate neurodegenerative disease, 
including PD, and precede additional pathogenic processes (i.e., apoptosis) (Clark & 
Kodadek, 2016; Mosley et al., 2012; Sparkman & Johnson, 2008; Walker et al., 2015; 
Zitvogel, Kepp, & Kroemer, 2010). Uniquely having reported roles in both inflammation and 
apoptosis, we hypothesized that CNS PKR expression was serving a pro-apoptotic function 
following HFD + MPTP. We observed a HFD-mediated increase in fas-associated death 
domain (FADD) expression in the hippocampus, which has previously been implicated as a 
mechanism of PKR-mediated apoptosis (von Roretz & Gallouzi, 2010). FADD is an 
intracellular adaptor protein that can consequently activate the initiator caspase, caspase-8, in 
response to extracellular stress signals (Balachandran et al., 1998). FADD-activated caspase-
8 can go on to either directly activate the executioner caspase-3, or promote Bcl-2 activation 
that leads to mitochondrial release of cytochrome c (Xiao-Ming, 2000). In HeLa CCL-2 
epithelial cells treated with staurosporine, an apoptosis-inducing bacterial alkaloid, PKR was 
shown to induce apoptosis through FADD/caspase-8 signaling. This activation was not 
dependent on PKR phosphorylation, nor eIF2-α phosphorylation (von Roretz & Gallouzi, 
2010). Additionally, the PKR/FADD apoptotic pathway has been shown to mediate Aβ-
induced cell death in SH-SY5Y neurons (Couturier et al., 2010). Future studies should 
identify the extracellular mechanism responsible for activating PKR, as Fas-FADD are not 
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the only pathways involved in caspase-8/PKR-mediated apoptosis, but also involve TNF-
TNFR1 interactions (Gil & Esteban, 2000). 
Concurrently, we also observed a DIO-mediated increase in hippocampal NF-κB p65 
protein expression. As DIO induces neuroinflammation, and inflammatory processes are 
mediated via NF-κB signaling, we expected to observe an increase in PKR-induced NF-κB 
expression. This activation of the NF-κB pathway occurred either from direct activation from 
FADD through TNFR1 or Fas-induced apoptosis (W.-H. Hu et al., 2000; Ranjan & Pathak, 
2016), or through PKR itself (Zamanian-Daryoush et al., 2000). Furthermore, PKR-mediated 
activation of NF-κB does not require catalytically active PKR (Bonnet et al., 2000). What is 
unclear in our studies is whether NF-κB is activating as an anti-apoptotic response to limit 
PKR-mediated apoptosis, or is activating apoptosis to promote cell death following 
inflammation.  
4.6 Conclusion 
These data add to the rapidly accumulating literature that systemic inflammation, 
through detrimental host factors such as diet-induced obesity, can predispose the brain to 
additional environment insults. As one sustains multiple inflammatory “hits” over the course 
of their lifetime, this damage synergistically promotes neuronal dysfunction and 
progressively precipitates the development of neurodegenerative disease. Diet-induced 
obesity produces systemic inflammation, which following a Parkinsonian insult, elicits PKR 
activation in the brain that appears to serve an apoptotic function. As there are currently no 
disease-modifying therapies for PD, this work implicates PKR as a therapeutic target of 
interest to reduce neuronal cell death and also highlights the importance of modifiable 
lifestyle factors and their capacity to improve brain health.  
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Figures and Tables 
Table 4.1 Hippocampal type I interferon gene expression profile after 12 weeks of diet 
induced obesity (DIO). 
 
Male C57/BL6 mice were fed a 60% High Fat Diet (HFD) for 12 weeks, brains micro-dissected, and qPCR 
performed using Type I Interferon Arrays (Qiagen). Data excluded for genes of interest that did not have 
expression for all group samples. Data represented as mean fold change ± 95% confidence intervals, relative to 
control. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA. (n = 3-4 per group) 
P  v a lue S ig ? C o ntro l D ie t Hig h F a t  D ie t D if fe re nc e S E o f  d if fe re nc e t  ra t io df
Adeno s ine  deaminas e , RNA-s pec ific 0.25474 1 1.89075 -0.890753 0.707417 1.25916 6
Bcl2-as s o c ia ted a thano gene  3 0.876367 1 0.690858 0.309142 1.90428 0.162341 6
Bo ne  marro w s tro mal ce ll antigen 2 0.542993 1 0.379971 0.620029 0.961791 0.644661 6
Cas pas e  1 0.815607 1 0.711513 0.288487 1.18395 0.243665 6
Caveo lin 1, caveo lae  pro te in 0.655584 1 0.355756 0.644244 1.37347 0.469062 6
CD70 antigen 0.43822 1 2.62599 -1.62599 1.89042 0.860121 4
Cyclin-dependent kinas e  inhibito r 1B 0.314461 1 0.20754 0.79246 0.721989 1.09761 6
Chemo kine  (C-X-C mo tif) ligand 10 0.939742 1 1.04798 -0.0479831 0.603793 0.0794694 5
Eukaryo tic  trans la tio n initia tio n fac to r 2-a lpha  kinas e  2 0.0130312 * 1 2.98846 -1.98846 0.527529 3.76938 5
Guanyla te  binding pro te in 1 0.486896 1 2.52657 -1.52657 2.03479 0.750232 5
His to co mpatibility 2, blas to cys t 0.809481 1 0.38536 0.61464 2.38675 0.257522 4
His to co mpatibility 2, D regio n lo cus  1 0.825411 1 0.445643 0.554357 2.40572 0.230433 6
His to co mpatibility 2, K1, K regio n 0.566 1 2.30771 -1.30771 2.15383 0.607155 6
Inte rfero n gamma inducible  pro te in 30 0.357632 1 1.707 -0.706998 0.709719 0.996166 6
Inte rfero n-induced pro te in with te tra trico peptide  repea ts  1 0.790155 1 0.653592 0.346408 1.24492 0.278258 6
Inte rfero n-induced pro te in with te tra trico peptide  repea ts  3 0.855536 1 0.705374 0.294626 1.55025 0.190051 6
Inte rfero n induced trans membrane  pro te in 1 0.746801 1 0.510139 0.489861 1.44885 0.338104 6
Inte rfero n induced trans membrane  pro te in 2 0.720757 1 1.73383 -0.733829 1.95834 0.374719 6
Inte rfero n a lpha  2 0.801975 1 1.68934 -0.689342 2.62959 0.262148 6
Inte rfero n a lpha  4 0.855427 1 0.601427 0.398573 2.09559 0.190196 6
Inte rfero n (a lpha  and be ta ) recepto r 1 0.846759 1 1.18219 -0.182189 0.902924 0.201777 6
Inte rfero n (a lpha  and be ta ) recepto r 2 0.472673 1 1.4379 -0.437898 0.571598 0.766094 6
Inte rfero n be ta  1, fibro blas t 0.583847 1 0.297313 0.702687 1.20083 0.585167 5
Inte rfero n regula to ry fac to r 1 0.729228 1 1.55182 -0.55182 1.52122 0.362749 6
Inte rfero n regula to ry fac to r 2 0.935332 1 1.17402 -0.174023 2.05702 0.0845995 6
Inte rfero n regula to ry fac to r 3 0.845943 1 0.457379 0.542621 2.67476 0.202867 6
Inte rfero n regula to ry fac to r 5 0.951718 1 0.886665 0.113335 1.79541 0.0631247 6
Inte rfero n regula to ry fac to r 7 0.68295 1 0.356991 0.643009 1.49911 0.428926 6
Inte rfero n regula to ry fac to r 9 0.795328 1 0.619408 0.380592 1.40338 0.271197 6
ISG15 ubiquitin-like  mo difie r 0.963308 1 1.02916 -0.029156 0.607974 0.0479559 6
Inte rfero n-s timula ted pro te in 0.871342 1 0.687276 0.312724 1.85032 0.169011 6
Myelin and lympho cyte  pro te in, T-ce ll diffe rentia tio n pro te in 0.568172 1 0.162551 0.837449 1.38728 0.603664 6
Met pro to -o nco gene < 0.0001 **** 1 19.1648 -18.1648 1.07009 16.975 5
N-myc (and STAT) inte rac to r 0.902381 1 0.774567 0.225433 1.7621 0.127934 6
2'-5' o ligo adenyla te  s ynthe tas e  1B 0.712526 1 0.55921 0.44079 1.14074 0.386408 6
P ro te in kinas e  C, ze ta 0.876966 1 1.24096 -0.240964 1.49161 0.161546 6
P ro teas o me (pro s o me, macro pa in) 28 s ubunit, be ta 0.670699 1 0.438747 0.561253 1.25618 0.446793 6
Src  ho mo lo gy 2 do main-co nta ining trans fo rming pro te in B 0.176027 1 4.77372 -3.77372 2.3957 1.57521 5
Signa l trans ducer and ac tiva to r o f trans criptio n 2 0.725585 1 0.143236 0.856764 2.32887 0.367889 6
Trans po rte r 1, ATP -binding cas s e tte , s ub-family B (MDR/TAP ) 0.746435 1 0.484296 0.515704 1.52298 0.338615 6
Vas cular endo the lia l gro wth fac to r A 0.884764 1 0.622636 0.377364 2.4956 0.151212 6
Glucuro nidas e , be ta 0.611096 1 0.423068 0.576932 1.07593 0.536217 6
Heat s ho ck pro te in 90 a lpha  (cyto s o lic ), c las s  B  member 1 0.812466 1 0.654725 0.345275 1.39271 0.247916 6
 
 
152 
Table 4.2 . Striatal type I interferon gene expression profile after 12 weeks of diet-induced 
obesity (DIO).  
Male C57/BL6 mice were fed a 60% High Fat Diet (HFD) for 12 weeks, brains micro-dissected, and qPCR 
performed using Type I Interferon Arrays (Qiagen). Data excluded for genes of interest that did not have 
expression for all group samples. Data represented as mean fold change ± 95% confidence intervals, relative to 
control. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA. (n = 3-4 per group)  
P  v a lue S ig ? C o ntro l D ie t Hig h F a t  D ie t D if fe re nc e S E o f  d if fe re nc e t  ra t io df
Adeno s ine  deaminas e , RNA-s pec ific 0.650892 1 0.545157 0.454843 0.931468 0.488308 4
Bo ne  marro w s tro mal ce ll antigen 2 0.995501 1 1.00794 -0.00794101 1.32379 0.00599869 4
Cas pas e  1 0.215636 1 4.30122 -3.30122 2.2465 1.46949 4
Caveo lin 1, caveo lae  pro te in 0.603727 1 1.75493 -0.754928 1.34179 0.562625 4
Chemo kine  (C-X-C mo tif) ligand 10 0.0827788 1 6.53451 -5.53451 2.40447 2.30176 4
Eukaryo tic  trans la tio n initia tio n fac to r 2-a lpha  kinas e  2 0.00147621 ** 1 5.64932 -4.64932 0.59807 7.77388 4
His to co mpatibility 2, M regio n lo cus  3 0.304407 1 2.69088 -1.69088 1.43645 1.17712 4
Inte rfe ro n gamma inducible  pro te in 30 0.509409 1 2.26799 -1.26799 1.75253 0.723517 4
Inte rfe ro n-induced pro te in with te tra trico peptide  repea ts  1 0.779692 1 0.731068 0.268932 0.89885 0.299196 4
Inte rfe ro n-induced pro te in with te tra trico peptide  repea ts  3 0.0113118 * 1 6.47439 -5.47439 1.23227 4.44253 4
Inte rfe ro n induced trans membrane  pro te in 1 0.0120015 * 1 6.85938 -5.85938 1.34191 4.36644 4
Inte rfe ro n induced trans membrane  pro te in 2 0.0744325 1 2.70334 -1.70334 0.710006 2.39906 4
Inte rfe ro n (a lpha  and be ta ) recepto r 2 0.478577 1 1.80427 -0.804265 1.03013 0.78074 4
ISG15 ubiquitin-like  mo difie r 0.949216 1 1.12097 -0.120968 1.78479 0.067777 4
Inte rfe ro n regula to ry fac to r 9 0.947187 1 0.916842 0.083158 1.17971 0.0704902 4
Myelin and lympho cyte  pro te in, T-ce ll diffe rentia tio n pro te in 0.514576 1 1.69515 -0.695148 0.973346 0.714184 4
Max binding pro te in 0.106483 1 4.7725 -3.7725 1.81704 2.07617 4
N-myc (and STAT) inte rac to r 0.004674 ** 1 8.17609 -7.17609 1.25839 5.7026 4
Amino peptidas e  puro mycin s ens itive 0.993727 1 0.987198 0.012802 1.5306 0.00836403 4
2'-5' o ligo adenyla te  s ynthe tas e  1A 0.0064731 ** 1 8.80351 -7.80351 1.49789 5.20967 4
P ro myelo cytic  leukemia 0.00186012 ** 1 17.4096 -16.4096 1.56729 10.4701 3
P ro te in kinas e  C, ze ta 0.0808114 1 4.58868 -3.58868 1.54441 2.32366 4
P ro te in kinas e , inte rfe ro n induc ible  do uble  s tranded RNA dependent ac tiva to r 0.000271531 *** 1 37.8288 -36.8288 3.05507 12.055 4
P ro teas o me (pro s o me, macro pa in) 28 s ubunit, be ta < 0.0001 **** 1 42.0707 -41.0707 0.998429 41.1353 4
Regula to r o f chro mo s o me co ndens a tio n (RCC1) and BTB (P OZ) do main co nta ining pro t 0.843257 1 1.36107 -0.361073 1.71187 0.210924 4
Split hand/fo o t malfo rmatio n (ec tro dac tyly) type  1 0.0154931 * 1 9.24119 -8.24119 2.03555 4.04864 4
Signa l trans ducer and ac tiva to r o f trans criptio n 1 0.0618656 1 2.72844 -1.72844 0.672094 2.57173 4
Signa l trans ducer and ac tiva to r o f trans criptio n 2 0.127445 1 2.91753 -1.91753 0.999327 1.91882 4
Tnf recepto r-as s o c ia ted fac to r 3 0.712052 1 0.356361 0.643639 1.62374 0.396393 4
Glucuro nidas e , be ta 0.765022 1 1.36422 -0.364222 1.13838 0.319949 4
Hypo xanthine  guanine  pho s pho ribo s yl trans feras e 0.798918 1 0.706166 0.293834 1.07935 0.272233 4
Heat s ho ck pro te in 90 a lpha  (cyto s o lic ), c las s  B member 1 0.00451958 ** 1 5.94391 -4.94391 0.858984 5.75553 4   
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Figure 4.1 Weight gain by High Fat Diet (HFD). 
Male C57/BL6 mice were ad-libitum fed a 60% HFD for A) 12 weeks in one study and for B) 14 weeks in a 
follow-up study. Mice fed a HFD gained approximately twice the amount of body weight as mice fed a standard 
control diet. Total weight gain was comparable between both obesity studies. Data shown as mean difference in 
body weight ± 95% confidence intervals. (n = 3-5 per group) 
A. 
B. 
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Figure 4.2 Hippocampal PKR gene expression was induced by High Fat Diet (HFD), MPTP, 
and dual HFD+MPTP challenge, 1 day post-MPTP.  
Male C57/BL6 mice were fed a HFD for 14 weeks and then challenged with 5 mg/kg MPTP (4x I.P., every 2 
hours) or saline. Brain samples were collected either 1 or 7 days post-MPTP. qPCR was performed on the 
striatum and hippocampus for A) pro-inflammatory cytokines, B) inflammasome-related, and C) PKR. The 
magnitude of PKR gene expression in the hippocampus was not additive under dual-DIO+MPTP challenge. 
Data represented as mean fold change ± 95% CI on a Log2 scale. Significance above bar denotes difference 
from control, with between group differences denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p 
< 0.05 by 1-way ANOVA (n = 3-5 per group).   
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Figure 4.3 Hippocampal PKR gene expression dissipates by 7 days post-MPTP.  
Male C57/BL6 mice were fed a High Fat Diet for 14 weeks and then challenged with 5 mg/kg MPTP (4x I.P., 
every 2 hours) or saline. Brain samples were collected either 1 or 7 days post-MPTP. qPCR was performed on 
the striatum and hippocampus for A) pro-inflammatory cytokines, B) inflammasome-related, and C) PKR. The 
only gene changes were to IL-1β and NLRP3 being downregulated by MPTP and HFD+MPTP, along with a 
difference in hippocampal PKR gene expression. Gene expression was not detectable (ND) in the striatum for 
HFD+MPTP samples. Data represented as mean fold change ± 95% CI on a Log2 scale. Significance above bar 
denotes difference from control, with between group differences denoted by line. ****p < 0.0001, *** p < 
0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA (n = 3-5 per group).   
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Figure 4.4 Hippocampal PKR expression is not likely mediated by astrocyte (GFAP) or 
microglial (IBA1) activation. 
Male C57/BL6 mice were fed a High Fat Diet for 14 weeks and then challenged with 5 mg/kg MPTP (4x I.P., 
every 2 hours) or saline. Brain samples were collected either 1 or 7 days post-MPTP. qPCR was performed on 
the striatum and hippocampus for A) glial-fibrillary acidic protein (GFAP), B) ionized calcium binding adaptor 
molecule 1 (IBA1). The only gene expression changes were MPTP-mediate GFAP upregulation in the striatum, 
1 day post-MPTP. Data represented as mean fold change ± 95% CI on a Log2 scale. Significance above bar 
denotes difference from control, with between group differences denoted by line. ****p < 0.0001, *** p < 
0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA (n = 3-5 per group). 
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Figure 4.5 Dual HFD+MPTP induces inverse expression between phosphorylated PKR (p-
PKR) and total PKR in the hippocampus, 1 day post-MPTP.  
Following 14 weeks of diet-induced obesity with 60% kcal HFD, male C57/BL6 mice were acute challenged 5 
mg/kg MPTP (4x I.P., every 2 hours) or saline. A) Protein analysis indicated a negative relationship between 
PKR and p-PKR (Thr451), following HFD+MPTP treatment. B) There were no changes to stereotypical PKR 
activators or downstream substrates. Data represented as mean fold change ± 95% CI on a linear scale. Cropped 
Western Blot images show group representative samples run from the same gel, with corresponding 
housekeeping control. Significance above bar denotes difference from control, with between group differences 
denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA. (n = 3-5 per group)  
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Figure 4.6 MPTP treatment induced pro-inflammatory expression in the hippocampus, 1 day 
post-MPTP.  
Protein analysis with western blotting indicated that modest MPTP (5 mg/kg, 4x I.P. every 2 hours) was 
sufficient to induce IL-1β expression in, along with a significant increase in pro-TNF-α in the HFD+MPTP 
group. NLRP3 protein expression was significantly decreased with HFD+MPTP. Data represented as mean fold 
change ± 95% CI on a linear scale. Cropped Western Blot images show group representative samples run from 
the same gel, with corresponding housekeeping control. Significance above bar denotes difference from control, 
with between group differences denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-
way ANOVA. (n = 3-5 per group)  
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Figure 4-7 Diet-induced obesity with a HFD induced concurrent increases in apoptotic and 
inflammatory protein expression, in the hippocampus.  
Western blotting in the hippocampus 1 day post-MPTP revealed that HFD alone increased apoptotic FADD and 
NF-κB p65 proinflammatory protein expression, while Pro-Caspase-8 expression was significantly increased 
from control with HFD+MPTP. Data represented as mean fold change ± 95% CI on a linear scale. Cropped 
Western Blot images show group representative samples run from the same gel, with corresponding 
housekeeping control. Significance above bar denotes difference from control, with between group differences 
denoted by line. ****p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 by 1-way ANOVA. (n = 3-5 per group)  
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Supplemental Table 4.1. Primer sequence information for qPCR assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Forward (5’ → 3’) Reverse (5’ → 3’) 
IL-1β GCTTCAGGCAGGCAGTATC AGGATGGGCTCTTCTTCAAAG 
TNF-α AGCCGATGGGTTGTACCTTG ATAGCAAATCGGCTGACGGT 
IL-6 ACCGCTATGAAGTTCCTCTC CTCTGTGAAGTCTCCTCTCC 
NLRP3 GCTCCAACCATTCTCTGACC AAGTAAGGCCGGAATTCACC 
ASC AGGAGTGGAGGGGAAAGC AGAAGACGCAGGAAGATGG 
PKR GATGGAAAATCCCGAACAAGGAG AGGCCCAAAGCAAAGATGTCCAC 
GFAP GGTTGAATCGCTGGAGGAG CTGTGAGGTCTGGCTTGG 
IBA1 CTTGAAGCGAATGCTGGAGAA GGCAGCTCGGAGATAGCTTT 
β-Actin GTGACGTTGACATCCGTAAAGA GCCGGACTCATCGTACTCC 
GAPDH AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
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CHAPTER 5.    SUMMARY AND CONCLUSIONS 
 
 As introduced in the introduction to this dissertation, Parkinson’s disease (PD) is a 
neurodegenerative disorder that currently has no disease-modifying therapies.  As such, the 
current course of treatment can only attempt to manage primary symptoms. Although 
clinically defined as a movement disorder, the non-motor symptoms of PD substantially 
compromise quality of life for patients. Pathologically, these symptoms predict disease state 
progression and suggest an underlying pathogenic mechanism, beyond the primary 
synucleinopathy. Neuroinflammation has recently been implicated as a form of chronic 
immune activation that can progressively promote a neurodegenerative cascade in the brain. 
Not only are these events capable of driving disease development in PD, but they can 
maintain a vicious cycle of neurodegeneration. This early pathogenic process holds a high 
degree of therapeutic potential because it can lead to the development of early diagnostic 
tools and drug candidates that can substantially alter the progression of disease.  
However, the challenge associated with the study of neuroinflammation and 
neuroimmunology is that these processes have both adaptive and maladaptive functions. The 
goal of this work has been to examine the double-stranded RNA-dependent protein kinase 
(PKR) as a mechanism by which various host factor detriments promote neuroinflammation, 
that can subsequently contribute to Parkinsonian neurodegeneration. In doing so, it is our 
goal to highlight the signaling conservation in cell stress responses that can contribute to and 
precipitate PD development. 
In Chapter II, our first aim was to characterize central nervous system (CNS) PKR 
neuroinflammatory gene expression following acute, systemic bacterial challenge with 
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lipopolysaccharide (LPS) to determine dose and temporal kinetics. The magnitude of 
hippocampal and striatal PKR gene expression did not vary between LPS dose intensity (5 
mg/kg or 1 mg/kg I.P), nor duration of LPS challenge (3 or 24 hours). This was an 
unexpected finding. Inflammatory responses generally correspond to the magnitude of the 
stimuli, as evidenced by pro-inflammatory cytokine expression in these studies. TNF-α gene 
expression was greatest with 5 mg/kg LPS at 3 hours post-LPS, lower with 1 mg/kg LPS at 3 
hours post-LPS, and lowest with 1 mg/kg LPS at 24 hours post-LPS. We hypothesized that 
PKR expression would behave in this manner, but the magnitude of its gene expression did 
not vary with the magnitude of LPS challenge. This suggests that PKR may not be acting as a 
terminal neuroinflammatory effector, but more so as a signal transducing node. Further 
supporting evidence for this claim is that there was no observable IBA1 gene induction, 
indicating an absence of microglial activation. 
Our second aim was to determine the capacity in which a systemically administered 
PKR inhibitor (PKRi) can ameliorate an LPS-induced PKR inflammatory phenotype in the 
CNS. Using 1 mg/kg LPS at 24 hours post-LPS, we repeated our PKR and 
neuroinflammatory phenotype from the LPS dose and duration study. We also pre-treated 
LPS-challenged animals with the PKR inhibitor imoxin at two doses, 0.5 mg/kg or 1.0 
mg/kg, that were administered 2 and 24 hours pre-LPS. By pre-treating with imoxin, we 
wanted to know if LPS-induced neuroinflammation would be attenuated because of PKR’s 
diminished activity. Imoxin was hypothesized to decrease this phenotype. The lower 0.5 
mg/kg imoxin dose reduced neuroinflammation to a greater extent, but did not completely 
abolish LPS-induced neuroinflammation. The dose difference may be attributed to PKR 
activation kinetics. The observation that imoxin did not reduce LPS-induced 
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neuroinflammation to baseline suggests that there are non-PKR-mediated mechanisms 
contributing to inflammatory signal propagation in the brain. Thus, PKR does not appear to 
act as a sole regulator of neuroinflammation, but rather a signal transmission node.  
Chapter III initially characterized murine CNS PKR expression following influenza 
challenge to determine the dose and temporal kinetics of this response. If PKR served as a  
mediator of influenza-induced neuroinflammation, we hypothesized that its induction would 
have occurred early (3-5 days post-infection) and occurred in conjunction with pro-
inflammatory cytokine expression, as others have shown hippocampal neuroinflammation by 
4 days post-infection (DPI) (Jurgens et al., 2012). From our initial influenza studies, we 
learned that infection resulting in substantial sickness led to delayed PKR induction in the 
striatum and hippocampus (15 DPI). This observation did not support our hypothesis. 
Follow-up studies were performed in vitro where immortalized macrophages were infected 
with influenza and the conditioned media was used to treat immortalized microglia. This 
treatment led to proinflammatory cytokine induction, providing direct evidence that infection 
of peripheral inflammatory immune cells can produce soluble factors which can activate 
microglia to produce a proinflammatory profile. 
This conditioned media was also used to treat immortalized rat dopaminergic neurons 
in a cell viability assay, in which neurons were dual-treated with influenza-conditioned 
media and the Parkinsonian neurotoxin, rotenone. Cell loss was additive in 
influenza+rotenone treated samples, compared to influenza- and rotenone-alone conditions. 
This highlighted the synergistic potential of influenza-induced neuroinflammation and 
Parkinsonian-relevant stress. From in vivo studies to examine this multi-hit model of 
influenza and PD, we were unable to replicate the original magnitude of influenza-induced 
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PKR expression in the brain. However, we observed modest PKR protein changes and gained 
insight into the potential influence of strain differences. Returning to our original 15 DPI 
samples, we identified that PKR expression led to the induction of downstream apoptotic and 
inflammatory expression. These results suggest that PKR may serve as an influenza-induced 
stress response that promotes inflammation and apoptosis. 
The objective of Chapter IV was to characterize CNS PKR expression in a murine 
model of diet-induced obesity and determine the extent to which it contributes to MPTP-
induced Parkinsonian pathogenesis. After identifying striatal and hippocampal PKR gene 
expression from microarrays performed on the brains of mice fed a chronic high-fat diet, we 
performed a follow-up study using a mouse model of diet-induced obesity (DIO), in 
combination with MPTP. We hypothesized that PKR expression would be greatest in obesity 
+ MPTP samples, compared to obesity-, or MPTP-alone. Only the hippocampus exhibited 
PKR expression in DIO and DIO + MPTP animals, but this expression was mediated by 
obesity and the magnitude of expression did not vary between these two groups. PKR 
signaling coincided with obesity-mediated induction of apoptotic and inflammatory 
signaling. Additionally, PKR expression did not appear dependent on astrocyte or microglial 
activation and is likely mediated by neurons, as a cell stress signal. 
MPTP models of neurotoxicity have a well-characterized neuroinflammatory 
signature. From our use of MPTP in our diet-induced obesity studies, we saw up-regulation 
of PKR at 24 hours post-MPTP, which would support a potential role for PKR in MPTP-
induced microglial activation. Following MPTP challenge, microglia activation generally 
occurs by 24 hours post-MPTP and can remain elevated through at least 7 days post-MPTP 
(Członkowska, Kohutnicka, Kurkowska-Jastrzębska, & Członkowski, 1996). MPTP-induced 
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astrocyte activation can occur between 3-4 days post-MPTP (Breidert et al., 2002), although 
the role of astrocytes in neuroinflammatory processes and Parkinsonian syndrome is much 
less understood. The chronic activation of microglia and subsequent astrocyte activation, 
combined with CNS infiltration by adaptive T lymphocytes, creates a vicious 
neuroinflammatory cycle that promote neuronal distress and neurodegeneration (Hirsch et al., 
2016).  
We have observed LPS- and MPTP-induced PKR expression following acute 
challenge (i.e., 24 hours post challenge) and we have also observed delayed PKR expression 
following influenza and diet-induced obesity (2 weeks and 12 weeks post challenge). Given 
that we were unable to observe evidence of stress-induced microglial activation in all three of 
our experimental conditions, operationally defined by gene expression of IBA1, we cannot 
reasonably infer that PKR expression is dependent on microglial activation. Although our 
LPS and influenza studies suggest that PKR expression may coincide with astrocyte 
activation, we did not observe similar patterns of GFAP and PKR expression in our obesity 
study. Given that MPTP-induced astrogliosis is a latent event (3-4 days post-MPTP), our 
observed upregulation of GFAP may not be indicative of bona fide morphological activation 
of astrocytes. Additionally, expression of the pro-inflammatory cytokines TNF-α and IL-1β 
occurs early following MPTP challenge (6-24 hours post-challenge), while IL-6 upregulation 
is often delayed (7 days post-challenge). As we had initial evidence (Lu et al., 2012) that 
implicated PKR upstream of NLRP3 and subsequent IL-1β production, we would have 
reasonably expected PKR expression to solely exist as an acute phase stress response 
(Machado 2016). However, we observed PKR expression at delayed time points, in which 
(relatively) acute phase cytokine production had dissipated. This does not support a direct 
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role for PKR as a direct neuroinflammatory regulator. What we can reasonably conclude is 
that CNS PKR expression can occur both early (LPS & MPTP) and delayed (Influenza & 
Obesity) following immune inflammatory challenge. Future studies should utilize cell-
specific in vitro experimental designs to delineate the role of PKR in specific CNS cell types.  
Together with existing literature implicating PKR as a neuron-derived stress response 
signal, we conclude that CNS PKR expression most likely localizes to neurons, occurs 
rapidly, and can remain elevated over the course of inflammatory challenge. Although 
entirely context-dependent, this early PKR expression likely functions as a pro-survival 
signal related to apoptotic signal transduction. We have no evidence of classic cell death to 
suggest that our observed CNS PKR expression is detrimental to cell health. Although 
sustained expression of PKR may lead to pro-apoptotic changes within the CNS, this early 
expression likely acts a compensatory response to stressful cell stimuli. Future studies should 
take care to temporally define PKR expression and any coinciding cell death that may occur, 
which would clarify if PKR functions as a terminal death-related cell signal. 
Collectively across immune challenges with LPS, influenza, and diet-induced obesity, 
we have identified the novel expression of PKR, whose induction in these host contexts is 
outside of its non-canonical antiviral function. In addition to identifying PKR expression in 
brain regions relevant to Parkinsonian neurodegeneration, we have shown that its CNS 
induction across seemingly unrelated inflammatory disease states serves as a broad cell stress 
response. As PKR expression does not appear to correspond to the intensity of inflammatory 
stimuli, as do stereotypic pro-inflammatory mediators (i.e., cytokines), PKR likely acts as a 
signal transduction node that elicits downstream effectors to mount various cell responses. 
FADD/caspase-8-mediated apoptosis and NF-κB p65-mediated inflammation are two 
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downstream signals that likely mediate the mechanism of neuroinflammation-induced PKR 
expression. Important next steps in determining PKR’s candidacy as a neurotherapeutic 
target against PD will be i) to determine whether PKR’s expression is to promote cell 
survival via apoptotic pathways, and ii) if pharmacologically manipulating PKR expression 
will improve disease state outcomes, and iii) if these improvements can be substantial enough 
to modify the course of disease progression in the brain.  
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APPENDIX. SUPPLEMNTAL DATA 
The purpose of this study was to examine the capacity for Imoxin (IMX), a PKR inhibitor 
that blocks kinase autophosphorylation, to ameliorate diet-induced obesity (DIO)-induced 
PKR activation and neuroinflammation, and minimize the severity of MPTP-induced 
neuronal damage. Male C57BL/6 mice were fed either a control diet (10.2% kcal fat, 58Y2) 
or a high-fat diet (61.2% kcal fat, 58Y1) for 14 weeks, collecting body weight weekly. At the 
start of week 12, began daily administration of the PKR inhibitor IMX (0.5 mg/kg SC or 
saline) for 14 days. At end of 14 weeks of feeding, we administered MPTP (4x 5 mg/kg IP at 
2 hour intervals) or saline to respective groups and sacrificed 24 hours later. Brains were 
micro-dissected for the striatum and hippocampus. Groups included: Control Diet (CD) (n = 
8), CD + MPTP (n = 8), High Fat Diet (n = 8), HFD + IMX (n = 8), HFD + MPTP (n = 8), 
and HFD + IMX + MPTP (n = 8). Samples were processed for gene and protein expression. 
qPCR was performed on striatum and hippocampus for: Actin and GAPDH housekeeping, 
PKR, NLRP3, ASC, TNF-α, IL-1β, IBA1, and GFAP. Western blotting was performed on 
hippocampal samples for: PKR, PACT, phosphor-eIF-2α, RIP1K, IKKi, NF-κB, TNF-α, 
NLRP3, and CDK2. 
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